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ABSTRACT 
 
The dentate gyrus (DG) is a neurogenic niche in the adult mammalian 
brain where new neurones are formed from neural stem/progenitor cells 
(NSPCs) throughout life. These adult born neurones play a key role in 
learning and memory, however, this process is not fully understood.  
Calorie restriction (CR) has been shown to modulate the DG and 
improve cognition albeit via unknown mechanisms. The gut hormone 
ghrelin, which is acylated by Ghrelin-O-acyl transferase (GOAT), is elevated 
during CR and travels via the blood to the brain where it binds to its 
receptor, GHSR, in several sites, including the hippocampus. We show that 
acyl-ghrelin significantly increases adult hippocampal neurogenesis (AHN) 
in the DG.  
Immunofluorescent analysis of adult male GHSR-eGFP mice showed 
no GHSR expression in Sox2+, Nestin+ or Ki67+ NSPCs in the DG, but 
confirmed high expression on mature DG NeuN+ cells, suggesting a non-cell 
autonomous mechanism of action. Following this, we show that CR enhances 
AHN in wild-type but not GHSR-KO mice, demonstrating that CR induces 
AHN in a GHSR-dependant manner. 
To determine whether un-acylated ghrelin treatment negatively 
affects AHN, wild-type and GOAT-KO mice, which have an absence of 
circulating acyl-ghrelin, were treated with either vehicle or unacylated-
ghrelin. Wild-type mice treated with un-acylated ghrelin showed a 
significant reduction in proliferating (Ki67+) cells and immature (DCX+) 
neurones in the subgranular zone of the DG. Similarly, neurogenesis was 
impaired in GOAT-KO mice. 
Lastly, to determine whether our rodent work was relevant to 
humans, circulating acyl-ghrelin was quantified in patients diagnosed with 
Parkinson’s disease dementia (PDD). Notably, fasted and post-prandial 
plasma acyl-ghrelin levels were significantly reduced in PDD patients 
relative to healthy age-matched controls. 
In summary, the results from this thesis suggest that acyl-ghrelin may 
be a biomarker for dementia, shown in PDD, and that elevating circulating 
acyl-ghrelin or reducing unacylated-ghrelin represents a novel therapeutic 
approach for preventing the decline in AHN. 
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Chapter 1 General Introduction 
 
1.1 Ghrelin 
Ghrelin is a 28 amino acid orexigenic hormone that is produced by cells 
in the lining of the stomach, its name comes from the proto-Indo-European 
word Ghre, which means “growth” or “to grow” (Inui, 2004). This was first 
described by Kojima et al. in 1999 as a regulator of growth hormone (GH) 
release. It had previously been discovered that an unknown endogenous 
ligand acting through a G-protein coupled receptor (GPCR), GHS-R, 
stimulated the release of GH from the pituitary (Howard et al., 1996). Kojima 
then revealed that the post-translational addition of octanoic acid to the 
ghrelin peptide stimulated GH release, indicating that the n-octanoic acid 
was essential for ghrelin activity (M Kojima et al., 1999). 
1.1.1 Acylation of Ghrelin. 
Ghrelin is a result of proteolytic cleavage of the precursor peptide 
preproghrelin to proghrelin, which is the native form of the peptide. It is this 
pro-ghrelin peptide that undergoes a distinctive post-translational alteration, 
via the addition of an octanoyl group (the process of acylation) to the highly 
conserved 3rd serine residue of its structure (Figure 1.1). The enzyme that 
performs this acylation is ghrelin-O-acyl-transferase (GOAT) (Gutierrez et 
al., 2008; Yang, Brown, Liang, Grishin, & Goldstein, 2008). Ghrelin exists in 
two forms, active or acyl-ghrelin (AG) and the, so-called, inactive un-
acylated form (UAG). UAG is the most abundant form of this hormone, 
consisting of approximately 90% of total circulating ghrelin (Nishi, Yoh, 
Hiejima, & Kojima, 2011a).  
Obestatin is another product of the ghrelin gene that has an opposing 
effect to ghrelin on appetite, it is anorectic (J. V. Zhang et al., 2005). It is a 23-
2 
 
amino acid peptide which is found in the gastrointestinal tract that reduces 
food intake, body weight and gastric motility, and mediates it’s effects 
through its own GPCR GPR-39 (Lacquaniti, Donato, Chirico, Buemi, & 
Buemi, 2011; J. V. Zhang et al., 2008).  
 
 
Figure 1.1 The structure of ghrelin and activation by acylation.  
Ghrelin comes in 2 forms active (acylated) and inactive (des-acylated). Activation occurs upon the 
addition of an octanoyl group to the 3rd serine residue, facilitated by the enzyme GOAT. This allows 
interaction with the ghrelin receptor GHSR1a, the inactive form cannot activate GHSR1a (Taken from 
Andrews 2011). 
 
GOAT, the enzyme that catalyses the activation of ghrelin was 
discovered by 2 separate labs in 2008, they both used genome database 
searches to identify MBOAT4 (membrane-bound o-acyltransferase). The 
knockdown of MBOAT4 in the medullary carcinoma TT cell line resulted in 
the prevention of ghrelin acylation, and this was also seen in a knockout 
(KO) mouse model of MBOAT4, indicating that MBOAT4 was GOAT 
(Gutierrez et al., 2008; Masayasu Kojima, Hamamoto, & Sato, 2016; Yang et 
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al., 2008). GOAT is a membrane-bound enzyme that has multiple 
transmembrane domains, and is one of at least 16 acyltransferase enzymes 
(Hofmann, 2000). Topographically, GOAT has 11 transmembrane domains 
and a re-entrant loop which are hydrophobic; these are separated by short 
hydrophilic loops with the N-terminus in the lumen of the endoplasmic 
reticulum and the C-terminus in the cytosol. It also contains conserved 
asparagine (Asn307) and histidine (His338) residues. His338 is thought to be 
involved in the catalytic properties of the active site, whereas Asn307 is 
thought to be essential for interactions with substrate and transport 
(Masumoto et al., 2015; Taylor et al., 2013). It is distributed similarly to 
ghrelin in the gastrointestinal organs, mainly the stomach.  
 
Figure 1.2 Topographic representation of GOAT. 
11 transmembrane domains with 1 re-entrant loop, within the membrane of the ER. Blue arrows 
indicate the conserved H338 in the ER lumen and N307 in the cytosol. Image taken from Masumoto et al. 
2015. 
 
Ingested medium chain fatty acids (MCFA) are the predominant source 
of n-octanoic acid (Nishi et al., 2005), suggesting that the acylation of ghrelin 
may be modulated by dairy products such as milk and oils such as coconut 
oil and palm kernel oil (Lemarié, Beauchamp, Legrand, & Rioux, 2016). 
1.1.2 Role in energy homeostasis and orexigenesis 
Ghrelin plays a role in energy homeostasis; it stimulates appetite via 
orexigenic neurones in the hypothalamus and is expressed in the stomach (M 
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Kojima et al., 1999).  In a study performed in the laboratory of Tamas 
Horvath it was shown that immunoreactive ghrelin cell bodies are found in 
the paraventricular, arcuate, vetro- and dorsomedial hypothalamic nuclei, 
and in the ependymal layer of the third ventricle, whereas ghrelin knockout 
animals did not show ghrelin immune-reactive cells in the same areas or the 
stomach (Cowley et al., 2003). They found that ghrelin was present in axons 
and that they made synaptic contacts with dendrites from neuropeptide Y 
(NPY)/ Agouti-related protein (AGRP) and pro-opiomelanocortin (POMC) 
neurones in the hypothalamus that are part of the appetite regulation 
pathway. Electrophysiology studies performed on hypothalamic slices 
treated with 50nM ghrelin, showed an increase in the NPY neuron activity 
which ceased upon wash-out. This indicated that ghrelin was enhancing the 
release of NPY and AGRP. Also, ghrelin’s effect on POMC neurones was 
examined using patch-clamp recordings of identified POMC neurones from 
hypothalamic slices. Ghrelin treatment caused hyperpolarisation, an increase 
in GABA secretion and a reduction in POMC neurone activation, resulting in 
a reduction in anorexigenic signalling. Even in the absence of GABA 
receptor, ghrelin treatment caused the hyperpolarisation of POMC neurones 
suggesting that this was causing the secretion of another factor, in all 
probability NPY. This work displayed ghrelin’s ability to induce 
neurotransmitter and orexigenic peptide release to control energy 
homeostasis (Cowley et al., 2003). The following year Howard Chen also 
found that NPY and AGRP mediated the orexigenic effects of ghrelin. 
AGRP/NPY double knockout (KO) mice were used to show that ghrelin 
treatment did not affect food intake, compared to wild type controls where 
ghrelin increased food intake by more than 100%. This work supports the 
knowledge that ghrelin’s orexigenic action requires NPY and AGRP (H. Y. 
Chen et al., 2004). 
Ghrelin works in conjunction with another hormone, leptin. Where 
ghrelin induces orexigenic effects, leptin inhibits appetite by increasing 
anorexigenic peptide signalling and causing weight loss by decreasing 
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appetite and the storage of fats (Farooqi et al., 2001; Licinio et al., 2004). 
Leptin is produced in adipose tissue, travels through the blood stream and 
can cross the blood-brain barrier (BBB), where in the hypothalamus, it 
mediates the effects of anorexigenic peptides such as POMC, brain-derived 
neurotrophic factor (BDNF), and cocaine-and amphetamine-regulated 
hormone (CART) and supresses the activity of  NPY/AGRP hypothalamic 
neurones (Klok, Jakobsdottir, & Drent, 2007). 
A recently identified circulating antagonist to ghrelin’s action is liver-
expressed antimicrobial peptide 2 (LEAP2). This is also expressed in GI 
organs and the liver, and its release is inhibited by fasting. LEAP2 
antagonises ghrelin action by binding directly to the ghrelin receptor and 
preventing its activation by ghrelin. Therefore, it prevents ghrelin induced 
food intake, GH release and the maintenance of stable glucose levels during 
calorie restriction (Ge et al., 2017). 
Asprosin is another orexigenic hormone that is expressed in adipose 
tissue and upon fasting stimulates the release of glucose from the liver 
(Romere et al., 2016). In a similar way to ghrelin, it can cross the BBB to act 
on the hypothalamus and elicit a feeding response. It activates AgRP+ 
neurones to stimulate appetite and inhibit anorexigenic POMC+ neurones 
(Duerrschmid et al., 2017). 
The synergy between ghrelin and the recently identified LEAP2 and 
asprosin, particularly within the CNS, have yet to be elucidated. 
1.1.3 Lessons from Ghrelin KO mice 
The extra-hypothalamic actions of ghrelin can be begun to be 
understood through the use of ghrelin KO mouse models. Ghrelin KO mice 
have shown decreases in dendritic spine length and synapse formation. 
Another finding from the work performed by Sabrina Diano was that ghrelin 
induced long-term potentiation (LTP) in the hippocampus, this in tandem 
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with the increase in synapse formation is important for spatial learning and 
memory. Following ghrelin replacement in these mice, neurone spine length 
and density was increased to WT levels and showed a significant 
improvement in memory based behavioural tasks, including the T-maze foot 
shock avoidance test and the novel object recognition (NOR) test to measure 
hippocampal memory. Furthermore, mice that exhibit an Alzheimer’s-like 
disease phenotype (SAMP8 mice) showed improvements in memory 
retention following peripheral treatment with ghrelin (Diano et al., 2006). In 
another study, the lab of Seungjoon Park showed with the use of ghrelin KO 
(GKO) mice that ghrelin was responsible for the stimulation of adult 
hippocampal neurogenesis (AHN). 8-9 week old C57BL/6 GKO male mice 
and age-matched wild type controls were treated with saline or ghrelin 
peptide (80µg/kg, i.p.) once a day for 8 days.  Mice were also administered 
BrdU (50mg/kg) twice a day for the final 3 days of ghrelin injections. 
Immunohistochemical analysis demonstrated that GKO+saline mice had 
decreases in progenitor cells, proliferating cells, new-born immature and 
mature neurones, which were all rescued to WT levels with ghrelin 
treatment. Also, these GKO mice exhibited memory deficits in a Y-maze 
novel object recognition test, which is hippocampal dependant memory (Li, 
Kim, Kim, & Park, 2013). 
The KO of ghrelin receptor, GHSR1a, has also demonstrated similar 
findings with regards to memory function. In a study at the lab of Roy Smith, 
C57BL/6 ghsr KO mice and wild type controls were behaviourally assessed. 
In rota-rod testing, which measures balance and motor co-ordination by 
placing mice on a rotating rod, and a hot-plate test, where mice were placed 
on an hot-plate and their nociceptive response to pain was measured, there 
was no difference between WT and KO’s. Also, KO’s showed increased 
anxiety-like behaviour in the open field test, where locomotor behaviour of 
the mice was observed by placing them in the centre of an acrylic chamber 
and measuring their activity in the first 5 minutes, by moving from the centre 
in significantly less time than WT mice. The KO mice also exhibited 
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impairments in contextual fear conditioning (foot shock and freezing time 
assessed), where KO mice showed significantly less freezing time compared 
to WT, 30 days following the initial foot-shock, indicating this memory 
impairment (Albarran-Zeckler, Brantley, & Smith, 2012). 
These data suggest that ghrelin or synthetic analogues could potentially 
be used as a therapy in neurodegenerative disorders associated with 
cognitive decline.  
 
1.2 The Role of G-Protein Coupled Receptors (GPCR’s) 
GPCR’s are the most abundant cell surface receptors that convey 
extracellular signals across cell membranes, which is sub-divided into 4 sub-
families based on their properties; rhodopsin-like A, secretin-like B, frizzled 
receptors and glutamate/metabopric C receptors (Jastrzebska, 2013). They 
typically consist of 7 transmembrane (TM) domains connected by varying 
length intracellular and extracellular loops (ECL). They have conserved 
elements such as disulphide bonds between ECL2 and TMIII, D[E]RY motif 
atop of TMIII and the NPxxY motif in TMVII. These highly diverse GPCR’s 
interact with a small quantity of heterotrimeric G proteins. These molecular 
switches consist of 3 subunits (α, β and γ) with a nucleotide binding pocket 
within the α-subunit where the conversion of GDP to GTP occurs, causing 
conformational changes and the G-protein to dissociate from the GPCR, 
allowing downstream signalling to happen (Jastrzebska, 2013; Katrich, 
Cherezov, & Stevens, 2013). GPCR’s can function as monomers; they have 
been shown to homo- and hetero-dimerise/oligomerise.  This dimerization 
allows for alteration and efficiency of signal transduction, and allow for more 
control of physiological functions (Milligan, 2007).  
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1.2.1 Ghrelin Receptor 
Ghrelin has two GPCR’s, the main functioning receptor, growth 
hormone secretagogue receptor 1a (GHSR1a) and a truncated splice-variant 
form of the receptor, GHSR1b. GHSR1a was first characterised before the 
discovery of its endogenous ligand, ghrelin. GHSR was established as a 
receptor that controlled GH release in the pituitary and hypothalamus 
(Howard et al., 1996). The functionally active GHSR1a is predominantly 
expressed in the anterior lobe of the pituitary gland and in the arcuate 
nucleus of the hypothalamus, an area important for ghrelin’s orexigenic 
activity (Camiña, 2006). It is through GHSR1a that ghrelin mediates its effects 
on energy homeostasis. GHSR1a is expressed on NPY/AGRP expressing 
neurones in the arcuate nucleus which promote food intake (Willesen, 
Kristensen, & Rømer, 1999).  
GHSR1b, the truncated form of the receptor that only has 5TM’s, has been 
shown to hetero-dimerise with GHSR1a, causing conformational changes 
that prevent GHSR1a activation by ghrelin binding (Leung et al., 2007). In 
vitro (HEK-293 cells) GHSR1a forms homo-dimers, but when GHSR1b 
mRNA expression exceeds GHSR1a mRNA expression analysed by 
quantitative real-time RT-PCR, it reduced the cell surface expression of the 
functionally active receptor, thus having a dominant-negative effect. The 
absence of TM6 and TM7 in GHSR1b may affect ghrelin’s ability to recognise 
the receptor due to an altered binding pocket, or are required for direct 
interaction (Leung et al., 2007; Mary et al., 2013). GHSR1b also has been 
shown to modulate GHSR1a in striatal and hippocampal neurone cell 
cultures, and with HEK-293T cells. These were used to show that low levels 
of GHSR1b expression with GHSR1a promotes GHSR1a trafficking to the 
plasma membrane, whereas higher GHSR1b expression prevented GHSR1a 
function. Also, in these striatal and hippocampal neurone cultures GHSR1a-
GHSR1b heteromers interacted with dopamine-1 receptor (D1R) allowing for 
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Gs/olf  (G-proteins Gαs/Gαolf) protein-dependant ghrelin signalling 
(Navarro et al., 2016). 
 
1.3 Calorie Restriction 
The beneficial effects of calorie restriction (CR) are conserved across 
species. CR has been shown to increase life-span 2- to 3-fold in yeast, worms 
and flies, and increase life expectancy in mice by 30-50%. A similar trend has 
been reported in monkeys, but the effect in humans has yet to be determined, 
however it does aid in the prevention of diabetes, obesity and hypertension 
and reduces the risk of cancer and heart disease (Fontana, Partridge, & 
Longo, 2010). In another study CR has led to the decline in loss of memory 
and learning function and other age-associated deficiencies in humans 
(Witte, Fobker, Gellner, Knecht, & Floel, 2009). Further studies in rhesus 
monkeys have shown that CR can reduce the prevalence of age-related 
deaths when the regime is introduced at early age or in later adult life 
(Colman et al., 2014; Mattison et al., 2017). Also, in mouse models of ageing 
and neurodegenerative disease, restricting diet has had beneficial effects on 
protecting the loss of hippocampal, cortical and striatal neurones by 
increasing the production of BDNF (W Duan, Lee, Guo, & Mattson, 2001).  A 
better understanding of CR physiology could help develop CR mimetics for 
the treatment of age-related disorders. 
1.3.1 CR and Ageing 
With an increasingly aged population and an increase in the incidence 
in dementia and neurodegenerative disorders, CR has been shown to reduce 
the effects of ageing on the production of new neuronal progenitor cells. A 
study in Nestin-GFP reporter mice (6 months old) showed that increased 
exposure to a CR regime; 1 week of 80% of ad-libitum fed mouse consumption 
then 60% of ad-libitum fed for 12 months (n = 12), resulted in an increase in 
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dividing cells in the DG of the hippocampus. Mice were injected with the S-
phase markers, CldU (5-chloro-2’-deoxyuridine, 128mg/kg) 24 hours prior 
and IdU (5-iodo-2’-deoxyuridine, 173mg/kg), 2 hours prior to terminal 
anaesthesia. Immunohistochemical analysis of Nestin-GFP+CldU+ and 
Nestin-GFP+IdU+ cells in the SGZ of the DG showed a 2-fold increase, and 5-
fold increase, respectively, of new-born neural progenitor cells, in aging mice 
that underwent 12 months CR compared to ad-libitum fed controls. However, 
analysis of immature neuronal cells (DCX+) did not show the same response, 
suggesting that CR increases the proliferative capacity of progenitor cells (J.-
H. Park et al., 2013). Prolonged CR has also been shown to illicit 
improvements in memory function. A study performed by Angela Kuhla 
showed that C57BL/6 mice (4-week old) that underwent 4 (n = 10), 20 (n = 
10) and 74 weeks (n = 10) of CR feeding (60% of food consumed by ad-libitum 
fed controls) had improvements in working memory, tested using the morris 
water maze (MWM). MWM specifically tests for spatial learning, which is 
hippocampal specific, where mice have to locate a submerged platform in 
opaque water. Ad-libitum fed mice showed an age-related decrease in their 
performance in the task, whereas those that underwent long-term CR (74 
weeks) had improved performance scores (an increase in platform crossings). 
A separate group of mice that were introduced to a CR regime later on, at 66 
weeks old for 12 weeks (n = 10), did not demonstrate the same effect. This 
indicates that life-long CR is required for improved memory function with 
increased age (Kuhla et al., 2013). 
1.3.2 CR and Ghrelin 
CR is thought to mediate its beneficial effects on the brain via 
hippocampal plasticity and neurogenesis, and one possible mediator is 
ghrelin (Zane B Andrews, 2011). Ghrelin regulates aspects of hippocampal 
neurogenesis; ghrelin (80µg/kg for 8 days) administered to male 8-week old 
adult mice via intra-peritoneal injection, and the effects on neural progenitor 
cell differentiation and proliferation were quantified within the dentate 
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gyrus (DG) of the hippocampus. Ghrelin significantly increased the number 
of new-born cells and immature neurones in the sub-granular zone (SGZ) of 
the DG following treatment. This suggests that administration of ghrelin 
increases cell proliferation, and could potentially be used therapeutically for 
disorders involving learning and memory (Moon, Kim, Hwang, & Park, 
2009). Much work on ghrelin regulation of adult hippocampal neurogenesis 
(AHN) has been done in the lab of Seungjoon Park.  Using ghrelin KO mice 
they found that genetic ablation of ghrelin caused a reduction in progenitor 
cell proliferation in the SGZ which was restored to wild-type levels upon 
ghrelin treatment. These KO animals also had deficits in hippocampal 
dependent memory tasks (Y-maze and NOR test), which were reversed upon 
ghrelin treatment (50 µg/kg/day, for 28 days) (Li, Chung, et al., 2013). As 
restriction of diet has been shown to positively modulate new adult-born cell 
survival (Jaewon Lee, Seroogy, & Mattson, 2002; H. R. Park & Lee, 2011), the 
S. Park group provided a link between CR, ghrelin and AHN. Again, using 
ghrelin KO mice and wild type (WT) littermates (male 8-10 week old) that 
were CR’ed (every other day fed, 24 hour fast followed by 24 hour fed) or ad 
libitum fed for 3 months. They reported that stomach and hippocampal levels 
of ghrelin were increased in WT mice that underwent CR, and that survival 
of new adult-born cells was enhanced in WT CR’ed mice, which was not 
observed in ghrelin KO’s (Kim et al., 2015). 
 
1.4 Adult Neurogenesis 
Adult neurogenesis is the process by which new neurones are produced 
in the adult brain and was first recognised in rats by Joseph Altman in 1965. 
Using autoradiographs and histological analysis of rats that had been 
administered intraperitoneal (i.p.) injections of thymidine-H3 to label 
dividing cells, they found labelled cells in the basal granule cell layer (GCL) 
of the dentate gyrus (DG) as shown in Figure 1.3. In this study they 
examined multiple brains of male rats ranging from 6 hours to 9 months of 
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age, where they discovered a decrease in the number of labelled cells with 
increasing age of the animals. The higher cell numbers in younger rats was 
attributed to a higher rate of cell proliferation which declined with age, but 
did not cease (Altman & Das, 1965). To examine this further, in 1977 Michael 
Kaplan and James Hinds performed a study to identify neurogenesis in the 
DG of the adult rat. They used injections of thymidine-H3 in 3 month old rats 
that lived for 30 days following injection, and used electron microscopy to 
identify neurones and labelled granule cells in the DG and olfactory bulb 
(OB). Contesting the notion that the adult brain remains static in adulthood 
(Kaplan & Hinds, 1977). Studies have also used the thymidine analogue 5-
bromodeoxyuridine (BrdU) that incorporates into the DNA of dividing cells 
in the S-phase of the cell cycle (del Rio & Soriano, 1989). 
 
Figure 1.3. Autoradiographs of the dentate gyrus depicting thymidine-H3 cells in rats. 
 10 day old rat injected with thymidine-H3 and sacrificed 2 months following the last injection. Granule 
cells are labelled in the DG (A) and most notably in the basal GCL (B). A = 100x; A = 256x. Image taken 
from (Altman & Das, 1965). 
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This technique has allowed for the advancement of AHN analysis, 
due to the ability to use confocal microscopy and immunofluorescent 
detection.  A study from the lab of Fred Gage looked at the human brains 
ability generate new neuronal cells through life, and they achieved this by 
using the post-mortem hippocampal brain tissue of cancer patients ( n = 5, 
aged 57 - 72) who had been administered one dose of BrdU (250mg; 
2.5mg/ml, 100ml) as part of their treatment. Immunohistochemical analysis 
revealed BrdU+ cells in the human DG (compared to a non-BrdU treated 
cancer control), the same neurogenic area seen in adult mice and rats. 
Double-fluorescent labelling revealed that these new-born cells also 
expressed mature neuronal marker NeuN, confirming neurogenesis 
(Eriksson et al., 1998).  More recently, carbon-14 dating has been used to 
birth-date new neurones in the adult human brain. Due to nuclear weapons 
testing in the 1950’s and 1960’s the levels of atmospheric carbon-14 were 
greatly increased. Following the ban of above-ground nuclear testing in 1963, 
carbon-14 levels have decreased. In this work from Jonas Frisen’s lab, tissue 
samples from individuals born before and after the nuclear bomb tests 
showed that new neurones are produced in the adult human striatum and 
hippocampus, at the same rates seen in rodents (Ernst et al., 2014; Spalding et 
al., 2013; Spalding, Bhardwaj, Buchholz, Druid, & Frisén, 2005).  
1.4.1 Adult Hippocampal Neurogenesis 
AHN occurs in 2 distinct regions in the adult mammalian brain, the 
sub-ventricular zone (SVZ) of the lateral ventricles where new-born neurones 
migrate along the rostral migratory stream and integrate into the OB, and the 
SGZ of the DG where new-born neurones migrate across the GCL and 
integrate into existing hippocampal circuitry (Figure 1.4). The hippocampus 
is important for episodic memory, which involves the capacity to learn, store 
and recollect information (Dickerson & Eichenbaum, 2010). The SGZ of the 
DG is highly neurogenic mainly due to the two types of neural progenitor 
cells being in such close proximity to the granule cells (GCs) in the DG, 
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which consists of both immature and mature neurones. There are many other 
cell types in this unique microenvironment, such as astrocytes, that may help 
promote the differentiation and integration of new-born cells into the 
neuronal circuitry (Zhao, Deng, & Gage, 2008a). There are 4 phases of AHN; 
precursor cell phase, early survival, post-mitotic maturation and late survival 
(Kempermann, Jessberger, Steiner, & Kronenberg, 2004; Steiner et al., 2006). 
During these phases the developing cells express different protein markers 
and have different morphologies. In the precursor cell stage the progenitor 
cells have a radial glial-like morphology and express markers such as Nestin 
and GFAP, and are classified as type 1 neural stem/progenitor cells (NSPCs). 
Through expansion and survival these cells then become less glial-like and 
express markers such as Sox2, type 2 NSPCs. Following post-mitotic 
maturation these early mature cells begin to extend axons and dendrites, and 
express the marker for immature neurones, doublecortin (DCX). After the 
late survival and maturation stages, these cells have become mature dentate 
granule neurones whose axons extend out to the CA3 and dendrites into the 
molecular layer, and express the protein marker NeuN (Hanson, Owens, & 
Nemeroff, 2011; Kempermann, Song, & Gage, 2015).  
The mechanisms in which new adult born mature neurones are 
incorporated into the existing neuronal network are recently better 
understood. Tassilo Jungenitz found that at the mature stage of new adult-
born granule cell development (21 days onwards), these cells became 
synaptically integrated, and used markers of synaptic activity and plasticity, 
immediate-early genes (IEGs) that code for transcription factors e.g. c-Fos 
and Arc, and DCX expression to decipher this. 8-13 week old Sprague 
Dawley rats were administered a 2 hour high frequency stimulation (HFS) to 
induce LTP, which resulted in an increase of both c-Fos+ and Arc+ expression 
in calbindin+ mature granule cells in the DG. They also showed that 
immature DCX+ cells do not express c-Fos or Arc, but mature DCX- cells are 
c-Fos+. Following injection of BrdU (200mg/kg) and 2-hour HFS, BrdU+ cells 
that also expressed c-Fos and Arc were observed initially at 21 days post-
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injection, and increased with advancing cell age, reaching 75% at 35 days 
post-injection. The same pattern was observed when cells were analysed for 
Egr-1 expression. These data indicate that as new adult-born dentate granule 
cells mature they become more synaptically active (Jungenitz, Radic, 
Jedlicka, & Schwarzacher, 2013). The IEG Egr-1, also known as zif268, is also 
involved in the integration of new-born neurones. In a study by Alexandra 
Veyrac, zif268-KO mice exhibited increased cell death of new adult-born 
neurones 2-3 weeks after their birth, defects in dendrite and dendritic spine 
development, and disruption in the recruitment of new adult-born neurones 
following spatial learning and memory tasks, resulting in impaired long-
term memory (Veyrac et al., 2013). 
Interestingly, it has been shown that ghrelin treatment induces c-Fos 
and Egr-1 expression in the arcuate nucleus of fasted and normally fed rats. 
Male Wistar rats were administered saline (0.2ml, n= 12), ghrelin (10µg, n 
=14) or unacylated ghrelin (10µg, n = 12) via jugular vein catheter injection, 
where half of each group were also fasted for 48 hours prior to treatment, 
and killed 90 minutes later. Immunohistochemical analysis revealed that 
ghrelin treatment in both fasting and normally fed groups resulted in an 
increase the number of c-Fos+ and Egr-1+ cells in the arcuate nucleus 
(Hewson & Dickson, 2001). 
 
Recently it has been shown that there are similarities between 
embryonic and post-natal DG neurogenesis. Single-cell RNA sequencing was 
performed in micro-dissected DG’s from mice ranging from embryonic day 
(E) 16.5 to post-natal day (P) 132. Data analysis unearthed 4 distinct groups 
of cells; immune cells such as microglia and macrophage, vascular cells such 
as endothelial cells, glial cells, and neuronal cells, with dentate granule cells 
being the predominant cell type (immature granule cells, radial glial-like 
cells (RGL) and mature granule cells). The types of cells did not change over 
time, but the quantity of each cell type differed and their position in the DG. 
RGL’s of the DG seemed to be mostly quiescent during development, but 
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after development they entered the cell-cycle and become neuronal 
intermediate progenitor cells (nIPC’s) and commit to a neuronal lineage. This 
process was conserved from E16.5 to P132 (Hochgerner, Zeisel, Lönnerberg, 
& Linnarsson, 2018). 
 
 
Figure 1.4 Process of Neurogenesis in the Dentate Gyrus. 
Type 1 (radial glial-like) and type 2 (non-radial) progenitor cells, progress through the process of 
neuronal development which takes approximately 2 months, from the SGZ and up through the GCL 
before integrating into existing circuits. Image taken from Zhao et al. 2008 with annotation. 
1.4.2 Regulation of AHN 
AHN is enhanced by exercise and enriched-environments. Exercise 
increases the rate of proliferation of precursor cells in the SGZ of the DG and 
enriched-environments promote their survival (Fabel et al., 2009). Enriched 
environments involved stimulation from innate objects in combination with 
social stimulation (Kempermann, Kuhn, & Gage, 1997). In a study performed 
in the laboratory of Gerd Kempermann, it was shown by co-labelling new 
cells with the thymidine analogue BrdU and the mature neurone marker 
NeuN, that voluntary wheel running alone increased the number of new 
neurones in murine hippocampi. Moreover, exposure to an enriched 
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environment increased their survival. With the combination of both exercise 
and environmental enrichment, there was a significant increase in the 
amount BrdU/NeuN expressing cells in the DG, therefore an increase in 
neurogenesis. It was concluded that physical activity elicits a greater 
neurogenic response only in conjunction with cognitive stimuli such as an 
enriched environment (Fabel et al., 2009). Notably, exercise and enriched 
environment also reduced the formation of amyloid-β plaques, reinstated 
neurogenesis and improved cognition in transgenic mouse models of 
Alzheimer’s Disease (Mu & Gage, 2011).  
Neurogenesis is also affected by anti-depressants. Anti-depressants 
have been shown to increase hippocampal neurogenesis in human cells and 
mammals (Taupin, 2006). The anti-depressant Sertraline was incubated with 
human hippocampal progenitor cells in-vitro for 72 hours during their 
proliferation phase and for the following 7 days of differentiation. Sertraline 
increased the number of MAP-2 positive neurones by 28%, but had no effect 
on immature DCX positive neuroblasts. When these cells were only treated 
in the proliferation phase to see if treatment induced differentiation, it was 
shown to have no effect on MAP-2 positive neurones but increased the 
number the DCX positive immature neuronal cells. When cells were only 
treated in the differentiation phase, no effect was seen on either cell type. 
These findings indicated that tricyclic and selective serotonin reuptake 
inhibitor anti-depressants induced differentiation in proliferating cells. In 
addition, BrdU labelled cells, following 72 hours of treatment with Sertraline 
in the progenitor cell phase, revealed a reduction in the number of BrdU-
positive cells, supporting the idea that progenitor cells cease proliferation 
and begin developing into neurones (Anacker et al., 2011). Another study 
performed by Luca Santarelli also demonstrated the positive effect of anti-
depressants, in this case Fluoxetine, on AHN. Adult mice (n = 7-10) were 
treated with fluoxetine or vehicle for 5, 11 or 28 days and administered BrdU 
(75mg/kg x4) on the last day of treatment, before being killed the following 
day. This resulted in a 60% increase in BrdU+ cells in the DG after both 11 
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and 28 days of anti-depressant treatment and a decreased latency to feeding 
in the novelty-supressed feeding test, compared to vehicle control. This effect 
was lost following low dose X-ray treatment (5 Gy on days 1, 4 and 8) to the 
SGZ of the DG, resulting in an 85% decrease in the BrdU+ cells specific to the 
SGZ, which were not protected by chronic fluoxetine treatment (28 days, 
BrdU administered on day 27). The irradiated mice also showed no change in 
latency to feeding following fluoxetine treatment, compared to non-
irradiated controls. These data suggest that fluoxetine action requires AHN 
to elicit its behavioural effects (Santarelli et al., 2003). 
1.4.3 Role of AHN in Hippocampal-dependent Learning and Memory 
A relationship between neurogenesis and hippocampal-dependent 
learning and memory has been shown in a study by Sandrine Thuret, using 
MRL/MpJ mice that have reduced levels of adult neurogenesis and age-
matched C57BL/6 control mice (10 week old, n = 10 per group). In order to 
examine neurogenesis in these mice, BrdU was administered (50µg/g) daily 
for 6 days, with analysis taking place 24 hours and 4 weeks after the last 
injection. Immunohistochemical analysis in the DG showed that MRL/MpJ 
mice had 60% fewer BrdU+ cells than C57BL/6 controls 24 hours after the last 
BrdU injection; interestingly this difference was not seen in the SVZ. At 4 
weeks post final BrdU injection, MRL/MpJ mice had 75% fewer BrdU+ cells 
compared to controls and that 80% of those surviving cells in the DG also 
expressed the mature neuron marker, NeuN. Therefore, MRL/MpJ mice 
produce 75% fewer neurones in the DG compared to C57BL/6 mice. Spatial 
memory was tested via the MWM. Testing was divided into blocks 
consisting of 4 separate trials; the first block of 4 trials was performed with a 
visible stage. The following 12 blocks were performed with the platform 
hidden. The platform was then removed 24 hours after the last block of trials 
and in the actual test period that followed, the time spent in the platform 
area was measured. The MRL/MpJ mice spent less time in the platform area 
compared to C57BL/6 controls, indicating that spatial memory was 
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impaired. Recognition memory was also tested with the visual-paired 
comparison task, where exploration time of a novel object was monitored. 
MRL/MpJ mice spent 50% less time exploring a novel objection, 24 hours 
after exploring 2 similar objects, whereas C57BL/6 controls spent most of 
their time exploring the novel object. These results indicating that 
hippocampal neurogenesis is associated with learning and memory function 
(Thuret, Toni, Aigner, Yeo, & Gage, 2009). AHN has also been shown to 
conserve hippocampal memory function by the modulation of LTP. Analysis 
in Wistar ST rats showed that when the hippocampal LTP network was 
artificially saturated, rats demonstrated impaired memory function in 
response to contextual fear conditioning (CFC, using foot-shock to induce 
hippocampal-dependent fear memory). With the decay of LTP, 
improvements in the capacity of memory function were observed. Also, 
neurogenesis was ablated by x-ray irradiation and resulted in a delay in 
memory capacity recovery, as these rats displayed lower freezing times in 
the CFC task and lower rate of neurogenesis (fewer BrdU+NeuN+ cells in the 
DG). In contrast, irradiated rats analysed in a voluntary wheel exercise, 
which was used to boost neurogenesis, showed an increased rate of LTP 
saturation decay and recovery in memory function when subjected to CFC. 
These results show a maintenance function of AHN on hippocampal-
dependent memory (Alam et al., 2018). In humans, AHN has been shown to 
reduce the interference in memories when taking part in a pattern separation 
task following aerobic exercise. Healthy young adults (n = 13, BMI ≤ 25) that 
led sedentary lifestyles participated in a 6-week course of high intensity 
interval training to improve aerobic fitness. Following this 6-week period, 
participants underwent cognitive testing. Those who responded to the 
exercise regime (8% increase in peak oxygen uptake) underwent visual 
neurogenesis-dependent pattern separation testing, where participants were 
shown 88 images of everyday objects, of which 16 were repeated images, 16 
were similar (lures) and 24 were not related (foils). Participants were shown 
these images at random (2500ms each). After a delay a second set of 112 
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images was presented (48 repeated, 48 lures and 16 foils). The ability to 
distinguish between similar lures was increased in these responders by 12%, 
compared to testing before the exercise regime. Participants that did not 
respond to exercise did not show any increase in performance (Déry et al., 
2013). 
 In terms of the causative effects of AHN on cognitive function, this 
has been demonstrated by Amar Sahay. By increasing AHN, they showed a 
significant improvement in pattern separation memory. The increase in new-
born neurones was achieved by the genetic knockdown of the pro-apoptotic 
gene Bax in mice, which resulted in increased new-born neurone survival. 
Mice with this augmented AHN demonstrated enhanced performance in 
pattern separation tasks (Sahay et al., 2011). Conversely, AHN ablation  in 
mice by focal x-irradiation, which resulted in a significant decrease in the 
immature neuronal cell pool, showed a pronounced decrease in the ability of 
mice to discern between stimuli with low spatial separation in a pattern 
separation task (Clelland et al., 2009). 
1.5 Cognitive Decline and Ageing 
Cognitive decline is part of the normal ageing process, and comes with 
increased societal, monetary and personal burdens. It has been shown across 
species that ageing elicits changes in memory processes. Episodic and spatial 
memory declines with age, making it more difficult to navigate 
environments (Leal & Yassa, 2015). The ability to distinguish similar contexts 
is also reduced, with older adults showing reduced efficiency in pattern 
separation tasks (Holden, Hoebel, Loftis, & Gilbert, 2012). Synaptic inputs 
into the DG and CA3 decline, indicating lesser synaptic activity (Leal & 
Yassa, 2015).  Structural changes also occur in the brain due to ageing, 
including a reduction in grey matter and white matter volume caused by 
neuronal death and diminishing the communication between hippocampal 
structures. The accumulation of protein aggregates such as amyloid-β, 
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associated with Alzheimer’s disease (AD), exacerbates neuronal death in the 
brains of non-AD aged individuals (Deary et al., 2009; Harada, Love, & 
Triebel, 2013) and is thought to contribute to cognitive decline (Miller et al., 
2017). 
As we have an ever-increasing aged population, the prevalence of 
cognitive decline and neurodegenerative disorders increases. Parkinson’s 
disease (PD) is the second most prevalent neurodegenerative disorder that 
currently affects approximately 145,000 people in the UK, that’s 1 person 
diagnosed in every 350 adults (Parkinson’s UK (www.parkinsons.org.uk), 
2018). PD is characterised by the progressive loss of dopaminergic (DA) 
neurones from the substantia nigra pars compacta (SNpc) that project to the 
striatum, which are located in the mid-brain, and leads to a deterioration of 
motor function through mechanisms that are still unknown. The most 
recognisable symptoms of PD are resting tremor, slowness in movement and 
stiffness. There are pre-motor dysfunction characteristics such as weight loss, 
reduction in appetite and disruption of sleeping patterns. Due to these 
symptoms arising prior to those that involve motor function, the suggestion 
is that the initial pathogenic action may transpire outside of the nigrostriatal 
DA pathway or the pathway controls other aspects of physiology  (Bayliss & 
Andrews, 2013).  
1.5.1 Parkinson’s disease, AHN and Cognitive Decline 
In a 20 year longitudinal study, one of the largest studies performed on 
PD patients, 83% of patients that survived the study developed dementia 
(Hely, Reid, Adena, Halliday, & Morris, 2008) and most recently 25-30% of 
PD patients have dementia associated to PD (Davis & Racette, 2016; Willis et 
al., 2012). This indicates that cognitive decline and dementia in PD is an issue 
that requires more research. 
The loss of dopaminergic neurones, which is characteristic of PD, impairs 
proliferation of precursor cells in the SGZ of the DG in human PD post-
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mortem brains. Dopamine innervation and denervation was showed to affect 
cell proliferation in the DG. MPTP-treated C57BL/6 mice, which induces 
SGZ dopaminergic fiber (DAT) loss, were also administered BrdU (8x 50 
mg/kg every 6 hours). Immunofluorescent staining revealed that new-born 
cells express DAT, and that the number of PCNA+ precursor cells in the DG 
were significantly reduced in MPTP-treated mice compared to controls, 
which was reversed 70 days following MPTP administration. 
Immunohistochemical analysis of adult human DGs revealed that compared 
to controls (n = 3), PD (n = 3) and PD with cognitive impairment (n = 5) 
brains showed significantly reduced numbers of Nestin+ and β-III-tubulin+ 
cells, indicating reduced levels of precursor cell proliferation in the DG. 
These data indicate that reduced AHN in the PD brain may lead to cognitive 
decline (Höglinger et al., 2004). 
Cognitive deficits in PD have been associated with impairments in AHN. 
A study performed by Keith Wesnes and David Burn showed that PD 
patients had a significant decrease in object pattern separation performance, 
a task specific for the hippocampus and DG neurogenesis. A cohort of 72 PD 
patients (27 female and 45 male, mean age of 70.1) took part in the study as 
well as 62 age and gender matched controls. The object pattern separation 
task involved the presentation of 20 images of everyday objects (1 shown 
every 3 seconds) with a 12 minute interval followed by presentation of 20 
novel images mixed with the original set that were very similar. Participants 
were required to press either a YES or NO button with regards to whether 
the image was a novel or an original image. PD patients showed no 
difference to controls in recognising the original images, but showed a 
significant decrease (p = 0.0001) in the ability to discern between the highly 
similar images, which is indicative of impaired DG function and potentially 
neurogenesis (Wesnes & Burn, 2014).  
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1.5.2 Parkinson’s disease and Ghrelin 
Ghrelin has been shown to have a neuroprotective effect in mouse models 
of PD (Jiang, Li, Wang, & Xie, 2008).  Andrews et al. 2009 showed that GHS-R 
was present in the SNpc and that administration of ghrelin increased both 
dopaminergic neurone firing in this region and the number of mitochondria 
in these cells. PD-like symptoms were induced in mice with 1-methly-4-
phenyl-1,2,5,6 tetrahydropyridine (MPTP) leading to dopaminergic neurone 
loss. However, ghrelin pre-treatment resulted in a marked decrease in 
dopaminergic neurone loss in the SNpc of these mice. As ghrelin has shown 
to exhibit a neuroprotective effect in rodent models of PD, serum total 
ghrelin levels were measured in human PD patients after fasting and 
postprandially. PD patients (n = 39, aged 62-73) had a slower recovery in 
ghrelin levels compared to a control group (n = 20, aged 55-63). As PD 
patients often have impaired gastric motility, there may also be a disruption 
in the secretion of ghrelin that may increase the incidence of dopaminergic 
neurone damage. These pre-clinical and clinical data suggest that ghrelin 
may represent a possible biomarker for PD (M. M. Unger et al., 2011). Further 
work is needed to validate these findings in humans. 
 
1.6 Aims and Hypothesis 
As discussed, several published studies have demonstrated the 
beneficial effects of CR on hippocampal function. Work from the lab of Mark 
Mattson showed that dietary restriction, in the form of alternate day feeding, 
promoted survival of new adult born cells in the mouse DG and increases the 
level of the neurotrophic factor, BDNF (W Duan et al., 2001; Jaewon Lee et 
al., 2002). Also, CR has been shown to elicit improvements in age-related 
cognitive decline in a mouse model of Alzheimer’s disease, with longer-term 
CR inducing positive effects on behaviour impairments in aged 3xTgAD 
mice. CR was shown to improve exploratory behaviour in these mice by 
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showing greater distance travelled in an open field test compared to controls, 
as well as having reduced levels of amyloid-beta and phosphorylated-tau 
proteins (Halagappa et al., 2007).  
Ghrelin has been shown to enhance cognitive performance by crossing 
the blood-brain-barrier and improving the density of synapses formed in the 
hippocampus. This in turn enhanced spatial learning and memory in mice 
administered ghrelin or ghrelin mimetic, and rescued memory impairments 
observed in ghrelin knocked-out mice (Diano et al., 2006). Similarly, ghrelin 
improved long-term memory function in rats when administered directly to 
the hippocampus prior to behavioural testing  (Carlini, Ghersi, Schiöth, & de 
Barioglio, 2010). Ghrelin agonists have also been shown to illicit positive 
effects on cognitive function in models of Alzheimer’s disease. A study 
examining the effect of the ghrelin agonist, LY444711,  on the TgAPPSwDI 
mouse model showed that it induced spatial memory improvements in a 
water maze task and also resulted in a reduction in amyloid-beta and 
inflammation markers (Dhurandhar, Allison, van Groen, & Kadish, 2013). 
Similar findings were also demonstrated in a further study using the 
LY44471 compound and  TgAPPSwDI mouse model (Kunath et al., 2015). 
Little is known about the function of un-acylated ghrelin, even though 
it makes up approximately 90% of circulating ghrelin (Nishi, Yoh, Hiejima, & 
Kojima, 2011b). However, UAG has an antagonistic effect compared to 
acylated ghrelin in downregulating gluconeogenesis in hepatocytes (Gauna 
et al., 2005) and reducing the insulin secretion response in humans (Broglio 
et al., 2004). Whilst it appears to have no effect on LTP and synaptic plasticity 
compared to acylated ghrelin (L. Chen et al., 2011), it is not known whether 
UAG regulates AHN.  
The non-motor symptoms of PD could be attributed to a dysfunction in 
the ghrelin system and evidence has shown that PD patients display several 
symptoms that would make the investigation of blood plasma, for a potential 
biomarker, worthy. Along with motor dysfunction in PD, patients experience 
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gastrointestinal dysfunction and impaired gastric motility (Pfeiffer, 2003; M. 
M. Unger et al., 2010). They also experience weight loss (Fiszer et al., 2010; 
Lorefält, Toss, & Granérus, 2009) and loss in appetite (Aiello, Eleopra, & 
Rumiati, 2015). A recent study has also shown that ghrelin’s response to 
feeding is attenuated in PD patients (N. Song et al., 2017), although those that 
exhibited cognitive impairments were not included. It would be useful for 
diagnostic purposes to determine whether PD patients that exhibit cognitive 
impairments also have an attenuated ghrelin response. 
Whilst these studies clearly demonstrate the beneficial effects of CR and 
ghrelin on hippocampal function, it is not known whether these paradigms 
modulate AHN. Indeed, little is known about the expression of important 
ghrelin-axis proteins in the neurogenic niche of the hippocampus. Similarly, 
little is known about the role of unacylated-ghrelin – the so-called inactive 
form of the peptide – in regulating hippocampal learning and AHN.  
This thesis will test the hypothesis that ghrelin increases AHN and 
mediates a pro-neurogenic effect of CR on AHN and cognitive function. It 
will also examine whether ghrelin may be used as a potential biomarker of 
cognitive decline or dementia in humans. 
 
The aims of this thesis are to: 
1. Elucidate the expression pattern of key ghrelin-axis proteins in extra-
hypothalamic brain regions associated with learning and memory, 
including the neurogenic niche of the hippocampus. 
2. Determine whether CR enhances AHN and memory in a GHSR-
dependent manner. 
3. Determine whether UAG and GOAT modulate AHN. 
4. Determine whether circulating levels of key ghrelin-axis proteins 
represent biomarkers of cognitive decline and dementia in humans 
diagnosed with PD. 
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Chapter 2 General Methods 
 
2.1 Tissue preparation 
Mouse brain tissue was collected and underwent intra-cardial fixation 
with 4% paraformaldehyde (PFA) (Sigma Aldrich, St Louis, USA), sunk in 
30% sucrose prior to being stored at 4C in the cold room and submerged in 
PBS (Sigma Aldrich, St Louis, USA) with 0.1% Sodium Azide (Sigma Aldrich, 
St Louis, USA), until required for analysis. 
 
2.2 Tissue Sectioning 
Mouse brain tissue were taken from cold storage and kept from 
thawing with the use of dry ice. The dry ice was crushed using a pestle and 
mortar, and the tissue placed in this. The tissue was mounted using Jungs 
Tissue Freezing Medium (Leica Biosystems) and sectioned using a Freezing-
stage Microtome (Zeiss, Microm HM 450). Coronal sections at a thickness of 
30µm were collected sequentially into 12, 24 or 96-well Nunclon plates. The 
tissue was collected using a 1:6 or 1:12 ratio, so that each well gives a 
representation of the whole rostro-caudal extent of the brain (with each 
section being 180µm or 360µm apart). The tissue sections were maintained in 
PBS+0.1% sodium azide (Sigma Aldrich, St Louis, USA) at 4°C for long-term 
storage and prevention of microbial growth. 
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2.3 Immunohistochemical staining protocols 
All immunohistochemical (IHC) protocols used within this thesis are 
published and generally used protocols of the free-floating method of IHC 
staining (Hornsby et al., 2016, 2018; Kent et al., 2015). 
 
2.3.1 Standard protocol of immunofluorescent staining for multiple 
targets. 
Mouse brain tissue sections were removed from storage plates and 
placed into 12-well Nunclon plates containing 1x PBS. Sections were washed 
3 times for 5 minutes on a rocker, at room temperature (RT). Sections were 
permeabilised with the application of methanol (Fisher Scientific, 
Loughborough, UK) to each well, and the plate placed at -20˚C for 2 minutes. 
The methanol was removed and sections were washed in 1x PBS as above. 
Following this, tissue was blocked with either 5% normal goat serum (NGS) 
in 0.1% PBS-T (1x PBS + 0.1% Triton-X) or 5% normal donkey serum (NDS) 
in 0.1% PBS-T, to prevent any non-specific binding of antibodies, for 60 
minutes at RT. The block was subsequently removed and the primary (1˚) 
antibodies diluted in 0.1% PBS-T were applied to the sections and incubated 
either for 1 hour or overnight, at RT or at 4˚C in the cold room, on a rocker. 
Following the antibody incubation, sections were washed as before, and 
fluorescent secondary (2˚) antibody diluted in 0.1% PBS-T was applied for 30 
minutes at RT; the plate protected from light from this point to prevent 
photo-bleaching. Following this, sections were washed as before in 1x PBS. 
The next 1˚ antibody diluted in 0.1% PBS-T was applied for 1 hour at RT or 
overnight at 4˚C. After this incubation, the sections were washed as before, 
and the appropriate 2˚ antibody was applied for 30 minutes at RT. 
Finally, the sections were washed as before with 1X PBS, and the 
sections were mounted on to Superfrost+ slides (VWR International) using 
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1x TBS in a glass petri dish, and cover-slipped with 50µl of Prolong Gold 
Hardset mountant (P36930, Life Technologies). Slides were left to set 
overnight at RT in a slide wallet and subsequently stored at 4˚C until 
analysed. 
 
2.3.2 Standard protocol of immunofluorescent staining for multiple 
targets requiring antigen retrieval (AR), with citrate buffer. 
As stated in the above protocol (2.3.1), brain tissue sections were 
washed with 1x PBS, permeabilised with methanol and washed a further 
time with PBS. Due to the nature of some targets they required antigen 
unmasking with the following antigen retrieval (AR) step. Sodium citrate 
buffer was applied to the sections in each well and the plate placed in an 
incubator for 60 minutes at 70˚C.  The protocol continues as 2.3.1. 
 
2.3.3 Standard protocol of immunofluorescent staining for the target 
Bromo-deoxyuridine (BrdU). 
To allow for the successful staining of the target BrdU, which is 
located within the nucleus, an alternative antigen retrieval method is 
required. The protocol starts as stated above (2.3.1) with the following 
amendments. Following the methanol step, a DNA denaturation step was 
required to allow the staining of incorporated BrdU; tissues incubated in 2M 
HCl for 30 minutes at 37°C. The HCl was removed and Sodium Borate buffer 
(pH 8.4) was applied for 10 minutes, on a rocker at RT. The sections were 
then washed with 1X PBS as described above. 
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2.3.4 Standard method of immunohistochemical staining using Nickel-
enhanced Di-amino benezidine (Ni-DAB). 
Mouse brain sections were washed twice in 1X PBS for 10 minutes each, 
followed by a 10-minute wash in 0.03% PBS-T, they were then incubated in 
1.5% Hydrogen Peroxide (H2O2) in 1X PBS for 20 minutes to quench any 
endogenous peroxidases.  Sections were again washed in 1X PBS and 0.03% 
PBS-T as described above, after which 5% NGS/NDS block in 0.03% PBS-T 
was applied to the sections and incubated for 60 minutes at RT. Sections 
were incubated in 1˚primary antibody diluted in 0.03% PBS-T and 2% 
NGS/NDS, this was left to incubate overnight at 4˚C in the cold room, on a 
rocker. Sections were washed as before and incubated in 2˚secondary 
biotinylated antibody diluted in 0.03% PBS-T and 2% NGS/NDS, was 
applied to the sections and incubated for 70 minutes at RT and also covered 
from light. Following another wash series, a premixed ABC (Avidin-biotin 
complex) solution was applied (0.4%A +0.4%B in 0.03%PBS-T, premixed for 
30 minutes before application); this was incubated for 90 minutes at RT. 
Subsequently, sections were washed 2 times in 1X PBS for 10 minutes each, 
and washed in Sodium Acetate (pH6) for 10 minutes. Tissues were reacted in 
Ni-DAB and glucose oxidase solution for between 5-10 minutes. Following 
this reaction the sections were washed 2 times in 1X PBS. 
The sections were mounted onto glass slides as described previously, 
and allowed to dry overnight. The slides were subjected to a dehydration 
and delipifying series of 70% EtOH, 95% EtOH, 2 times 100% EtOH and 2 
times Histoclear. Sections were placed into these solutions for 3 minutes 
each, after which they were cover-slipped with Entellan mounting medium 
(Cat No: 1.07960.0500, Merck Millipore, UK). 
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2.3.5 Standard method of immunohistochemical staining using Ni-DAB 
with targets that require AR with Citrate Buffer. 
This protocol is as stated in 2.3.4, with the following additional AR step. 
Following the second set of washes with 1X PBS and 0.03% PBS-T, sodium 
citrate buffer (pH6) was applied to the sections in each well and incubated 
for 60 minutes antigen retrieval at 70˚C. The excess citrate buffer is removed 
and protocol continues as described above. 
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Chapter 3 Phenotypic Characterisation of 
the ghrelin receptor (GHS-R) in the adult 
mouse brain 
 
3.1 Introduction 
 
3.1.1 Ghrelin Receptor 
Ghrelin mediates its biological effects through its receptor, growth 
hormone secretagogue receptor (GHSR). This receptor was first discovered 
by A. D. Howard in 1996, as a protein regulating growth hormone (GH) 
release (Howard et al., 1996). It is a G-protein coupled receptor consisting of 
7 transmembrane domains, GHSR1a, and a truncated version of this receptor 
consisting of only 5 transmembrane domains, GHSR1b, which has been 
shown to form heterodimers with GHSR1a and regulate its signalling ability 
and its ability to form dimers with other GPCR’s (Navarro et al., 2016) . 
Ghrelin undergoes post-translational modification, whereby an octanoyl 
group is added by ghrelin o-acyl transferase (GOAT) to proghrelin to enable 
binding and signalling via GHSR (Gutierrez et al., 2008). It has been shown 
that both forms of ghrelin have the ability to cross the blood-brain barrier 
(BBB) (Banks, Op, Robinson, & Heiman, 2002), but it is AG that travels across 
the BBB and binds to GHSR located in the hippocampus (Diano et al., 2006). 
GHSR is expressed in regions of the brain which are important for 
learning and memory consolidation, one of these being the dentate gyrus 
(DG) situated in the hippocampus (Guan et al., 1997). With the use of in-situ 
hybridisation of GHSR mRNA, the DG showed high mRNA levels for the 
receptor along with many other brain regions, such as the multiple 
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hypothalamic nuclei (anteroventral preoptic nucleus, arcuate nucleus, 
paraventricular nucleus), CA2 and CA3, and the substantia nigra pars 
compacta in the brain stem.  
 
3.1.2 GHSR-eGFP transgenic mouse model 
Due to the difficulty in producing antibodies of adequate selectivity 
and sensitivity against GPCRs, because of cell surface receptors lacking in 
sufficient antigenicity (Reichenbach, Steyn, Sleeman, & Andrews, 2012), the 
GHSR-eGFP mouse model has been used to determine expression of GHSR 
in the adult mouse brain. It has shown greater sensitivity in mRNA 
expression of GHSR in extra-hypothalamic regions such as the hippocampus. 
This reporter mouse model was made by inserting multiple copies of an 
adapted bacterial artificial chromosome (BAC RP23-358A16) that contains 
the GHSR gene, into which an enhanced GFP coding sequence was been 
incorporated into the translational start site of GHSR (Mani et al., 2014). 
 
Figure 3.1 Representative images of GHSR-eGFP expression in the granule cell layer of the DG. 
Greater endogenous eGFP expression via fluorescence (A) in comparison to eGFP immunoreactivity, 
showing eGFP+ cells in the DG (B). Image taken from (Mani et al., 2014). 
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3.1.3 Aim of Chapter 
The aim of this chapter is to characterise GHSR1a expression in cells 
involved in the process of post-developmental hippocampal neurogenesis. In 
turn, this will aid us in beginning to clarify ghrelin’s action in the 
hippocampus and how it regulates AHN. 
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3.2 Materials & Methods 
 
3.2.1 Mice 
Adult male GHSR-eGFP reporter mice (n = 6) were utilised for this 
study. These mice were generated by the GENSAT (Gene Expression 
Nervous System Atlas) project at Rockefeller University. These transgenic 
mice contain several copies of an altered bacterial artificial chromosome that 
contains the GHSR gene (BAC RP23-358A16), where a sequence coding for 
enhanced GFP is inserted at the translational start site of GHSR (Mani et al., 
2014). 
 
3.2.2 Tissue Preparation 
Mouse brain samples were collected following fixation, as stated in the 
general methods 2.1. All procedures were performed with ethical approval at 
Monash University, Australia. Swansea University’s Animal Welfare and 
Ethical Review Panel (AWERP) approved the studies. 
 
3.2.3 Tissue Sectioning 
Mouse brain issue was sectioned as stated in the general methods 2.2. 
Sections were collected specifically into a 12-well Nunclon plate, using a 1:6 
ratio. 
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3.2.4 Immunofluorescent staining of Type I NSPC’s, proliferating cells 
and mature granule cells with GHSR-GFP. 
See protocol 2.3.2, with the following amendments. 
5% NGS in 0.1% PBS-T was applied to the tissue for 1 hour at RT. The 
block was subsequently removed and the primary (1˚) antibodies Nestin, 
Ki67, or NeuN along with GFP (see Table 3.1) in 0.1% PBS-T, were applied in 
a cocktail (all together) and incubated overnight at 4˚C, on a rocker. Sections 
were subsequently washed as before in 1x PBS, and the appropriate 
secondary (2˚) antibodies in 0.1% PBS-T (see Table 3.2) were applied to the 
tissues and incubated for 30 minutes at RT. 
Finally, tissue sections were washed as before in 1x PBS and, mounted 
and coverslipped as previously stated (2.3.1). 
 
3.2.5 Immunofluorescent staining of Type II NSPC’s with GHSR-GFP. 
See protocol 2.3.2, with the following specifics. 
A block of 5% NGS in 0.1% PBS-T was applied for 60 minutes at RT. 
Excess block was removed, the 1˚ antibody for Sox2 was applied in 0.1% PBS-
T (see Table 3.1) and incubated overnight at 4˚C on a rocker. Subsequently, 
the appropriate 2˚ antibody was applied (see Table 3.2) for 30 minutes at RT. 
Sections were washed as before in 1x PBS. The 1˚ antibody for GFP in 0.1% 
PBS-T was applied for 1 hour at RT. After this incubation, the sections were 
washed as before, and the appropriate 2˚ antibody was applied (see Table 2) 
for 30 minutes at RT. 
Finally, tissue sections were washed as before in 1x PBS and mounted 
onto glass slides, as previously mentioned above in 2.3.1. 
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Table 3.1: List of Primary Antibodies used. 
Target Cell Type Species Company & Cat. 
No. 
Dilution 
GFP GHSR Chicken Abcam (Ab13970) 1:1000 
NeuN Mature Granule 
cells 
Mouse Millipore (MAB377) 1:1000 
Sox2 Type II NSPCs Rabbit Abcam (Ab97959)
  
1:500 
Nestin Type I NSPCs Mouse Abcam (Ab6142)
  
1:1000 
Ki67 Proliferating 
cells 
Rabbit Abcam (Ab16667) 1:500 
 
 
Table 3.2: List of Fluorescent Secondary Antibodies used. 
Secondary Ab Company & Cat. No Dilution 
Alexa Fluor 488 Goat α-Chicken IgG (H+L) Molecular Probes 
(A11039) 
1:500 
Alexa Fluor 568 Goat α-Mouse IgG (H+L) Molecular Probes 
(A11004) 
1:500 
Alexa Fluor 568 Goat α-Rabbit IgG (H+L) Molecular Probes 
(A11011) 
1:500 
 
3.2.6 Analysis of fluorescent immunoreactivity. 
Fluorescently labelled tissue sections (4 sections per mouse, n = 6 mice 
per each analysis) were analysed for their immunoreactivity using a Zeiss 
Imager M1 microscope with Axiocam MRm. High resolution imaging of co-
localised proteins throughout the z-axis was performed using a Laser 
Scanning Confocal Microscope (LSCM) (Zeiss LSM 710). The brain regions 
were defined by their Bregma co-ordinates with the use of The Mouse Brain 
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Atlas (Paxinos, G., Franklin, 2012). Representative images of the 
immunoreactivity seen are displayed in the results section. 
  
38 
 
3.3 Results 
 
3.3.1 Phenotypic Characterisation of GHSR in the Dentate Gyrus of adult 
mice. 
The DG of the adult mammalian hippocampus is a neurogenic niche 
where new neurones are generated throughout life. AG has been shown to 
enhance AHN (Kent et al., 2015), we sought to determine whether ghrelin’s 
receptor, GHSR1a, was expressed within this neurogenic niche. 
In order to establish general GHSR expression in the adult murine 
hippocampus and to determine the cell specific expression of this receptor, 
fluorescent immunohistochemical staining was performed on 30µm thick 
coronally cut hippocampal sections, were collected from adult GHSR-eGFP 
reporter mice (n = 6, 4 sections stained per mouse). Antibodies against type I 
(Nestin+) and type II (Sox2+) neural stem progenitor cells (NSPCs) were used, 
along with markers for proliferating cells (Ki67+) and mature granule cells 
(NeuN+), to determine co-localisation with GHSR (eGFP+). General extra-
hypothalamic expression of GHSR was observed in regions associated with 
learning and memory (Figure 3.2), the hippocampus, cingulate cortex, 
entorhinal cortex and the basal lateral amygdala. GHSR is strongly expressed 
in the DG in the GCL cell bodies, with some expression observed in the hilus. 
Also, axonal projections to the CA3 were immunoreactive for GHSR. As 
shown in Figure 3.3, no co-localisation was observed between the GHSR-
eGFP+ cells in the DG and type I or type II NSPCs. However, Sox2+ cells were 
closely associated with GHSR-eGFP+ cells (Figure 3.4), which could suggest a 
possible paracrine relationship. Similarly, proliferating Ki67+ cells were not 
co-localised with GHSR-eGFP+ cells (Figure 3.5). All mice stained showed the 
same immunoreactive pattern as shown in the representative images. 
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Figure 3.2. General GHSR-eGFP expression in the hippocampus and other areas associated with 
learning and memory. 
Extra-hypothalamic expression of GHSR is confirmed in adult male GHSR-eGFP mice, robust 
expression in the learning and memory centres; hippocampus, cingulate cortex, entorhinal cortex and 
the basal lateral amygdala.  Scale bar = 50µm. Inset images = 40x. 
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Figure 3.3. GHSR is not expressed on Type I (Nestin+) or Type II (Sox2+) NSPC’s. 
GHSR-eGFP+ cells (green) are highly expressed in the GCL of the DG, but show no co-localisation with 
Type I NSPC’s (A-C) or with Type II NSPC’s (D-F) (red). N = 6, 4 slices per mouse. Scale bar = 50µm 
(Hornsby et al., 2016). 
 
Figure 3.4. Close association of GHSR-GFP+ cells with Type II SOX2+ NSCs suggests a possible 
paracrine function. 
Example orthogonal image showing GHSR-GFP+ cells (green) with Type II Sox2+ NSCs (red) are not 
co-localised, but have a close proximity to each other. N = 6, 4 slices per mouse.  Scale Bar = 10µm 
(Hornsby et al., 2016). 
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Figure 3.5. Proliferating cells (Ki67) do not express GHSR in the DG. 
No co-localisation is shown between GHSR-eGFP+ cells (green) and Ki67+ expressing proliferating cells 
(red) (A-C). N = 6, 4 slices per mouse.  Scale bar = 50µm (Hornsby et al., 2016). 
 
These findings suggest that GHSR has no direct effect on NSPCs or 
dividing cells. In contrast, we observed extensive co-localisation of GHSR-
eGFP+ with the mature granule cell marker, NeuN (Figure 3.6). Indicating 
that, differentiated neuronal cells within the GCL express GHSR.  
 
 
Figure 3.6. Mature Granule cells (NeuN+) express GHSR in the DG. 
Extensive co-localisation of GHSR-eGFP+ cells (green), and NeuN+ in mature granule cells (red) (A-C) 
of the DG. Scale bar = 50µm (Hornsby et al., 2016). 
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3.4 Discussion 
The aim of this chapter was to phenotypically characterise the 
expression of the ghrelin receptor, GHSR, in the neurogenic niche of the 
hippocampus. The GHSR-eGFP transgenic mouse model was used to give 
accurate representation of GHSR expression in the DG via eGFP 
immunoreactivity. 
The results from this work firmly indicate that GHSR is expressed 
predominantly on mature NeuN+ granule cells in the GCL of the DG, and 
that these neurones appear to show close association with type II Sox2+ 
NSPCs, an example of which is shown in Figure 3.4.  
We know that the adult brain generates new neurones following 
embryonic development (Altman & Das, 1965), and that this continuous 
qualitative process occurs in specific neurogenic niches, the SGZ of the DG of 
the hippocampus and the SVZ of the lateral ventricles (Gonzallez-Perez, 
2012). These new adult born neurones functionally integrate into the existing 
neural circuits (Aimone et al., 2014) and contribute to normal brain function, 
and aid in learning and memory (Deng, Aimone, & Gage, 2010). AHN has 
been shown to be important for the encoding of pattern separation memory, 
the ability to distinguish between contexts that have slight changes or the 
ability to utilise memories obtained from stimuli that are similar in time 
and/or space. A study in adult rats where AHN was removed by x-
irradiation of the hippocampus, showed that these rats performed worse in 
pattern separation tasks where stimuli were presented with low spatial 
separation, compared to controls (Clelland et al., 2009). 
The main cell type produced in this unique microenvironment, are 
mature granule cells (NeuN+). These cells functionally integrate by sending 
axonal projections into the CA3 region where they form excitatory synaptic 
boutons (Kempermann et al., 2015). My work using GHSR-eGFP reporter 
mice shows that ghrelin’s receptor, GHSR, is predominately expressed on 
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these mature NeuN+ granule cells in the DG. The expression observed with 
this immunofluorescent staining is in line with that demonstrated by Mani et 
al. 2014. Identical GHSR expression was shown in the hippocampus, 
cingulate cortex, lateral entorhinal cortex and the basal lateral amygdala in 
the GHSR-eGFP mice used in this study, compared to Mani et al. 2014. 
Notably, the receptor was not expressed on either radial glial-like type I 
Nestin+ or non-radial glial-like type II Sox2+ NSPCs located in the DG 
(Figure 3.3), which are cells key to the expansion phase neurogenesis. These 
type I NSPC’s are quiescent progenitors with long radial-glial like 
projections, that become activated in response to physiological activity such 
as exercise, give rise to type II NSPC’s (Ladran, Tran, Topol, & Brennand, 
2013; Lugert et al., 2010). Type II NSPC’s are multipotent and give rise to 
immature neurones, granule cells, glial and astrocytic cells, as well as more 
type II NSPC’s. They divide asymmetrically as to not deplete the stem cell 
pool and are self-renewing (Suh et al., 2007). However, Sox2+ NSPCs and 
GHSR+ cells, presumably neurones, were in close proximity within the SGZ. 
These findings indicate that whilst ghrelin-GHSR signalling may not directly 
regulate NSPCs there may be indirect modulation via soluble paracrine 
factors that promote neurogenesis, and add that an extra control over the 
modulation of AHN.  
With this in mind, it is understood that ghrelin does mediate paracrine 
effects, by increasing intracellular Ca2+ signalling between neurones and 
glial cells (Avau et al., 2013).  Ghrelin could possibly have a similar effect on 
pro-neurogenic molecules such as brain-derived neurotrophic factor (BDNF) 
within the DG. BDNF is highly expressed in the hippocampus and is 
important for neuronal plasticity (Beck & Pourié, 2013) and promoting 
neurogenesis (Rossi et al., 2006).  BDNF in the DG has also been shown to be 
needed for the consolidation of pattern separation memory, as it stimulates 
immature neurones (Bekinschtein et al., 2013, 2014). Also, intrinsic factors 
such as Wnt proteins, and both its canonical and non-canonical signalling, 
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play an important role in AHN regulation, from the determination of granule 
cell fate to the control of maturation of neuroblasts (Schafer et al., 2015). 
Fibroblast growth factor 2 (FGF-2) is another soluble factor that could 
communicate between GHSR+ neurones and Sox2+ NSPCs. It has been 
shown to be important for the maturation of progenitor cells in the 
hippocampus (neurogenesis), as demonstrated by FGF-deficient mice. These 
mice had no change in the number of proliferating cells compared to WT, but 
showed a specific decrease in the number of new-born mature neuronal cells 
in the DG, suggesting that FGF-2 is important for the process of 
differentiation into mature neuronal cells (Werner, Unsicker, & von Bohlen 
und Halbach, 2011). This was work done following on from previous 
findings by Yoshimura et al. 2001, who showed that endogenous FGF-2 was 
essential for neuro-progenitor proliferation and differentiation in the adult 
DG, following brain injury in mice.  
Ghrelin-GHSR induced AHN could also be induced via another 
mechanism. Physical activity has been shown to promote AHN in male 
Sprague-Dawley rats. Rats that had been selectively bred to be high 
responders to activity (HRT) and low responders (LRT) underwent 
prolonged aerobic exercise by voluntary wheel running, endurance running 
on a treadmill or high intensity interval training (HIIT). The HRT mice that 
had undergone wheel running and  endurance training showed the greatest 
increase in DCX+ cells in the hippocampus compared to sedentary controls, 
after 6-8 weeks of training (Nokia et al., 2016). 
To summarize, GHSR is expressed in regions of the brain that are 
important for learning and memory, and is specifically expressed in mature 
dentate granule neurones in the GCL of the DG, but shows no expression on 
type I and II NSPC’s or proliferating cells. This suggests that circulating AG 
has the ability to cross the BBB and stimulate AHN via its receptor GHSR 
present in the neurogenic niche of the DG, and facilitate this in a cell-extrinsic 
manner. 
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Chapter 4 The direct and indirect effects of 
ghrelin on adult hippocampal plasticity 
 
4.1 Introduction 
Calorie restriction (CR) or a low-calorie diet has been associated with 
the amelioration of learning and memory. CR is an evolutionary conserved 
process that occurs in various species and reduces the incidence of disease 
and promotes longevity (Fontana et al., 2010). It has been shown in mouse 
models of ageing and neurodegenerative disease that restricting diet has a 
beneficial effect; protecting against the loss of hippocampal, cortical and 
striatal neurones (W Duan et al., 2001). This has also led to a reduction in 
spatial learning and memory deficits and age-associated physiological 
impairments in humans such as insulin sensitivity and glucose handling 
(Witte et al., 2009). Longitudinal studies in adult rhesus monkeys (7-14 years 
old, 46 males and 30 females) have shown that CR (30% less calories to 
controls) can reduce the incidence of age-related deaths when the regime is 
introduced at an early age or later in adult life. In this study they measured 
age-related and all-cause mortality, which were both improved by CR, as 
was the incidence of age-related disorders like diabetes, neoplasia and 
sarcopenia (Colman et al., 2014). In light of this, it can be hypothesised that 
the introduction of a CR diet to adults suffering from age-related diseases, 
such as Parkinson’s disease and Alzheimer’s could benefit from it (Gräff et 
al., 2013).  Studies have looked at CR as a way to delay or prevent the onset 
of such disorders, shown in rhesus monkeys that had undergone 6 months of 
30% CR then treated with a neurotoxin (MPTP) to induce hemiparkinson 
condition. They showed elevated DA levels and better locomotor activity 
compared to ad lib controls (Maswood et al., 2004), and it has shown to 
reduce amyloid-β peptides in squirrel monkeys when CR was implemented 
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in early adulthood, lessening AD amyloidosis (Qin et al., 2006). The effects of 
CR have not been investigated once the disorder has been established. 
 
 CR is thought to mediate its beneficial effects, in part, by promoting 
hippocampal plasticity and neurogenesis, and one possible mediator is 
thought to be ghrelin (Zane B Andrews, 2011). CR was initially shown to 
increase the number of new-born cells in the DG of rats (3 month old males, 
ad lib n = 24, 30% CR n = 24, for 3 months). Rats were treated with the 
thymidine analogue bromodeoxyuridine (BrdU, 50mg/kg) daily for 5 days, 
and the CR group showed a significant increase in BrdU+ cells in the DG of 
the hippocampus (J Lee, Duan, Long, Ingram, & Mattson, 2000). Following 
this, a study demonstrated that the presence of ghrelin was required for CR 
to have its pro-neurogenic effect, with the use of ghrelin KO mice. This was 
performed by CR in WT and ghrelin KO mice (24 hour fast followed by 24 
hour fed regime) for 3 months, with ad libitum fed controls, which were also 
administered BrdU (50mg/kg, i.p.) daily for 12 days. It was observed that 
only within the WT CR group was there an increase in the survival  of new 
adult-born cells in the DG (Kim et al., 2015). The orexigenic peptide hormone 
ghrelin is known to bind to its receptor GHSR, expressed in the 
hippocampus (Diano et al., 2006) and ghrelin increases following CR (Lutter 
et al., 2008). It has also been shown to promote cell proliferation in the 
hippocampus (Johansson et al., 2008; Moon et al., 2009). 
 
4.1.1 Aim of this Chapter 
 The aim of this work is to determine the mechanisms by which ghrelin 
mediates its neurogenic effect with the use of ghrelin and GHSR knockout 
mouse models, and whether manipulating ghrelin levels directly via AG 
injection and/or indirectly by CR will facilitate improvements in AHN and 
learning and memory in mice.  
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4.2 Materials & Methods 
 
4.2.1 Mice and Experiments 
 
4.2.1.1 GHSR-eGFP mice. 
Adult male GHSR-eGFP reporter mice were used in this study, as 
described in 2.2.1. This 4-day experiment was designed to determine the 
effects of direct and indirect elevations of AG on neurogenesis. AG levels 
were increased directly by injection (1mg/kg i.p) 1 hour before the end of the 
fast, indirectly by calorie restriction (CR) (16 hour overnight fast) or a 
combination of the two, in order to quantify IEG expression following short-
term exposure to CR and/or AG. There were 4 groups (n=4 per group); wild 
type (WT), CR, AG and CR+AG. Mice were terminally anesthetised with 
sodium pentobarbital, transcardially perfused with 0.9% solution of NaCl, 
followed by perfusion with 4% paraformaldehyde (PFA) solution. The brains 
were then immersed in 4% PFA overnight and placed in 30% sucrose 
solution for cryoprotection until sunk.  
 
4.2.1.2 GHSR knock out mice. 
12 week old adult male and female GHSR knockout (KO) mice (homozygous 
loxP TB-flanked KO) (Zigman et al., 2005) and WT littermates were 
individually housed under normal laboratory condition for 7 days before the 
start of the experiment (12 hours light, 12 hours dark), so that animals 
acclimatised to the conditions and that ad-libitum (AL) levels of feeding could 
be monitored for each genotype. Mice were separated into 4 groups; AL fed 
WT, AL fed GHSR KO, CR WT and CR GHSR KO (6 male and 6 female per 
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group, n=12 per group). CR was set at 70% of the total calories of the AL fed 
group, and the CR mice were exposed for the first 14 days of the experiment. 
Mice were administered the thymidine analogue BrdU (50mg/kg) (B5002, 
Sigma Aldrich) on days 4-7 to label newly dividing cells. Following the 14 
days of CR, mice were able to feed AL for the rest of the experiment. On days 
31-44 the mice underwent behavioural testing; contextual fear condition 
(CFC), for assessment of hippocampal dependant memory, which was 
performed by Dr Katia Amstalden, Texas A&M University (see below 4.2.1.4 
and Figure 4.1). Full schematic is shown in Figure 4.5. 
These mice were gifted from Prof. Jeffery Zigman of the University of 
Texas Southwestern (Dallas, Texas, USA), and were from crosses between 
mice that were heterozygous for the GHSR KO allele and C57/BL6 animals 
for >10 generations, to prevent producing recombinant inbreeds. All animal 
experiments were performed at Texas A&M University. 
 
4.2.1.3 Ghrelin Knockout mice. 
Female C57/BL6 WT and Ghrelin KO littermate mice, ranging from 5 to 
16 months of age underwent a 28-day experiment. On experimental days 4 to 
7 mice were administered once-daily injections of BrdU, 50mg/kg i.p (B5002, 
Sigma Aldrich) dissolved in saline (0.9% NaCl, pH7). On day 27 the mice 
were either fasted overnight (during the dark phase) or not; lights off 6pm-
6am with the standard laboratory chow removed. Approximately half of the 
CR group were refed for 1 hour during the light phase (10am-11am), 
resulting in 6 different groups. On day 28 the mice underwent terminal 
anaesthesia with isofluorane, following which they were decapitated, the 
trunk blood collected and the brain tissue removed and bisected. One 
hemisphere was sectioned for immunohistochemical analysis, and the other 
was frozen at -80˚C for future protein/RNA/DNA extraction. Full schematic 
is shown in Figure 4.9. 
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These Ghrelin KO mice were a gift from our collaborator Prof. Yuxiang Sun 
of Baylor College of Medicine, that had been back crossed into a homozygoes 
C57/BL6 genetic background >/= to 10 generations. 
 
4.2.1.4 Behavioural Testing: Contextual Fear Conditioning 
 
Figure 4.1 Diagram depicting CFC behavioural test. 
Graphic illustrating the different stages of the CFC paradigm (Hornsby et al. 2015). 
 
Contextual fear conditioning (CFC) assesses hippocampal-dependant 
memory formation and function, with the test used specifically looking at 
context-dependant fear memory by measuring freezing behaviour following 
foot shock ((Kent et al., 2015; van Woerden et al., 2007). AHN has been 
shown to be important for enhancing this type of context-dependant fear 
memory (Kitamura et al., 2009). WT and GHSR KO mice underwent CFC in 
the following way; for 30 minutes a day, 6 days before the conditioning, mice 
were moved to a test room, where the apparatus was cleaned with 70% EtOH 
before introducing the animals to the chamber. The animals were pre-
introduced to a non-aversive environment (25cm x 25cm Coulbourn Habitest 
chamber with wire grid floor) for 7.5 minutes. 2 days later mice were 
introduced to the same conditioning chamber that was distinct due to the 
addition of a coloured wall panel, for 2.5 minutes before being given a 2 
second foot-shock (0.5 mA). 2.5 minutes later another 2 second foot-shock 
was given, before being returned to its home cage. CFC was then measured 
by observing freezing behaviour in the absence of a foot-shock, when mice 
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were placed back into the conditioning chamber for 2.5 minutes 1, 6 and 12 
days after the initial conditioning (Figure 4.1). During this period, the 
presence and absence of freezing was recorded via camcorder placed directly 
above the cage. A trained person, blind to the genotype of the mice, scored 
freezing behaviour every 5 seconds over the 2.5 minute period. 
 
4.2.2 Tissue Preparation 
GHSR-eGFP mouse brain samples were collected and fixed as stated in 
the general methods 2.1, until required for analysis. All procedures were 
performed with ethical approval at Monash University, Australia. Swansea 
University’s Animal Welfare and Ethical Review Panel (AWERP) approved 
the studies. 
C57/BL6 and Ghrelin KO mouse brain samples underwent immersion 
fixation in 4% PFA overnight at 4˚C. Subsequently, they were cryoprotected 
in 30% sucrose solution until they had sunk, after which they were stored in 
PBS with 0.1% Sodium Azide at 4˚C until required for analysis. 
 
4.2.3 Tissue Sectioning 
Mouse brain tissue was sectioned as stated in the general methods 2.2. 
Sections were collected specifically into 24-well Nunclon plates, in a ratio of 
1:12.  
 
4.2.4 Immunoflurescent staining of immediate early gene (IEG) activation 
in GHSR-eGFP mice. 
For co-localisation of eGFP with the IEG’s, c-Fos and Egr-1, protocol 
2.3.2 was used with the following amendments.  
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Antigen retrieval was performed using citrate buffer (pH6) for 20 
minutes at 90°C, then blocked with 5% NGS as previously stated. GFP 
antibody (see Table 4.1) was applied and incubated at 4°C overnight. 
Following secondary antibody application and incubation (Table 4.2) and 
washes, c-Fos or Egr-1 primary antibody diluted in 0.1% PBS-T (1:2000 or 
1:1000 respectively) were applied for overnight incubation at RT on a rocker. 
Following another wash of the sections, they were incubated in biotinylated  
secondary antibody diluted in 0.1% PBS-T for 60 minutes at RT. Sections 
were washed and then incubated for 30 minutes at RT with streptavidin 
AlexaFluor594 conjugate diluted in 0.1% PBS-T. Finally, sections were 
washed, with the addition of the nuclear counterstain, Hoescht (1:10,000), to 
the first wash. Sections were then mounted as described above. 
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Table 4.1 Primary antibodies used. 
Target Cell Type Species Company & Cat. 
No. 
Dilution 
GFP GHSR Chicken Abcam (Ab13970) 1:1000 
c-Fos IEG Rabbit Santa Cruz (Sc-52) 1:1000/1:2000 
Egr-1 IEG Rabbit Santa Cruz (Sc-189) 1:1000 
BrdU New adult-born 
Cells 
Rat ABD Serotec 
(MCA2060) 
1:400 IF 
1:3000 Ni-DAB 
NeuN Mature Granule 
Cells 
Mouse Millipore (MAB377) 1:1000/1:2000 
Sox2 Type II NSPCs Goat Santa Cruz (Sc-
17320) 
1:500 IF 
Sox2 Type II NSPCs Rabbit Abcam (Ab97959)
  
1:1000 Ni-DAB 
Nestin Type I NSPCs Mouse Abcam (Ab6142)
  
1:1000 
Ki67 Proliferating 
Cells 
Rabbit Abcam (Ab16667) 1:500 
DCX Immature 
neurones  
Goat Santa Cruz (Sc-8066) 1:500 
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Table 4.2 Secondary antibodies and conjugated used. 
Secondary Ab Company & Cat. No Dilution 
Alexa Fluor 488 Goat α-Chicken IgG (H+L) Molecular Probes 
(A11039) 
1:500 
Alexa Fluor 568 Goat α-Mouse IgG (H+L) Molecular Probes 
(A11004) 
1:500 
Alexa Fluor 568 Goat α-Rabbit IgG (H+L) Molecular Probes 
(A11011) 
1:500 
Alexa Fluor 488 Goat α-Rabbit IgG (H+L) Molecular Probes 
(A11034) 
1:500 
Alexa Fluor 488 Donkey α-Rabbit IgG 
(H+L) 
Molecular Probes 
(A21206) 
1:500 
Alexa Fluor 568 Donkey α-Goat IgG (H+L) Molecular Probes 
(A11057) 
1:500 
Alexa Fluor 488 Goat α-Rat IgG (H+L) Molecular Probes 
(A11006) 
1:500 
Biotinylated Goat α-Rabbit IgG Vector Laboratories 
(BA-1000) 
1:400 
Biotinylated Goat α-Mouse IgG Vector Laboratories 
(BA-9200) 
1:400 
Biotinylated Goat α-Rat IgG Vector Laboratories 
(BA-9400) 
1:400 
Biotin-SP-conjugated AffiniPure Donkey α-
Goat IgG (H+L) 
Jackson Laboratories 
(705-065-003) 
1:400 
Streptavidin Alexa Fluor 594 conjugate Invitrogen (S11227) 1:500 
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4.2.5 Immunofluorescent staining of proliferating NSPC’s, in GHSR-
eGFP mice. 
For co-localisation of Ki67 with the NSPC markers Nestin or Sox2, 
protocol 2.3.2 was used with the following amendments. 
Following AR, sections undergoing staining of Ki-67-Nestin were 
blocked in 5% NDS, whereas Ki67-Sox2 sections were blocked in 5% NGS, 
before incubation with Ki67 primary antibody incubation. Sections were 
washed as before in PBS and then incubated with fluorescent secondary 
antibody (see Table 4.2) for 30 minutes at RT. Subsequently, sections were 
incubated with primary antibody anti-Sox2 diluted in 0.1% PBS-T at RT for 
60 minutes or anti-Nestin primary antibody for 2 hours (Table 4.1). Sections 
were washed before 30 minute incubation at RT in appropriate secondary 
antibody (see Table 4.2) diluted in 0.1% PBS-T. After the final wash, sections 
were mounted as previously described. 
 
4.2.6 Immunofluorescent staining of new-born neuronal cells (BrdU-
NeuN), in GHSR -/- mice and WT littermates. 
See protocol 2.3.3, with the following changes. 
Tissues were incubated for 60 minutes at RT in a 5% NGS block in 0.1% 
PBS-T. After the removal of the block solution, the primary antibody anti-
BrdU diluted in 0.1% PBS-T (see Table 4.1) was applied. The plate was sealed 
and placed on a rocker overnight at 4°C. The primary anti-NeuN antibody 
was applied diluted in 0.1% PBS-T (see Table 4.1) and incubated for 60 
minutes at RT. Sections were washed as previously described, and the 
secondary antibody Biotinylated Goat anti-Mouse diluted in 0.1% PBS-T (see 
Table 4.2) was added to the sections for 60 minutes at RT. Excess secondary 
antibody was removed and the sections washed in 1X PBS as before, 
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Streptavidin AlexaFluor 594 diluted in 0.1% PBS-T (see Table 4.2) was then 
applied and incubated for 30 minutes at RT.  
 
4.2.7 Immunohistochemical staining for Type II NSPC’s (Sox2+) using 
Nickel enhanced DAB (di-aminobenzidine) (Ni-DAB). 
This was performed using the method stated in 2.3.5, with the 
following specifics.       
Following AR  and blocking in 5% NGS, the primary antibody anti-Sox2 
(Table 4.1) was applied to the sections and incubated overnight at 4˚C in the 
cold room, on a rocker. 
 
4.2.8 Immunohistochemical staining for immature neuronal cells (DCX) 
using Ni-DAB. 
This staining was performed as stated in the method 2.3.4, with the 
following specifics. 
Tissue sections were blocked in 5% NDS block in 0.03% PBS-T and 
incubated for 60 minutes at RT. Sections were incubated in primary antibody 
DCX was then applied to the sections, diluted in 0.03% PBS-T and 2% NDS, 
this was left to incubate overnight at 4˚C in the cold room, on a rocker.  
 
4.2.9 Immunohistochemical staining for new-born cells (BrdU) using Ni-
DAB. 
Mouse brain sections were washed in 2 times in 1X PBS, 10 minutes 
each followed by a wash on 0.03% PBS-T for 10 minutes. Sections were then 
incubated in 1X PBS with 1.5% H2O2 for 20 minutes at RT. Sections were 
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washed again in 1X PBS and 0.03% PBS-T as before, after which they were 
incubated in 2M HCl at 37˚C for 30 minutes followed by a wash in Borate 
Buffer for 10 minutes. Following a wash series the sections were immersed in 
5% NGS block for 60 minutes at RT. BrdU primary antibody (see Table 4.1) 
diluted in 0.03% PBS-T and 2% NGS was applied and the sections incubated 
overnight at 4˚C in the cold-room, on a rocker. Sections were washed as 
before and secondary biotinylated antibody diluted in 0.03% PBS-T and 2% 
NDS, was applied to the sections and incubated for 70 minutes at RT and 
also covered from light. Following another wash, a premixed ABC solution 
was applied (0.4%A +0.4%B in 0.03%PBS-T, premixed for 30 minutes before 
application); this was incubated for 90 minutes at RT. Subsequently, sections 
for were washed twice in 1X PBS for 10 minutes each, and the washed in 
sodium acetate (pH6) for 10 minutes. Tissues were reacted in Ni-DAB and 
glucose oxidase solution for between 5-10 minutes. Following this reaction 
the sections were washed 2 times in 1X PBS. 
The sections were then mounted into glass slides as described 
previously, and allowed to dry overnight. The slides were subjected to a 
counterstain process with methyl green. Methyl green was pre-heated at 
60˚C for at least 30 minutes prior to staining. The slides were rinsed with tap 
water, ~30 seconds per slide. The slides were then placed in the pre-heated 
methyl green for 5-10 minutes at 60˚C. Following this, the slides were 
washed in deionised H2O (ddH2O) until clear. In a fume hood, the slides 
were dipped into acetone 5-10 times, followed by an alcohol dehydrations 
series consisting of dipping the slides for 30 seconds in 2x 95% EtOH and 2x 
100% EtOH and 1x Histoclear. The slides were coverslipped as before. 
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4.2.10 Immunofluorescent staining of new-born neuronal cells 
(BrdU/NeuN), and new-born neuronally active cells (BrdU/c-Fos), in WT 
and Ghrelin KO mice. 
Mouse brain sections were washed 3 times in 1X PBS for 5 minutes each 
following which there was permeabilised in cold methanol and placed at -
20˚C for 2 minutes. Sections were washed again, as above, and incubated in 
2M HCl for 30 minutes at 37˚C. After a 10-minute wash in borate buffer, the 
sections were washed again in PBS after which a 5% NGS + 5% BSA (bovine 
serum albumin) (A7906-10KG, Sigma Aldrich) block diluted in 0.1% PBS-T 
was added and incubated at RT for 60 minutes. Upon removal of excess 
block the BrdU primary antibody diluted in 0.1% PBS-T was applied and left 
to incubate for 24 hours at RT. Following a wash series, the sections were 
incubated with fluorescent secondary antibody (see Table 4.2) for 30 minutes 
at RT, and protected from light. Following washes in PBS the tissue was 
incubated in primary antibodies for either c-Fos or NeuN (diluted in 0.1% 
PBS-T) were applied to the sections and incubated for 24 hours at RT, after 
which they were washed as before and the incubated in the appropriate 
biotinylated secondary antibodies diluted in 0.1% PBS-T (see Table 4.2) were 
applied and sections incubated for 60 minutes in the dark at RT. Sections 
were subsequently washed in PBS and ABC solution was applied (0.4%A 
+0.4%B in 0.1%PBS-T, premixed for 30 minutes before application) for 90 
minutes at RT. Following another set of washes in PBS, the tyramine signal 
amplification (TSA) system was used (bTyr 1:100 + H2O2 1:1000 in 0.1% PBS-
T), this solution was applied to the sections for 10 minutes at RT, after which 
they were washed. Streptavidin conjugate diluted in 0.1% PBS-T was then 
applied to the sections for 30 minutes at RT. Finally, sections were washed in 
PBS and then mounted into glass slides with Prolong Gold mounting 
medium (P36930, Life Technologies) and stored as described before. 
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4.2.11 Immunofluorescent staining of new-born neuronal cells (BrdU-
NeuN), in WT and Ghrelin KO mice. 
See protocol 4.2.6, with the following changes.  
After incubation of NeuN 1˚primary antibody, sections were washed in 
1X PBS as previously stated, followed by incubation in secondary antibody 
(Goat anti-Mouse AlexaFluor 568, see Table 4.2) was applied and the sections 
incubated for 30 minutes at RT. Sections were washed a final time as before, 
mounted onto glass slides and cover-slipped as previously stated. 
 
4.2.12 Analysis of fluorescent immunoreactivity. 
Fluorescently labelled tissue sections were analysed for their 
immunoreactivity using a Zeiss Imager M1 microscope with Axiocam MRm. 
High resolution imaging of co-localised proteins throughout the z-axis was 
performed using a Laser Scanning Confocal Microscope (LSCM) (Zeiss LSM 
710). 
 
4.2.13 Analysis of Ni-DAB immunoreactivity. 
Ni-DAB immunolabelled sections were analysed for their 
immunoreactivity using the Nikon Eclipse 50i microscope system and the 
NIS Elements F4 software. Cells were either counted manually where 
possible or with the use of ImageJ software. 
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4.2.14 Data and Statistical Analysis. 
4.2.14.1 IEG activation in GHSR-eGFP mice. 
For this analysis, n = 4 per group and 4 sections were chosen from each 
mouse (2 rostral and 2 caudal coronal sections, each section containing 2 
DGs) to undergo staining and fluorescent analysis. The immuno-labelled 
cells (Egr1-GFP and c-Fos-GFP) were counted manually using the 40x 
objective and scrolling through the z-axis of the whole GCL of the DG, 
CingC, BLA and LEnt. Area measurements of the DG were obtained from 
Hoescht counterstaining and measured using ImageJ software. The resulting 
cell counts by area were achieved by dividing average cell count by average 
area measurement. Statistical analysis was performed using Graphpad Prism 
7.0 software, using a One-way ANOVA with Fishers LSD post-hoc 
comparison test.  
4.2.14.2 Cell proliferation in the DG of GHSR-eGFP mice. 
For this analysis, n= 4 per group and 3 sections were chosen from each 
mouse (6 DGs in total) to undergo immunofluorescent staining (Ki67-Nestin 
and Ki67-Sox2) and analysis. The positive cells were counted as stated above 
(4.2.14.1). Percentages were calculated by dividing the number of double 
positive cells by the total of Ki67 positive cells and multiplying by 100.   
4.2.14.3 Effect of CR on AHN in the adult DG of GHSR KO mice. 
For the analysis of BrdU-NeuN staining in WT and GHSR KO mice; n = 
12 per group, whole well (1:12 ratio) sections with 10-16 sections per well, 
underwent immunofluorescent staining. Positive cells were counted in the 
GCL of the DG as described above (4.2.14.1). DGs were separated using  the 
Mouse Brain Atlas (Paxinos, G., Franklin, 2012) into rostral and caudal 
sections. Average cell counts were multiplied by 360 (1:12 series, each section 
360µm apart) to achieve number of cells per DG. Statistical analysis of the 
data was performed with Graphpad Prism 7, and due to there being 2 
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variable factors a 2-way ANOVA was performed with Tukey’s post hoc 
multiple comparisons test. 
4.2.14.4 Effect of genotype and CR on Type II NSPC number in WT and GHSR KO 
mice. 
For this analysis, n=8 (genotype) or n=4 (feeding) per group and 4 
sections (from each mouse chosen to undergo immunohistochemical Ni-DAB 
staining for Sox2. Images were collected as described above (4.2.13) and cell 
counts in the SGZ of the DG were obtained using ImageJ software. Average 
cell counts for each mouse were calculated by adding together each sections 
cell count and dividing by the number of sections. To obtain average cells per 
DG, average cell count is multiplied by 360 as described before (4.2.14.3). A 
Mann-Whitney test was performed for statistical analysis on the effect of 
genotype, comparing 2 groups. To assess the effect of CR (4 groups) a 2-way 
ANOVA followed by Tukey’s post hoc multiple comparisons test was 
performed. 
4.2.14.5 Effect of Ghrelin KO on basal neurogenesis levels. 
For the analysis of immunohistochemical staining of type II NSPCs 
(Sox2), proliferating cells (Ki67) and immature neurones (DCX) in the SGZ of 
the DG, n = 4-8 per group (WT and Ghrelin KO). ImageJ was used to draw 
around the GCL and produce cell counts. Immunofluorescent staining for 
new-born neurones (BrdU-NeuN), n = 9-12 per group. Cell counts were 
obtained by manual counting (4.2.12). Data was handled as above (4.2.14.4). 
A 2-tailed student t-test was performed with Graphpad Prism. 
4.2.14.6 Effect of CR on new-born neuronal cell activation in WT and Ghrelin-KO. 
For the analysis of BrdU-c-Fos immunofluorescent staining, n = 6 per 
group and ~4 sections per mouse. Cell counts and data statistical analysis 
was handled as mentioned before (4.2.14.3). 
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4.2.14.7 Effect of age on new-born neurone and cell activation. 
For the analysis of BrdU-c-Fos and BrdU-NeuN immunofluorescent 
staining n = 4-6 per group with 4 sections per mouse stained. Cell counts and 
data statistical analysis was handled as mentioned before (4.2.14.3). 
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4.3 Results 
 
4.3.1 The effects of acutely elevating AG levels directly and indirectly in 
the mouse brain. 
CR and AG have been known to cause improvements in cognitive 
function and AHN (J.-H. Park et al., 2013; Witte et al., 2009). For this 
experiment we sought to determine whether increasing levels of circulating 
AG by CR and/or AG injection would have any effect on hippocampal 
plasticity and neuronal cell activation in the key brain centres for learning 
and memory. The areas that we examined were; the DG, the cingulate cortex 
(CingC), the lateral entorhinal cortex (LEnt) and the basolateral amygdala 
(BLA), all areas shown to be important for learning and memory. 
 
4.3.1.1 CR and AG treatment enhance the expression of the IEG Egr-1 in the DG. 
To determine whether CR or AG induced the expression of IEG’s, Egr-
1 and c-Fos, in DG specific neurones in areas of the brain that are important 
for learning and memory, AG levels were elevated directly by injection and 
indirectly by CR, or a combination of the two in GHSR-eGFP mice. Following 
overnight CR, the expression of Egr-1 was increased in the DG (Figure 4.2B, 
P<0.05), CingC (Figure 4.2F, P<0.05) and BLA (Figure 4.2H, P<0.05). AG 
injection had a similar effect in elevating Egr-1 expression in the DG (Figure 
4.2B, P<0.05), CingC (Figure 4.2F, P<0.01) and BLA (Figure 4.2H, P<0.05). 
The combination treatment of CR and AG injection also increased Egr-1 
expression in the DG (Figure 4.2B, P<0.01), LEnt (Figure 4.2D, P<0.05), CingC 
(Figure 4.2F, P<0.05) and the BLA (Figure 4.2H, P<0.05). There was an 
increase in the number of double positive (GHSR-eGFP+ Egr-1+) cells in the 
CingC following CR, AG injection and the combined treatment (Figure 4.2F, 
63 
 
P<0.05; P<0.01; P<0.001 respectively). A similar observation was made in the 
BLA via combined treatment of CR and AG injection (Figure 4.2H, P<0.05). 
However, the same pattern was not observed with c-Fos. c-Fos 
expression was shown to decrease in the LEnt (Figure 4.3L, P<0.01) and BLA 
(Figure 4.3P, P<0.05) following AG injection, and CR resulted in a decrease in 
expression in the LEnt (Figure 4.3L, P<0.01). However, an increase in c-Fos 
expression was seen in both GHSR-eGFP- and GHSR-eGFP+ cells of the DG 
(Figure 4.3J, P<0.05; P<0.01), following AG injection, and an increase in c-
Fos+ cells in the LEnt (Figure 4.3L, P<0.05), due to the combined treatment of 
CR and AG injection. Also, an increase in c-Fos+ cells was shown in the 
CingC (Figure 4.3N, P<0.01) following AG injection. 
The Egr-1 work was performed by another member of the Davies 
Group, Yushi Redhead. I assisted in the supervision of this student - helping 
to optimise the protocols used, assisting with the imaging, cell counting and 
data analysis. 
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Figure 4.2 CR and AG enhance Egr-1 expression in areas of the brain important for learning and 
memory. 
Example images of Egr-1+ (A, C, E, G) after CR, AG or CR+AG in GHSR-eGFP mice. Increase in Egr-1+ 
cells in the DG (B), LEnt (D), CingC (F) and BLA (H). Scale bar = 40µm.  For statistical comparison a 
One-way ANOVA with Fishers LSD post-hoc analysis performed, *P<0.05, **P<0.01, ***P<0.001 vs 
control. All data shown as mean ± SEM. n=4 mice per group. Image taken from Hornsby et al., 2016. 
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Figure 4.3 CR and AG enhance Egr-1 expression in areas of the brain important for learning and 
memory, continued.  
Example images of c-Fos+ cells (I, K, M, O) after CR, AG or CR+AG in GHSR-eGFP mice. Cell counts of 
c-Fos+ in the DG (J), LEnt (L), CingC (N) and BLA (P). Scale bar = 40µm.  For statistical comparison a 
One-way ANOVA with Fishers LSD post-hoc analysis performed, *P<0.05, **P<0.01, ***P<0.001 vs 
control. All data shown as mean ± SEM. n=4 mice per group. Image taken from  Hornsby et al., 2016. 
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4.3.1.2 CR and AG had no effect on cell proliferation or the type of NSPC’s 
produced. 
In order to identify the effects on DG plasticity by indirectly elevating 
AG levels via CR and directly by i.p. injection of AG, or a combination of 
both (CR+AG), immunofluorescent staining for proliferating Ki67+ cells 
along with markers for either type I (Nestin+) or type II (Sox2+) NSPCs was 
performed. This was done to determine whether there was any differential 
effect on the NSPC pool. 30µm thick coronally cut hippocampal sections 
were collected from adult GHSR-eGFP mice from each treatment group (n=4) 
and immunofluorescently stained for either Ki67 and Nestin, or Ki67 and 
Sox2. All Ki67+ cells and double positive cells (Ki67+Nestin+, Ki67+Sox2+) 
were manually counted through the z-axis and through the entire rostro-
caudal extent of the brain. As can be seen in Figure 4.4, no significant effect 
was observed on overall rates of cell proliferation in the DG (Figure 4.4E), 
and there was no apparent effect on the proportion of type I and II NSPC’s 
that were being produced (Figure 4.4C, D). 
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Figure 4.4 Acyl-ghrelin injection and/or CR has no effect on cell proliferation in the DG. 
Representative confocal images of double immunofluorescent staining for proliferating (Ki67+) cells 
with type I radial (Nestin+) and type II non-radial (Sox2+) cells (A,B). Scalebar = 50µm. CR and AG 
treatment or the CR/AG combined showed no effect on the proliferation rates of Nestin+ and Sox2+ 
cells (C,D) in the mouse hippocampus, and there was no effect on the total number of differentiating 
cells in the DG (E) (P>0.05). Data represented as mean± SEM. 
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4.3.2 Acute CR enhances AHN and context dependant fear memory in a 
GHSR-dependant manner. 
Overnight CR increased DG Egr-1 expression, as this is important for 
functionally integrating new-born cells into the adult DG (Veyrac et al., 
2013), we analysed the effect of a 2 week period of CR on GHSR KO mice and 
their WT littermates. This experimental design allowed us to determine the 
effects of CR on the generation of new-born mature neurones in the adult 
DG, and whether this was dependent upon GHSR. 
 
Figure 4.5. Schematic of GHSR KO mice experimental time-line. 
Experimental paradigm of 2 week CR in WT and GHSR KO mice. BrdU (50mg/kg i.p. injection) was 
administered on days 4-7, behavioural testing on days 31-45, and mice terminally anaesthetized on day 
45. 
Immunofluorescent staining was performed on 30µm thick coronal 
mouse brain sections that were collected 31 days after the final day of CR 
(Day 45) (Figure 4.5), for the quantification of the number of new adult-born 
mature neuronal cells (BrdU+ NeuN+, see Figure 4.6). There was a 52% 
increase in the number of adult-born new neurones (BrdU+ NeuN+) in the 
rostral portion of the DG of WT CR mice compared to WT ad libitum (ad lib) 
fed mice. A 2-way ANOVA revealed a main effect of treatment (F(1, 44) = 
5.806, P = 0.0202) and a post-hoc Tukey multiple comparison test showed a 
significant difference between the WT CR and WT ad lib mice (P = 0.048) 
(Figure 4.6B). No effect was seen in the GHSR KO mice. Also, CR was shown 
to increase the fraction of new-born BrdU+ cells that became mature NeuN+ 
neuronal cells in WT mice (Figure 4.6C, P = 0.0108), but not in GHSR KO 
mice (P > 0.99). Finally, there was no observed difference in the total number 
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of new born cells for either treatment or genotype (Figure 4.6D, P > 0.05). In 
addition to this data there was no difference in the number of BrdU+ NeuN+ 
cells in the DG of WT ad lib mice and their GHSR KO counterparts (P = 
0.9812), suggesting that basal neurogenesis isn’t impaired in GHSR KO mice. 
These data indicate that GHSR is required for CR’s positive effects on AHN 
to occur. 
The same experimental WT and GHSR KO mice also underwent 
memory testing 17 days following the final day of CR, on day 31. The 
contextual fear conditioning (CFC) test was used to determine the effects of 
CR on hippocampal-dependent fear memory and is reported to be sensitive 
to changes in AHN (Kitamura et al., 2009). There was no difference between 
the GHSR KO and WT littermate mice during training in the “shock” part of 
the test, indicating that both groups could similarly attain and retain fear 
memory (2-way ANOVA, genotype (F (1,44) = 0.8882, P = 0.3511); treatment  
(F (1,44) = 0.009506, P = 0.9228)), shown in Figure 4.6E. Conversely, with the 
progression of time the CR WT mice displayed an improved retention of 
their fear memory, retaining it 12 days following their exposure to the fear 
condition, in comparison to the WT ad libitum (ad lib) fed group. Statistical 
analysis showed a significant interaction between genotype and treatment (2-
way RM ANOVA, F (6,88) = 2.971, P = 0.0109). Post-hoc multiple comparison 
showed a significant difference between WT CR and WT ad lib littermates 
(Tukey test, P = 0.0121) 12 days post-conditioning, but no significant 
difference was observed between the GHSR KO mice in either group 
(P=0.1837) (Figure 4.6E). Also observed was the gradual decline of fear 
memory in the WT ad lib over the 12 days, which reached statistical 
significance (Day 1 post-conditioning vs Day 12 post-conditioning in WT/ad-
libitum mice, P = 0.0179). The same was not seen in the ad lib fed GHSR KO 
mice (Day 1 post-conditioning vs Day 12 post-conditioning in GHSR KO / 
ad-libitum fed mice, P = 0.1889), implying that GHSR signalling is required in 
this memory retention extinction process. 
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This animal work was performed by Dr Katia Amstalden of Texas 
A&M University, Texas, USA, before the brains were shipped to Swansea 
University for analysis. 
 
 
Figure 4.6 A 2 week period of CR enhances AHN in the adult DG and improves context dependant 
fear memory. 
Representative image of   BrdU+ (red) and NeuN+ (green) cells in the DG. Scale bar = 50µm (A).  New 
adult born mature neuron cell number (B); neuronal differentiation rate in newly divided NSPCs (C) 
and number of new-born cells (D) in the rostral DG. n = 12 per group. 2-way ANOVA and Tukey’s 
post hoc test: *p < 0.05. Freezing in the absence of foot shock quantification. n = 12 per group. 2-way 
RM-ANOVA/Tukey’s: *p < 0.05 (E). All data shown are mean ± SEM Image taken from Hornsby et al. 
2016. 
 
71 
 
4.3.2.1 Acute CR has no effect on the Type II NSPC pool in the DG of WT and 
GHSR-KO mice. 
The WT and GHSR KO mice were also stained for type II NSPC 
marker Sox2, to determine the effect of genotype and/or CR on the stem cell 
pool. Sections were stained using Ni-DAB immunochemical protocol (n = 4 
per group) (Figure 4.7). Sox2+ cells were then counted using ImageJ and 
analysed in Graphpad Prism 7. Data analysis revealed no significant 
difference in Sox2+ cell number between GHSR-KO and WT littermates 
(Mann Whitney test, P = 0.7209; Figure 4.7B), indicating that the genetic KO 
has not adversely affected the stem cell niche. However, a significant increase 
in Sox2+ cells was reported in GHSR-KO CR compared to GHSR-KO ad lib 
fed mice (Tukeys’s multiple comparison test following 2-way ANOVA, P = 
0.0338, F(1, 12) = 8.799; Figure 4.7C). 
 
Figure 4.7 Genotype has no effect on the number of type II NSPC’s, and CR significantly increases 
type II NSPC number independent of GHSR. 
Representative immunohistochemical Ni-DAB staining of type II Sox2+ cells in the DG (A). Dashed line 
= SGZ. Scalebar = 100µm. No significant difference in Sox2+ cell number between WT and GHSR KO 
mice (B). Statistical analysis performed, Mann-Whitney test, n = 8 per group. CR has no effect on WT 
Sox2+ cell number, but elicits a significant increase in type II NSPC number in the GHSR KO mice, p = 
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0.0338. Statistical analysis performed, 2-way ANOVA followed by Tukey’s multiple comparison post-
hoc test, n = 4 per group. 
 
4.3.3 The absence of circulating ghrelin has no effect on the numbers of 
type II NSPC’s, proliferating cells, immature and new-born neuronal cells 
in the DG. 
As we demonstrate that the ghrelin receptor, GHSR, appears to be 
important in promoting the beneficial effects of CR on AHN and cognitive 
function, we sought to determine whether circulating ghrelin mediates this 
action. 
To analyse whether the genetic ablation of ghrelin affects AHN 
Ghrelin KO mice, that lack both active (AG) and inactive ghrelin (UAG), and 
their WT littermates were analysed by IHC for markers of type II NSPCs 
(Sox2+, Figure 4.8A), proliferating cells (Ki67+, Figure 4.8B) and immature 
neuronal cells (DCX+, Figure 4.8C). Immunofluorescent staining was also 
performed for new adult-born mature neurones (BrdU+ NeuN+, Figure 4.8D). 
Statistical analysis of cell counts (2-tailed Students t-test) revealed no 
significant difference between WT and ghrelin KO mice in any of the 
comparisons made. These data suggest that the absence of circulating ghrelin 
has no effect on rates of basal AHN.  
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Figure 4.8 Ghrelin KO mice, lacking in circulating AG and UAG, show no effects on basal rates of 
neurogenesis in the dentate gyrus. 
Ghrelin KO mice show no change in the number of Sox2+ NSPCs (n=8/group)(A), proliferating Ki67+ 
cells (n=4/group)(B), immature DCX+ neurones (WT n=6. ghrelin KO n=7)(D), and new-born 
BrdU+NeuN+ mature neurones (WT n=9, ghrelin KO n=12)(D), in the DG of the hippocampus. Scale 
bar = 200μm for A&B, 50μm for C&D, white arrow indicates BrdU+NeuN+ cell. Statistical analysis was 
done by 2-talied Student t-test. Scalebar = 200µm (A&B), 50µm (C&D). ns = not significant. All data 
represented as mean ± SEM (Hornsby et al., 2018). 
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4.3.3.1 Ghrelin KO mice show normal rate of new adult-born neurone activation 
following CR. 
To determine the effect of ghrelin KO on new adult-born neurone 
activation, hippocampal sections were immunofluorescently labelled with 
BrdU and the IEG marker c-Fos (Figure 4.9B, C), a marker of cell activation. 
Immunoreactivity following CR and CR-refeeding was also measured, to 
determine whether ghrelin mediates this cell activation. Analysis of the data 
by 2-way ANOVA and Tukey’s post-hoc multiple comparison tests showed 
there was no effect of genotype, F(1, 33) = 0.02195, P=0.8831. With regard to 
feeding regime, there was a significant increase in the number of BrdU+ c-
Fos+ cells in the WT CR group compared to WT ad-lib controls ( P=0.0444, 
Figure 4.9D), this was also observed between the ghrelin KO CR group and 
the ghrelin KO ad-lib group (P=0.0235). This indicates that these new-born 
neurones’ activity is sensitive to CR. Also, there was a significant increase in 
the number of double positive cells following CR-refeeding in the WT group 
compared to ad-lib fed WT controls (P=0.0288). From this analysis the overall 
effect of the feeding paradigm was highly significant, F(2, 33) = 12.83, 
P<0.0001, indicating that CR had an overall positive effect on new cell 
activation, be it independent of the presence of ghrelin. With regards to the 
subset of new-born cells that were inactive (BrdU+ c-Fos-, Figure 4.9E), these 
were not affected by genotype, F(1, 33) = 0.1967, P=0.6603, but their response 
to the feeding paradigm was significant across both WT and ghrelin KO 
groups, F(2, 33) = 5.764, P=0.0071. This indicates that the absence of 
circulating ghrelin does not affect the rate of new-born cell production that 
are not activated by CR. It was also observed that there was no effect of 
genotype on the total number of activated cells in the DG (c-Fos+, Figure 
4.9F), F (1, 33) = 1.321, P=0.2587. In addition, there was no significant 
response to feeding pattern in these cells (Figure 4.9F), F (2, 33) = 1.431, 
P=0.2536. The total number of new-born cells in the DG (BrdU+) was 
significantly increased by CR in both WT (WT ad lib vs WT CR, P = 0.0177) 
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and ghrelin KO’s (ghrelin KO ad lib vs ghrelin KO CR, P = 0.0026), showing 
that the effect of CR on new cell production is significant (feeding pattern, P 
<0.0001, F(2, 31) = 15.18), independent of genotype (P = 0.5132, F(1, 31) = 
0.4376) (Figure 4.9G). These data suggest that there may be another mediator 
of the beneficial effects of CR on the activation of these new-born cells in the 
DG of the hippocampus. 
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Figure 4.9 Mice lacking in circulating AG and UAG have no impairment in their response to CR. 
Experimental paradigm schematic (A). Representative confocal images of new adult-born active cells 
(BrdU+ c-Fos+) in WT (B) and Ghrelin KO (C) mice. Genotype has no effect on BrdU+ c-Fos+ (D), or the 
number of BrdU+ c-Fos- cells (E). Total c-Fos cell number in the DG was unaffected by genotype or 
feeding regime (F). Total BrdU cell number in the DG was increased by CR in both WT and KO (G).  
Scalebar = 50µm. n = 6/group. Statistical analysis performed 2-way ANOVA followed by post-hoc 
Tukey’s multiple comparisons test. * = p<0.05, ** = p<0.01. All data represented as mean ± SEM. 
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4.3.3.2 The effect of age on new neuronal cell survival and activation. 
Due to our interest in CR, AHN and cognitive decline in an aging 
population the effect of age was also analysed in these ghrelin KO mice and 
their WT littermates. Adult mice aged 6-7 months were compared to an aged 
group of 15-17 months of age, to determine whether age affected the rate of 
new adult-born neurone survival (BrdU+ NeuN+) and new adult-born cell 
activation (BrdU+ c-Fos+), in the presence and absence of ghrelin. This 
analysis consisted of 4 different groups; WT 6-7 month (n = 5), WT 15-17 
month (n = 4), ghrelin KO 6-7 month (n = 6) and ghrelin KO 15-17 month (n = 
5), that underwent overnight CR. The cell counts were statistically analysed 
using a 2-way ANOVA followed by Tukey’s post-hoc multiple comparisons 
test. The overall effect of genotype and age was not significant for BrdU+ 
NeuN+ cells (Figure 4.10A, E); genotype F(1,16) = 1.15, P=0.2994, and age 
F(1,16) = 0.03643, P=0.8510. However, a subset set of those new adult-born 
BrdU+ NeuN- cells - which are not mature neurones - do appear to be 
sensitive to age (Figure 4.10B, E). Indeed, there was a significant increase in 
the number of BrdU+ NeuN- cells in the aged mice compared to young, in 
both WT (WT 6-7 month vs WT 15-17 month, P=0.0143) and ghrelin KO 
(Ghrelin KO 6-7 month vs Ghrelin KO 15-17 month, P<0.0001) mice. This 
suggests an increase in new-born cell survival with a decrease in AHN and a 
potential increase in NSPC formation and or gliogenesis with advancing age. 
Similarly, there is no significant effect of age on new adult-born active cells 
(BrdU+ c-Fos+, Figure 4.10C, F), F(1,18) = 0.3184, P=0.5795. Conversely, there 
does appear to be a significant difference within the aged groups of mice 
(WT 15-17 month vs Ghrelin KO 15-17 month), with an elevation in the 
number of BrdU+ c-Fos- cells in the DG (P=0.0455), and difference in 
genotype overall (F(1,18) = 5.48, P=0.0309) (Figure 4.10D, F). This suggests 
that there may be another soluble mediator promoting this new adult-born 
cell survival, in aged mice, in the absence of circulating ghrelin. 
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Figure 4.10 Age has no overall effect on the number of new adult-born neurones and new adult-
born active cells in CR mice. 
No significant difference in the survival of new-born mature neurones (BrdU+ NeuN+, A) or new-born 
cell activation (BrdU+ c-Fos+, C) seen with age or genotype. However, the number of new non-neuronal 
cells (BrdU+ NeuN-) affected increased by with age in both CR-ed WT and ghrelin KO (B). With new 
cells that are not active (BrdU+ c-Fos-, D) there is a significant difference between the 15-17 month CR-
ed WT and ghrelin KO mice. Percentage proportion of new-born cells that are activated (F) and become 
mature neurones (E). Statistical analysis performed by 2-way ANOVA followed by Tukey’s post-hoc 
multiple comparisons test. n = 4-6/group. ns = not significant, * = P<0.05, **** = P<0.0001. 
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4.4 Discussion 
Different transgenic mouse models were used to decipher ghrelin’s 
mode of action; GHSR-eGFP mice and GHSR KO mice were used to define 
whether the presence of GHSR was necessary to facilitate the positive effects 
of CR and/or AG treatment on AHN. Ghrelin KO mice were used to 
determine if ghrelin is the circulating mediator that promotes these beneficial 
pro-neurogenic effects on basal rates of AHN and new cell activation in the 
DG.  
This work has shown that by elevating endogenous ghrelin levels by 
CR and exogenously via AG treatment, promotes AHN and neuronal cell 
activation in cells that express ghrelin receptor in the DG, and that the 
presence of GHSR is needed to facilitate this (Figure 3.4). Interestingly, the 
absence of circulating AG and UAG had no effect on basal rates of AHN or 
new adult-born cell activation in the DG, suggesting that ghrelin’s action on 
neurogenesis and cell activation may not be direct. Ghrelin could possibly 
induce other soluble factors that promote AHN and aid in memory 
consolidation, such as BDNF (Bekinschtein et al., 2013, 2014). 
Ghrelin treatment has been shown to induce the expression of IEG’s 
Egr-1 and c-Fos in the arcuate nucleus of fasted and fed mice (Hewson & 
Dickson, 2001). With this knowledge, CR’s and AG treatment’s effect on cell 
activation in cells that express GHSR in areas of the brain that are important 
for learning and memory was examined. This work showed that both CR 
and AG treatment elicits a significant increase in the expression of Egr-1 on 
cells that express GHSR and those that do not, in the DG. This suggests that 
GHSR activation induces Egr-1 expression in the DG. This is interesting, as 
Egr-1 expression specific to the DG is known to be important for the 
functional integration on new-born neurones in the DG. In a study using 
zif268 KO mice (Egr-1 KO) and WT mice (male, 2-3 months old) were 
administered BrdU (50mg/kg) to identify the effects of the KO on cell 
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proliferation, survival, and survival after memory testing (morris water-
maze – locate a hidden platform). It was shown that zif268 (Egr1) was 
required for the survival of new-born cells in the 2-3 week period after their 
birth, as zif268 KO mice showed decreased BrdU+ cells in the DG 21 days 
post injection (dpi) compared to WT, indicating increased apoptosis. 
However, this accelerated death didn’t affect the number to immature and 
mature neurones. Also, it was observed following training in the morris 
water-maze task, that WT mice spent more time in the correct quadrant for 
the platform than the KO mice, and significantly more crossings in the right 
area compared to KO’s, indicating that Egr1 is required for spatial learning 
and memory. Also, the dentate granule cells (DGC) in KO’s at 21 dpi had a 
reduced  GluR1 expression (when they should be receiving glutamatergic 
inputs) compared to WT and an imbalance in the expression of chloride 
cotransports NKCC1 and KCC2, meaning that there is a delay in the 
maturation of GABA- and glutamatergic functions of these new-born DGC’s  
(Veyrac et al., 2013). So, this increased expression of Egr1 following CR, 
which increases ghrelin levels, may promote the survival of these new-born 
neurones, allowing more new-born cells to mature and functionally 
integrate. 
 c-Fos expression was also significantly increased in the DG by AG 
treatment but not by CR. Egr-1 expression was also elevated in other areas of 
the brain important for learning and memory; the lateral entorhinal cortex, 
cingulate cortex and the basal lateral amygdala, following both AG treatment 
and the combination of AG treatment and CR. This is interesting as Egr-1 is 
known to have a function in synaptic plasticity and hippocampal memory 
formation (Bozon, Davis, & Laroche, 2002). The work in this chapter has 
shown that AG increased c-Fos expression in the DG, on both GHSR- and 
GHSR+ cells. Also, in the experiments in ghrelin KO mice, overnight fasting 
did significantly induce c-Fos expression, but only in new-born neurones. 
These data suggest that targets of c-Fos could also be mediating 
ghrelin/GHSR signalling. A recent study has looked at various stimuli that 
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target c-Fos in regards to neuronal activity. Mouse coritcol neurones in 
culture were treated with KCl (55nm), BDNF (10ng/ml) and forskolin 
(adenylate cyclase stimulator, 10µM), and all showed activation of c-Fos 
enhancers (e1-e2-e5, e1-e4-e5 and e1-e5, respectively) and increased c-Fos 
mRNA levels. Also, BDNF treatment in the mouse brain  induced activation 
of c-Fos enhancers in the hippocampus  (Joo, Schaukowitch, Farbiak, Kilaru, 
& Kim, 2015). 
Ghrelin has been shown to have a proliferative effect on hippocampal 
cells (Johansson et al., 2008) and neural progenitor cells (Li et al., 2014; Li, 
Chung, et al., 2013). However, from the data produced in this experiment 
indicated that CR and/or AG treatment had no effect on the rates of type I 
(Ki67+ Nestin+) and type II (Ki67+ Sox2+) NSPC proliferation, and had no 
effect on overall proliferation rates (Ki67+ cells), suggesting that acute AG 
treatment and a short period of CR (these mice were fasted for 16 hours, 
overnight) has no effect on cell proliferation. In comparsion to previous 
studies, this work shows a similar outcome to that of Yumi Kim who 
demonstrated that 3 months of CR had no effect on progenitor cell 
proliferation in WT and ghrelin KO mice (Kim et al., 2015), but conflicts with 
the work in Mark Mattson’s lab showing that CR increased proliferation of 
cells (J Lee et al., 2000). 
In light of the effect of overnight CR on IEG expression, a 2-week 
period of CR was used to understand the effects of longer-term CR on AHN. 
We show that this prolonged period of CR increases the number of new 
adult-born mature neurones (BrdU+ NeuN+) in the DG of the hippocampus, 
31 days after the last day of CR. This effect was not seen in GHSR KO mice, 
but in their WT littermates, showing that the receptor is required to facilitate 
the pro-neurogenic effects of CR. As ghrelin is not produced in the brain 
(Sakata et al., 2009), it may be circulating ghrelin that is crossing the blood 
brain barrier to modulate AHN, as has been shown by William Banks who 
that both AG and UAG can cross the BBB (Banks et al., 2002) and Tamas 
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Horvath showed that peripheral ghrelin acts on the hippocampus (Diano et 
al., 2006), or other unidentified ligands that interact with GHSR within the 
DG such as GHRH (growth hormone releasing hormone) a known agonist of 
GHSR (Casanueva et al., 2008). However, AHN is enhanced by peripheral 
treatment with AG (Kent et al., 2015) and CR increases ghrelin levels in 
plasma (Lutter et al., 2008), so it is highly likely that the pro-neurogenic 
effects of CR and the requirement of GHSR to facilitate this, is stimulated by 
ghrelin. 
These GHSR KO mice also showed deficits in retaining fear memory, 
which has been shown previously by Albarran-Zeckler et al. 2012,. CR 
showed to alleviate these deficits with GHSR KO mice, by demonstrating 
improvements in fear-memory retention. Contextual fear conditioning (CFC) 
is a hippocampal dependant test for learning and memory and sensitive to 
AHN (Kitamura et al., 2009), and the new mature neurones produced by 
AHN are important for pattern separation memory (Clelland et al., 2009).  
Although ghrelin has previously been shown to stimulate AHN in 
ghrelin KO mice  and promote the migration and division of NSPC’s (Li et 
al., 2014; Li, Chung, et al., 2013), this was not observed the ghrelin KO model 
that was used in this analysis. In addition, the absence of circulating AG and 
UAG had no effect on type II NSPC number, the rate of cell proliferation or 
the production of new adult-born neurones in the DG. Furthermore, CR had 
no effect on new adult-born cell activation in this mouse model.  This may be 
due to experimental differences. Our study used female C57BL/6 ghrelin KO 
mice that were ages between 5 and 16 months old, whereas Li et al used male 
C57BL/6 mice aged 8-9 weeks. So, there are differences in sex and age of 
mice used for each study. Also, ghrelin was elevated in our study via an 
overnight fast before being terminally anaesthetized, and the brain tissue 
was immersion fixed in PFA. Whereas the Li et al mice received ghrelin 
injections (80µg/kg) for 8 days and were transcardially perfused with PFA. 
So, the route by which ghrelin was elevated were different and the way in 
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which the tissue was fixed was different. All factors that may affect the 
outcome of an experiment. 
A limitation of the ghrelin KO model used in this chapter is it does not 
have any circulating AG and UAG, but it also lacks obestatin.  Treatment 
with obestatin in male Wistar rats produced improvements in novel object 
recognition behavioural memory testing with increased exploration, which is 
dependent on the hippocampus, and also an increase in latency time in the 
step-down test indicating increased memory retention (Carlini, Schiöth, & 
deBarioglio, 2007). Obestatin has also shown to enhance the proliferation of 
adult hippocampal progenitor cells (AHPs) in vitro.  Rat AHPs treated with 
various concentrations of obestatin (1, 10, 100 and 500nM) all showed a 
significant increase in cell proliferation and survival, and also a reduction in 
caspase 3 activity indicating anti-apoptotic effects also (Gargantini et al., 
2016). 
The GHSR KO mouse model also has its limitations. This is a germline 
KO; meaning that this mouse model underwent development without 
GHSR, so potentially there may have been some developed compensatory 
mechanisms to counteract this. Newer technologies that are 
chemogenetically based, such as DREADDs (designer receptors exclusively 
activated by designer drugs) could be of better use, as you would have 
control over when to KO a particular gene. These are being more readily 
used in neuroscience and signalling (Urban & Roth, 2015). 
 
These data suggest that CR mediates positive effects on AHN and 
learning and memory through GHSR signalling. However, ghrelin may not 
be the only peptide that triggers its downstream effects. 
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Chapter 5 The effect of UAG and AG on 
AHN  
 
5.1 Introduction 
The most abundant form of ghrelin in the circulation is the so-called 
inactive form, UAG, which makes up approximately 90% of circulating 
ghrelin. UAG is activated via the addition of an octanoyl group, and this 
octanoylation is executed by the enzyme GOAT (ghrelin-o-acyl transferase) 
in the stomach (Gutierrez et al., 2008; Yang et al., 2008). Following this post-
translational octanoylation AG can bind its receptor, GHSR (M Kojima et al., 
1999).  
More recent work has shown that ghrelin may undergo tissue specific 
acylation events, such as in the dentate gyrus of the hippocampus (Murtuza 
& Isokawa, 2018) and bone marrow where it promotes adipogenesis 
(Hopkins et al., 2017). Also, AG and UAG have been shown to have a 
synergistic relationship, where AG promotes and UAG down-regulates 
glucose output of hepatocytes (Gauna et al., 2005). Furthermore, with regard 
to synaptic plasticity and long term potentiation (LTP), AG has shown to 
prolong LTP in the DG whereas UAG has no effect on LTP (L. Chen et al., 
2011). These data suggest that regulating the octanoylation status of ghrelin 
may have important modulatory effects on ghrelin function in a tissue 
specific manner. 
Dendritic spines are protrusions from the neuronal membrane that 
consist of a head connected to the dendrite by a thin neck. These spines 
receive connections from excitatory synapses and contain Ca2+within these 
compartments which is essential for signalling and synaptic plasticity 
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(Nimchinsky, Sabatini, & Svoboda, 2002; Sabatini, Maravall, & Svoboda, 
2001). 
5.1.1 Aim of this chapter. 
As we have shown in previous chapters that elevation of AG, indirectly 
via CR and directly via AG treatment positively modulates neurogenesis in 
adult mouse brain, and that CR’s effects are dependent on GHSR, this 
chapter aims to determine whether UAG modulates AHN in the 
hippocampus. 
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5.2 Materials & Methods 
 
5.2.1 Mice 
All animal work in this chapter on the Regeneron GOAT KO mouse 
model (5.2.1.2) was performed in the lab of Zane Andrews of Monash 
University, Melbourne, Australia. All work was carried out with ethical 
approval from the institution. 
All animal work on the Taconic Farms GOAT KO mouse model was 
performed in the lab of Tim Wells of Cardiff University, UK. All work was 
carried out with the ethical approval from the institution. 
 
5.2.1.1 UAG treatment in WT and GOAT KO mice  
6 month old GOAT homozygous KO mice and their WT C57BL/6 
littermates, generated in Taconic Farms (Hudson, NY), underwent a 7 day 
treatment of either vehicle (sterile isotonic saline with BSA (1mg/ml) and 
heparin (5U/ml) at 0.5µl/h)) or UAG (48µg/day), which was administered 
via an indwelling jugular vein catheter attached to a subcutaneous osmotic 
mini-pump (Alzet, model 1007D). 1 day after the pumps were fitted, the mice 
received an i.p. injection of BrdU (50mg/kg) to label any dividing cells. After 
the 7 days, mice were anaesthetised with isoflurane and sacrificed by 
decapitation, and the brain tissue removed. 
 
5.2.1.2 AG treatment in WT and GOAT KO mice  
12 week old adult male C57BL/6 WT and GOAT KO from Regeneron 
were created using Velocigene technology where the GOAT gene ATG-stop 
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sequence was replaced with lac reporter gene with the BAC (bacterial 
artificial chromosome) (Yang et al., 2008). These mice underwent 7 days of 
i.c.v. (intracerebroventricular) infusions of either artificial cerebro-spinal 
fluid (ACSF) or AG (10µg/kg/day, www.polypeptide.com) in conjunction 
with BrdU (50mg/kg) using Alzet osmotic mini-pumps. The mice were 
separated into 4 groups; WT ACSF + BrdU, WT AG + BrdU, KO ACSF + 
BrdU and KO AG + BrdU. At the end of day 7 the mice were intra-cardially 
perfused with 4% PFA and the brain tissue collected. 
To allow for the longer-term analysis of treatment on AHN an 
additional cohort of these mice (same 4 groups) were maintained under 
normal laboratory conditions until day 28, before they were intra-cardially 
perfused with 4% PFA and the brain tissue collected.  
Finally, another subset of these WT and GOAT KO mice, that were 
approximately 12 weeks old, were sacrificed to undergo Golgi-Cox treatment 
for analysis of dentritic spine density (see 5.2.9). 
 
5.2.1.3 UAG treatment in WT mice  
12 week old WT C54BL/6 mice were given daily subcutaneous 
infusions of UAG (80µg/kg/day, www.polypeptide.com) for 7 days, via 
osmotic mini-pump (Alzet). Following the 7 days, mice were intra-caridially 
perfused with 4% PFA and the brain tissue collected. 
 
5.2.2 Tissue Preparation 
Mouse brain samples were collected following intra-cardial fixation 
with 4% paraformaldehyde (PFA) (Sigma Aldrich, St Louis, USA) and sunk 
in 30% sucrose prior to being stored at 4C in the cold room, submerged in 
PBS (Sigma Aldrich, St Louis, USA) with 0.1% Sodium Azide (Sigma Aldrich, 
88 
 
St Louis, USA), until required for analysis. All procedures were performed 
with ethical approval at Monash University, Australia. Swansea University’s 
Animal Welfare and Ethical Review Panel (AWERP) approved the studies. 
 
5.2.3 Tissue Sectioning 
Mouse brain tissue was sectioned as previously stated in the general 
methods 2.2. Sections were specifically collected into 12-well Nunclon plates, 
in a ratio of 1:12. 
 
5.2.4 Immunofluorescent staining of recently divided immature neuronal 
cells (BrdU-DCX) in 6 month old WT and GOAT KO mice. 
See protocol section 2.3.3, with the following specific details. 
Following DNA denaturation with 2M HCl and Borate buffer (pH6) and a 
series of washes, sections were blocked with 5% NDS in 0.1% PBS-T for 60 
minutes. Excess block was removed and a cocktail of both primary 
antibodies (Table 5.1) diluted in 0.1% PBS-T were applied and incubated for 
24 hours at 4˚C, on a rocker in the cold room. Sections were washed as before 
in 1X PBS, following which a cocktail of both secondary antibodies (Table 
5.2) diluted in 0.1% PBS-T was applied to the tissues, and incubated for 30 
minutes. Sections were washed a final time as before, with the addition of 
Hoechst nuclear counterstain (1:10,000; H3570, Life Technologies) to the first 
wash. Finally, sections were mounted as previously described.  
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Table 5.1 Primary antibodies used. 
Target Cell Type Species Company & Cat. 
No. 
Dilution 
BrdU New-born cells Rat ABD Serotec 
(MCA2060) 
1:400/1:3000 
DCX Immature 
neuronal cells 
Goat Santa Cruz (Sc-8066) 1:200 IF 
1:500 NiDAB 
NeuN Mature Granule 
cells 
Mouse Millipore (MAB377) 1:1000 
Ki67 Proliferating 
cells 
Rabbit Abcam (Ab16667) 1:500 Ni-DAB 
Sox2 Type II NSPCs Rabbit Abcam (Ab97959)
  
1:1000 Ni-DAB 
c-Fos IEG Rabbit Santa Cruz (Sc-52) 1:4000 Ni-DAB 
Egr-1 IEG Rabbit Santa Cruz (Sc-189) 1:4000 Ni-DAB 
 
 
5.2.5 Immunofluorescent staining of newborn mature neuronal cells 
(BrdU-NeuN) in 12 week old WT and GOAT KO mice. 
See protocol 2.3.3, with the following additional details.  
Following DNA denaturation and washes, described previously, 
sections were blocked in 5% NGS (diluted in 0.1% PBS-T) for 60 minutes. The 
excess block was removed and the BrdU primary antibody (Table 5.1) diluted 
in 0.1% PBS-T was applied for 24 hours at 4˚C in the cold room, on a rocker. 
Following this incubation, the sections were washed as before, and 
biotinylated secondary antibody (Table 5.2) diluted 0.1% PBS-T was applied 
to the sections, and incubated for 60 minutes, protected from light. Sections 
were washed, after which the Streptavidin conjugate diluted in 0.1% PBS-T 
was applied to the tissue and incubated for 30 minutes, following which the 
sections were washed again. Subsequently, the NeuN primary antibody 
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diluted in 0.1% PBS-T was applied to the sections and incubated for 24 hours 
at RT. Following another wash series the corresponding fluorescent 
secondary antibody was applied to the sections and incubated for 30 
minutes. Finally, the sections were washed as before, with the addition of 
Hoechst to the first wash, and sections were mounted and coverslipped as 
stated above. 
 
Table 5.2 Secondary antibodies and conjugates used. 
Secondary Ab Company & Cat. No Dilution 
Alexa Fluor 568 Donkey α-Goat IgG (H+L) Molecular Probes 
(A11057) 
1:500 
Alexa Fluor 488 Donkey α-Rat IgG (H+L) Molecular Probes 
(A21208) 
1:500 
Biotinylated Goat α-Rat IgG Vector Laboratories 
(BA-9400) 
1:400 
Streptavidin Alexa Fluor 594 conjugate Invitrogen (S11227) 1:500 
Alexa Fluor 488 Goat α-Mouse IgG (H+L) Molecular Probes 
(A11001) 
1:500 
Biotin-SP-conjugated AffiniPure Donkey α-
Goat IgG (H+L) 
Jackson Laboratories 
(705-065-003) 
1:400 
Biotinylated Goat α-Rabbit IgG Vector Laboratories 
(BA-1000) 
1:400 
 
5.2.6 Immunohistochemical staining of immature neurones (DCX) in WT 
and GOAT KO mice, using Ni-DAB. 
See protocol 4.2.8.  
Staining in this experiment was performed as previously mentioned.  
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5.2.7 Immunohisotchemical staining of proliferating (Ki67) cells, type II 
NSPC’s (Sox2) and active (Egr-1) neurones, in WT and GOAT KO mice, 
using Ni-DAB. 
See protocol 2.3.5 for method, with specifics below. 
Following the removal of excess citrate buffer, 5% NGS block in 0.03% 
PBS-T was applied to the sections and incubated for 60 minutes at RT. 
Primary antibody for Sox2, Ki67 or Egr-1 was then applied (see Table 5.1) to 
the sections, diluted in 0.03% PBS-T and 2% NGS, this was left to incubate 
overnight at 4˚C in the cold room, on a rocker. Sections were washed as 
before and secondary biotinylated antibody (see Table 5.2) diluted in 0.03% 
PBS-T and 2% NGS, was applied to the sections and incubated as stated 
previously. 
 
5.2.8 Immunohistochemical staining of active (c-Fos) neurones in WT and 
GOAT KO mice, using Ni-DAB. 
Please refer to the standard protocol in the methods section 2.3.4, with 
the following specifics. 
Sections were blocked in 5% NGS in 0.03% PBS-T for 60 minutes at RT. 
Following this, the primary anti-Egr-1 antibody diluted in 0.03% PBS-T with 
2% NGS was applied to the sections and incubated overnight at 4˚C on a 
rocker. Sections were washed in 1X PBS and 0.03% PBS-T as before, after 
which sections were incubated in the biotinylated secondary antibody 
diluted in 0.03% PBS-T with 2% NGS for 70 minutes at RT, protected from 
light. Following this, the sections were washed again and a pre-mixed ABC 
solution was applied and sections incubated for 90 minutes at RT, protected 
from light. To enhance the immunoreactivity, an additional amplification 
step was used; sections were incubated in biotinylated tyramine (bTyr) 
(diluted 1:100 in 0.03% PBS-T with 0.1% Triton-X) for 10 minutes at RT. 
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Sections were then washed 1 time in 1X PBS and 2 times in 0.03% PBS-T, 10 
minutes each, after which another ABC solution was applied to the sections 
for 90 minutes at RT. Subsequently, the sections were washed once in 1X 
PBS, twice in 0.03% PBS-T and once in sodium acetate for 10 minutes each. 
Sections were then reacted in Ni-DAB and processed as previously stated. 
 
5.2.9 Impregnation of WT and GOAT KO mouse brains with Golgi Cox 
solution. 
Golgi Cox staining of mouse brain tissue was performed using the FD 
Rapid GolgiStainTM Kit (PK401A, FD Neurotechnologies Inc.). Upon removal 
from the skull, brain tissue was rinsed quickly with Milli-Q water to remove 
any residual blood. The tissue was immersed in impregnation solution (equal 
volumes solution A and solution B, which contain mercuric chloride, 
potassium dichromate and potassium chromate, and stored at RT for 2 
weeks, in the dark. After the first 6 hours or after 1 day, the impregnation 
solution was changed. The tissue was then transferred into solution C and 
stored at RT for 72 hours or up to 1 week, in the dark. The solution C was 
replaced after the first 24 hours of immersion. 
The tissue was then rapidly frozen before sectioning by slowly dipping 
the tissue into pre-cooled iso-pentane, on dry-ice, for a few seconds. The 
tissue was placed on dry-ice for 1 minute, before being individually wrapped 
in foil and placed in a -80˚C freezer for storage. 
 
5.2.10 Sectioning and processing of Golgi-Cox impregnated brain tissue. 
WT and GOAT KO mice impregnated with Golgi-Cox were sectioned 
using a Leica CM1900 Cryostat with the chamber temperature set to -15˚C 
and the cutting stage temperature set to -10˚C. Tissue was cut to a thickness 
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of 120µm and placed onto glass slides that were rinsed in Solution C from the 
FD Rapid GolgiStainTM Kit (PK401A, FD Neurotechnologies Inc.). Slides were 
dried overnight at RT, and protected from light. The slides were processed in 
the following way; sections were rinsed 2x with Milli-Q water, 4 minutes 
each, they were then placed in a mixture of 1 part Solution D, 1 part Solution 
E and 2 parts Milli-Q water (DEQ solution) for 10 minutes. The slides were 
then dehydrated in a series of 50%, 75% and 95% EtOH for 4 minutes each, 
followed for 4x 4 minutes in 100% EtOH. Subsequently, the slides were 
delipified in Histoclear 3x 4 minutes, and coverslipped using Entellan 
mounting media. 
 
5.2.11 Analysis of fluorescent immunoreactivity. 
Fluorescently labelled tissue sections were analysed for their 
immunoreactivity using a Zeiss Imager M1 microscope with Axiocam MRm. 
High resolution imaging of co-localised proteins throughout the z-axis was 
performed using a Laser Scanning Confocal Microscope (LSCM) (Zeiss LSM 
710). 
 
5.2.12 Analysis of Ni-DAB immunoreactivity. 
Ni-DAB immuno-labelled sections were analysed for their 
immunoreactivity using a Nikon Eclipse 50i microscope system and NIS 
Elements F4 software. Cells were either counted manually where possible, or 
with the use of ImageJ software. 
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5.2.13 Analysis of Golgi-Cox staining. 
Dendritic spines were analysed from these slides using the Nikon 
Eclipse 50i microscope using a Nikon Plan 100x/1.25 oil objective objective. 
The images were then subsequently processed using ImageJ software in 
order to manually count dendritic spines. Spines were categorised into the 
following groups; mushroom, thin spine, stubby spine, branched and 
filopodium (Harris, Jensen, & Tsao, 1992; Hering & Sheng, 2001). 
 
5.2.14 Data and Statistical Analysis. 
5.2.14.1 Effect of UAG treatment on AHN in WT and GOAT KO mice. 
For the analysis of immunohistochemical Ni-DAB staining of 
proliferating cells (Ki67), immature neurones (DCX) and neuronally active 
cells (c-Fos), n = 5-6 per group and a whole well of hippocampal sections 
(approximately 10-16 sections per mouse) stained. Cells in the GCL of the DG 
were counted using ImageJ software (5.2.12); total cell counts for each mouse 
were divided by the number of sections counted to obtain an average. 
Average cell count was multiplied by 180 (1:6 collection of 30µm sections, 
180µm between each section) to obtain number of positive cells per whole 
DG.  
For the analysis of immunofluorescent staining of new-born immature 
neurones (BrdU-DCX), n = 5-6 per group and 4 DG sections selected for each 
mouse, and data handled as described in 5.2.11 and above.  
Statistical analysis of the data was performed with Graphpad Prism. 
Due to there being 2 variables (genotype and treatment) a 2-way ANOVA 
followed by Holm-Sidak post-hoc multiple comparison test was used. 
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5.2.14.2 Effect of UAG treatment on Type II NSPC pool in WT and GOAT KO 
mice. 
Analysis of immunofluorescent staining of type II NSPCs (Sox2), n = 4 
per group and 4-6 hippocampal sections stained. Data was collected and 
handled as described above (5.2.14.1). As there was one variable (genotype) a 
2-tailed unpaired t-test was performed on the data.   
5.2.14.3 Effect on AHN and Type II NSPCs in second GOAT KO (Regeneron) 
model. 
Analysis of immunohistochemical Ni-DAB staining of proliferating 
(Ki67) and immature neurone (DCX) cells in the GCL of the DG, n = 6 per 
group and 4 sections per mouse stained. Cell counts and area measurements 
of the GCL were done using ImageJ software. An average cell count for each 
mouse was multiplied by 360; sections were collected in 1:12 ratio (30µm 
sections, 360µm between sections), and divided by average area measured in 
µm2. Average number cells per µm2 were multiplied by 1000 to obtain 
average number cells per mm2.  
Analysis of immunohistochemical Ni-DAB staining of type II NSPCs 
(Sox2), n = 6 per group and 4 sections per mouse were stained. Images were 
analysed (5.2.12) and data handled as described above with the exception of 
area measurement. 
As there was one variable (genotype) a 2-tailed unpaired t-test was 
performed on the data.   
5.2.14.4 Effect on IEG expression in second GOAT KO model. 
For the analysis of IEG (Egr-1 and c-Fos) expression by 
immunohistochemical Ni-DAB staining, n=4-8 mice per group and 4 sections 
stained per mouse. Cell counts were obtained using ImageJ to analyse 
images taken (5.2.12). Data was handled as described above in 5.2.14.3, with 
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the exception of area. Due to there being 2 variables (genotype and 
treatment) a 2-way ANOVA followed by Tukey’s post-hoc multiple 
comparison tests were performed. 
5.2.14.5 Effect of genotype on dendritic spine formation. 
For the analysis of dendritic spines in WT and GOAT KO mice that 
underwent Golgi-cox treatment, n = 3 per group and 4-6 dendrites counted 
per mouse. Spines were counted as stated above (5.2.13) and the dendrite 
length measured using ImageJ. An average of each spine type was calculated 
(total of each spine type / number of dendrites) and an average length of 
dendrite analysed, average spine number was then divided by average 
dendrite length to obtain average number of spine type per µm2 which was 
then x1000 to obtain average spine number per mm2. Due to the multiple 
variables (spine type and genotype) the data was analysed statistically by a 
2-way ANOVA, followed by Fishers LSD post-hoc multiple comparisons test. 
5.2.14.6 Effect of short-term AG treatment on AHN in WT and GOAT KO mice. 
For the analysis of immunofluorescent staining for new-born neurones 
(BrdU-NeuN), n = 4-8 per group with 6-8 hippocampal sections stained per 
mouse. Positively stained cells were counted manually as mentioned 
previously (5.2.11) in the GCL of the DG. Data was handled as above 
(5.2.14.4). Due to the 2 variables in this experiment (genotype and treatment) 
a 2-way ANOVA followed by Tukey’s multiple comparisons test were 
performed on the data. 
5.2.14.7 Effect of UAG treatment on AHN in WT C57BL/6 mice. 
For the analysis of new-born neurones (BrdU-NeuN) in the GCL of the 
DG, n = 9 per group with 6-8 hippocampal sections undergoing staining. 
Positively stained cells in the GCL of the DG were manually counted as 
previously mentioned (5.2.11), and data was handled as described above 
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(5.2.14.4). A 2-tailed unpaired t-test was performed on the data due to only 
one variable of treatment. 
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5.3 Results 
Part of this work was undertaken by Joesph Bhart (Ki67 and DCX 
staining of UAG treated WT and GOAT KO mice) and Luke Roberts (Egr-1 
staining of ghrelin treated WT and GOAT KO mice), members of the Davies 
group. I assisted in their supervision and training of these students, and 
helped optimise and clarify the protocols used for both 
immunohistochemical staining and data analysis.  
 
5.3.1 UAG treatment of adult WT and GOAT KO mice leads to a 
reduction of AHN. 
6 month old GOAT KO mice (see 4.2.1.1) that underwent peripheral 
UAG treatment had a significant reduction in the number of proliferating 
Ki67+ cells (Figure 5.1A), immature DCX+ neurones (Figure 5.1C), and active 
c-Fos+ neurones (Figure 5.2A) in the SGZ of the DG, the region where AHN 
occurs.  
Statistical analysis of the DCX data (two-way ANOVA followed by the 
Holm-Sidak multiple comparisons test) revealed a main effect of genotype 
(WT and GOAT KO, P=0.0096, F(1, 19) = 8.287) and an interaction between 
treatment (Vehicle and UAG) and genotype (WT and GOAT -KO), P=0.0009 
and F(1, 19) = 15.33. The multiple comparisons test revealed that all other 
groups compared to WT-Vehicle treated mice there was a significant 
reduction in the number of DCX+ immature neurones in the SGZ of the DG 
(Figure 5.1C, D); WT-Vehicle vs WT-UAG P=0.0106, WT-Vehicle vs GOAT 
KO-Vehicle P=0.0003, WT-Vehicle vs GOAT KO-UAG P=0.0195. Also, 
analysis of the Ki67 data revealed a significant difference between the 
genotypes (P= 0.0175, F(1, 19) = 6.766) and the interaction between treatment 
and genotype (P=0.0074, F(1, 19) = 9.003) which is shown in (Figure 5.1A, B). 
The multiple comparisons test showed that all other groups in comparison to 
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WT-Vehicle treated mice, there was a significant decrease in the number of 
Ki67+cells in the SGZ of the DG; WT-Vehicle vs WT-UAG P=0.0056, WT-
Vehicle vs GOAT KO-Vehicle P=0.0020, WT-Vehicle vs GOAT KO-UAG P= 
0.0056.  
Finally, analysis of c-Fos+ cells in the DG showed a significant effect of 
UAG the main effect of treatment (P = 0.0391, F(1, 16) = 5.047) and interaction 
between genotype and treatment (P=0.0343, F(1,16) = 5.352) (Figure 5.2A, B). 
The Holm-Sidak multiple comparisions test indicated that in comparison to 
WT-Vehicle treatment mice, there was a significant decrease in neurone 
activation in the DG; WT-Vehicle vs WT-UAG P=0.0147, WT-Vehicle vs 
GOAT KO-Vehicle P=0.0377, WT-Vehicle vs GOAT KO-UAG (P=0.0377). 
These data demonstrate that UAG treatment inhibits cell proliferation, 
immature neurone number and neurone activation in the neurogenic niche of 
the hippocampus. Similarly, GOAT KO results in a reduction in basal levels 
of neurogenesis. 
 
5.3.1.1 Genetic knockout of GOAT or UAG treatment reduced the number of new-
born immature neurones and new-born non-neuronal cells in the SGZ of 
the DG. 
As these mice were administered BrdU, a thymidine analogue that 
incorporates into dividing cells, we investigated the effect of UAG treatment 
and GOAT KO on the production of new-born immature neurones (BrdU+ 
DCX+) in the DG (Figure 5.2C, D). Data analysis showed that the absence of 
GOAT reduced the survival of new-born immature neurones (main effect of 
genotype, P=0.0171, F(1, 18) = 6.896) (Figure 5.2D), and reduced the number 
of non-neuronal cells (BrdU+ DCX-); WT-Vehicle vs WT-UAG, P=0.0438, WT-
Vehicle vs GOAT KO-Vehicle, P=0.0487 (Figure 5.2E). 
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Figure 5.1 UAG treatment in WT and GOAT knockout mice impairs AHN.  
Representative images of Ni-DAB staining of Ki67+ (A) and DCX+ (C) cells in WT and GOAT-/- mice, 
that have been treated with vehicle or UAG. Reduction in the number of proliferating Ki67+ cells (B) 
and immature DCX+ neuronal cells (D)  in the DG. For statistical comparison a 2-way ANOVA with 
Holm-Sidak post-hoc analysis performed; *P<0.05, **P<0.01, ***P<0.001 vs WT-Vehicle. Data shown as 
mean ± SEM. n = 5-6 mice/group. Main 10x magnification images, scale bar = 2100µm, inset 40x 
images scale bar = 50µm (Hornsby et al., 2018). 
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Figure 5.2 UAG treatment in WT and GOAT knockout mice impairs AHN continued. 
Representative images of Ni-DAB staining of c-Fos+ (A) cells in WT and GOAT-/- mice, that have been 
treated with vehicle or UAG. Reduction in the number of neuronally active c-Fos+ cells (B) in the DG. 
New BrdU+DCX+ immature neurone (arrowhead) and BrdU+DCX- (arrow)(C) non-neuronal cell 
survival rate was reduced by GOAT KO (D, E). For statistical comparison a 2-way ANOVA with 
Holm-Sidak post-hoc analysis performed; *P<0.05, **P<0.01, ***P<0.001 vs WT-Vehicle. Data shown as 
mean ± SEM. n = 5-6 mice/group. Main 10x magnification images, scale bar = 2100µm, inset 40x 
images scale bar = 50µm (Hornsby et al., 2018). 
 
5.3.2 GOAT-KO mice show no significant effect on the type II NSPC pool 
compared to WT controls. 
The type II Sox2+ NSPC pool was analysed, in order to confirm that 
genetic ablation of GOAT did not cause any anatomical changes to the DG of 
these mice, and whether the absence of GOAT affected NSPC numbers. 
Analysis revealed no effect of genotype on Sox2+ cell number (P = 
0.8865). No gross morphological changes to the DG were observed by the 
genetic ablation of GOAT (Figure 5.3). 
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Figure 5.3 GOAT KO has no effect on type II NSPC number or structure of the DG.  
Representative fluorescent images of Sox2+ cells in the DG of the hippocampus, of WT and GOAT KO 
mice. Sox2+ cells (red), Hoechst nuclear counterstain (blue), scalebar = 100µm. Statisitical analysis 
performed, 2-tailed unpaired t-test, n = 4 /group, ns = no significance. 
 
5.3.3 A second GOAT KO model shows deficits in AHN, but not type II 
NSPC number. 
A second GOAT KO mouse model was also used (see 4.2.1.2) to 
quantify any effects on AHN.  Hippocampal brain sections from 12-week old 
male mice were immunohistochemically stained for markers of cell 
proliferation (Ki67+, Figure 5.4A) and immature neurone production (DCX+, 
Figure 5.4C). Analysis showed a decrease in these cell populations in the 
GOAT KO (n = 6) compared to WT controls (n = 6), however it was not 
significant. Statistical analysis of the dividing cell population (Ki67+) (2-tailed 
unpaired t-test) showed that the reduction did not reach significance (WT vs 
GOAT KO P = 0.0602), but indicated a deficit in the KO mice (Figure 5.4B). 
The immature neurone population (DCX+) was significantly reduced (WT vs 
GOAT KO P = 0.0234) (Figure 5.4D). Similar to the other GOAT KO mouse 
model used (Taconic farms), these KO mice had no change in the type II 
NSPC pool (P = 0.9770, Figure 5.4E, F). 
These data indicate that these GOAT KO mouse models have deficits 
in AHN, but that it is not due to a disruption to the NSPC pool from which 
these cells arise. 
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Figure 5.4 Regeneron (Yang et al, (2008) GOAT knockout mice have reduction in proliferating cells 
and immature neurone number, type II NSPC pool un-affected.  
Reduction in cell proliferation (A, B) and neurogenesis (C, D) in the DG of GOAT KO mice compared 
to WT controls. Type II NSPC (Sox2+) number comparable between WT and GOAT KO mice (E, F). 
Statistical analysis performed; 2-tailed t-test. Scalebar = 100µm. * P<0.05. Data shown as mean ± SEM. n 
= 6 mice/group (Hornsby et al., 2018). 
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5.3.4 Immediate Early Gene (IEG) expression was unaffected in the DG 
following 7 day acyl-ghrelin treatment in WT and GOAT KO mice. 
These WT and GOAT KO mice were treated with either vehicle 
(artificial cerebro-spinal fluid) or acyl-ghrelin for 7 days (10µg/kg/day i.c.v.), 
after which they were terminally anaesthetised. To determine whether acyl-
ghrelin treatment elicited a response in neuronal cell activation, in the 
presense and absence of the enzyme GOAT, the IEGs Egr-1 and c-Fos were 
analysed (Figure 5.5A, C).  
Upon statistical analysis of the data (2-way ANOVA followed by 
Tukey’s multiple comparison test) produced from immunohistochemical 
staining of the 2 targets, there was no significant change in expression of 
either IEG in the DG of the hippocampus (Figure 5.5B, D). There was no 
significant effect of genotype (Egr1, P = 0.9890, F(1, 12) = 0.0001993; c-Fos, P = 
0.1247, F(1, 18) = 2.594), no effect of treatment (Egr1, P = 0.2178, F(1, 12) = 
1.691; c-Fos, P = 0.8237, F(1, 18) = 0.05112), and no effect on interaction of 
genotype and treatment (Egr1, P = 0.3571, F(1, 12) = 0.9172; c-Fos, P = 0.6711, 
F(1, 18) = 0.1863). 
This indicates that the absence of GOAT does not affect neuronal cell 
activation, and there are no significant effects of acyl-ghrelin treatment on 
IEG cell number in this GOAT KO model (Regeneron). 
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Figure 5.5 IEG expression is un-affected by genotype or AG treatment in the Regeneron GOAT 
knockout mouse model.  
Representative images of Ni-DAB staining of IEGs Egr1+ (A) and c-Fos+ cells (C). Scalebar = 100µm. 
Data is expressed as mean ± SEM, n = 4-8 mice/group. Statisitical analysis performed; 2-way ANOVA 
followed by Tukey’s multiple comparisons test. ns = no significance. 
 
5.3.5 Genotype has no overall effect on dendritic spine formation. 
The brain tissue from WT and GOAT KO mice were impregnated with 
Golgi-Cox solution to allow for the analysis of dendritic spines (Figure 5.6). 
An n of 3 was used for each group and the different types of spines were 
counted on randomly chosen dendrites in the hippocampus. Statistical 
analysis using a 2-way ANOVA followed by a Fisher’s LSD multiple 
comparisons test, revealed no effect of genotype (P = 0.1276, F(1, 20) = 2.526), 
however there does appear to be a significant reduction in the number of 
stubby spines in the GOAT KO mice compared to WT controls (P = 0.0164, 
Figure 5.6B). There was an overall effect on spine type (P < 0.0001, F(4, 20) = 
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26.36), but no significance in the interaction of genotype and spine type (P = 
0.2327, F(4,20) = 1.526). 
These data indicate that the overall number of spines situated on 
hippocampal dendrites was not affected by genotype, but that the specific 
stubby spine type was significantly reduced in the absence of GOAT.  
 
 
Figure 5.6 GOAT knockout significantly decreased the number of Stubby dendritic spines.  
Representative images of dendrites stained with Golgi-cox, used for the analysis of different spine 
types (A). Scalebar = 10µm. n = 3/group. No overall effect of genotype, but a significant decrease in 
stubby spine number in GOAT KO mice (B). Schematic of dendritic spine types (C). Statistical analysis 
performed 2-way ANOVA and Fishers LSD post-hoc multiple comparisons test. Data displayed as 
mean ± SEM. 
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5.3.6 Period of time post-acyl-ghrelin treatment significantly affects rates 
of new neuronal cell production. 
Two sets of WT and GOAT KO mice were administered vehicle 
(artificial cerebro-spinal fluid) and BrdU or acyl-ghrelin and BrdU for 7 days. 
After 7 days of treatment one group were terminally anaesthetised for tissue 
collection on day 8, whilst the other group were maintained until day 28. 
This BrdU pulse-chase approach allowed analysis of new neurone 
survival/maturation via immunofluorescent staining and quantification of 
BrdU+/NeuN+ on day 28, 21 days following the end of treatment (Figure 5.7).  
Mice culled on day 8 showed no significant effect on new mature 
neurone survival/maturation (Figure 5.7A), no effect of genotype (P = 
0.1456, F(1, 12) = 2.422), treatment (P = 0.2334, F(1, 12) = 1.575) or interaction 
(P = 0.5073, F(1, 12) = 0.4672). In the population of new-born cells that are 
non-neuronal (Figure 5.7B), there appears to be a significant negative effect 
of treatment (P = 0.0310, F91, 12) = 5.97) in both WT and GOAT KO 
(genotype, P = 0.4495, F(1, 12) = 0.6112). This indicates that the 7 day 
treatment of acyl-ghrelin is negatively impacting the production of new 
adult-born non-neuronal cells in the DG. 
The group of WT and GOAT KO mice that were maintained until day 
28, 21 days after treatment, appear to show the opposite effect. New adult-
born mature neurone survival is positively modulated by acyl-ghrelin 
treatment (P = 0.0237, F(1, 14) = 6.438) in both WT and GOAT KO mice 
(genotype, P = 0.9263, F(1, 14) = 0.008863) (Figure 5.7C), but the subset of 
new-born cells that are not neurones are unaffected by treatment (P = 0.1443, 
F(1, 15) = 2.373) and genotype (P = 0.8135, F(1, 15) = 0.05766) (Figure 5.7D).  
This demonstrates that acyl-ghrelin treatment has a positive effect on 
AHN in the DG, with the presence and absence of GOAT at 28 days. 
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Figure 5.7 7 days of AG treatment appears to reduce new neuronal cell number, however after 28 
days new neuronal cell number increases. 
Short term (day 8) analysis of Acyl-ghrelin treatment has no significant effect on new mature neurone 
survival (BrdU+ NeuN+) (A) but significantly reduces new non-neuronal cell (BrdU+ NeuN-) (B) 
irrespective of genotype. Mice sacrificed on day 28 show a significant increase in BrdU+ NeuN+ cells 
following acyl-ghrelin treatment (C), with no overall effect on BrdU+ NeuN- cells (D). Representative 
confocal image of BrdU+ NeuN+ (arrowheads) and BrdU+ NeuN- cells in the SGZ of the DG (E). 
Scalebar = 50µm. n = 4-8 mice/group. Statistical analysis performed, 2-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test. Data displayed as mean ± SEM. 
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5.3.7 UAG treatment of WT mice does not affect AHN. 
12 week old WT C57BL/6 mice were subcutaneously administered 
saline or UAG (80µg/kg/day) for 7 days, to see if UAG treatment would 
have a negative effect on AHN. 
Immunofluorescent staining of hippocampal DG sections for new-
born mature neurones (BrdU+/NeuN+) (Figure 5.8) revealed that UAG 
treatment had no effect on BrdU+/NeuN+ cell number in the DG (P = 0.1831) 
and also had no effect on the sub-set of new-born cells that were non-
neuronal (BrdU+/NeuN-, P = 0.7179).  
These data suggest that short-term UAG treatment has no effect on 
AHN. 
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Figure 5.8 UAG treatment in WT C57BL/6 mice has no effect on the number of new adult-born 
neurones.  
Representative confocal images of NeuN+ (green), BrdU+ (red) and BrdU+NeuN+ (yellow, arrow) cells 
in the SGZ  of the DG, in WT-saline and WT-UAG treated mice. n = 9/group, statistical analysis 
performed; unpaired 2-tailed t-test, ns = no significance. Data represented as mean ± SEM. Scalebar = 
50µm. 
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5.4 Discussion 
Acyl-ghrelin has been shown to have pro-neurogenic effects, promote 
synaptic plasticity and AHN (Li, Kim, et al., 2013). However, the role of the 
unacylated form, UAG, appears to be a little unclear. In this chapter, UAG is 
shown to negatively regulate neurogenesis in the hippocampus, but not at 
the expense of the NSPC pool. Also, the genetic ablation of the acylating 
enzyme, GOAT, which results in increased levels of circulating UAG and no 
AG, had a negative effect on AHN. 
The 6-month old WT and GOAT KO mice from Taconic labs that 
received UAG infusion for 7 days had a significant reduction in cell 
proliferation (Ki67+), the number of immature neurones (DCX+) and cells that 
were active (c-Fos+) in WT mice. GOAT KOs had similar reductions which 
weren’t exacerbated by UAG treatment. There was also a significant 
reduction in the number of new adult-born immature neurones (BrdU+ 
DCX+) in the DG following UAG treatment in WT mice and in GOAT KOs, 
compared to vehicle treated WT controls. Similarly, the Regeneron 12-week 
old GOAT KO mice also showed deficits in cell proliferation and immature 
neurone number, but no effect on cell activation. Both models had intact 
NSPC pools, that were unaffected by the increase in circulating UAG and 
absence of AG. UAG is thought to be the inactive form of ghrelin (Masayasu 
Kojima, Hosoda, Matsuo, & Kangawa, 2001). However, there is increasing 
evidence of UAG having an antagonistic function to AG. For example, it 
prevents AG effects on secretion of insulin and glucose levels in human 
blood serum and plasma (Broglio et al., 2004), it reduces food intake that AG 
promotes in ddy mice who were i.p. injected with UAG (1-3nmol, n=15) 
(Asakawa et al., 2005), inhibits the output of glucose from porcine 
hepatocytes that is promoted by AG (Gauna et al., 2005) and quashes the 
effect of the GH-IGF1 axis by reduced serum levels in transgenic mice that 
overexpress UAG who also had a smaller phenotype (Ariyasu et al., 2005). In 
another study in GOAT KO mice and WT littermates (8-week old, male) that 
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were 60% CR for 1 week in order to lose body fat, and then fasted for 23 
hours. Following the fast, WT mice showed increases in GH levels, blood 
glucose, an increase in the marker of autophagy LC3II and number of 
autophagosomes in the liver, whereas GOAT KO mice were hypoglycaemic 
and reduced autophagy. This was reversed  to WT levels upon the 
administration of GH (15µg/24h) to the GOAT KO mice (Y. Zhang, Fang, 
Goldstein, Brown, & Zhao, 2015). All this bolsters the findings in GOAT KO 
models that increased levels of circulating UAG is causing a decline in 
aspects of neurogenesis and synaptic plasticity in the hippocampus, not just 
the absence of AG. 
Where these two GOAT KO models differ is in their effects on new-
born neurone production and cell activation (IEG expression). The Taconic 
labs mouse model exhibits a reduction in c-Fos expression in the GOAT KO 
compared to its WT controls, whereas no effect on Egr-1 or c-Fos was 
observed in the Regeneron model. This model also showed no effect of UAG 
treatment on new-born neurone production. These differences may be due to 
the difference in age of the mice used in each experiment. The Taconic labs 
model were 6 months old and may have shown more advanced impairment, 
whereas the Regeneron model mice were younger 12 weeks old. Dosage of 
UAG given, and the method in which it was administered to the Taconic labs 
model was a more physiological dose of 48µg/day via a jugular vein catheter 
which allowed the infusion to enter the brain through regular circulation. In 
contrast, the Regeneron model was administered a much higher dosage of 
80µg/kg/day via a more direct method of i.c.v. infusion. The method of 
delivery of BrdU may have had an impact on the numbers of new-born cells, 
the Taconic labs model only had 1 day of i.p. injection BrdU (50µg/kg/day), 
whereas the Regeneron model underwent a 7 day infusion of BrdU 
(50µg/kg) via subcutaneous osmotic mini-pump. Another difference 
between the 2 models is in way they were generated. The Taconic lbs model 
is a complete genetic ablation of GOAT, by deletion of the gene MBOAT4 
that codes for GOAT, whereas the Regeneron model uses Velocigene 
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technology that uses a bacterial artificial chromosome (BAC) vector to 
replace the coding region of GOAT with a LacZ reporter gene containing 
cassette and Neomycon resistance gene, done in mouse embryonic stem cells, 
that are then injected in C57BL/6 blastocysts. These differences may have 
had a severe effect on the way that UAG performed within the brain. 
In this final part of the study, brains from 12-week old WT and GOAT 
KO mice (Regeneron) were processed using Golgi-cox solution to dendritic 
spine number. It has previously been show that ghrelin promotes dendritic 
spine generation and reorganisation in the rat hippocampus (Berrout & 
Isokawa, 2012). Analysis demonstrated that compared to WT, these GOAT 
KO mice showed no significant change in the total number of the various 
spine types. However, there is a 53% reduction in the “stubby” spine in 
GOAT KO mice. These “stubby” spines are described as being an immature 
form of spine (Harris et al., 1992), suggesting that there may be a negative 
effect on spine maturation in the presence of higher UAG levels. 
Another group of the Regeneron mouse model were administered AG 
(10µg/kg/day) for 7 days and sacrificed the following day or allowed to live 
for a further 21 days, and sacrificed on day 28. This was to determine 
whether AG’s positive action on AHN would be affected by the absence of 
GOAT or by the presence of higher UAG levels. No significant effect was 
observed in new adult-born neurone production (BrdU+ NeuN+ cells) 
following the 7 days of AG treatment, however, 21 days following on from 
the AG treatment AHN was increased significantly (P = 0.0237)(compared 
the WT vehicle treated) independent of the presence of GOAT. These data 
suggest that AG’s pro-neurogenic effects were not attenuated by increased 
UAG levels in GOAT KO mice and that the effects were observed over the 
longer term. This suggests that AG is promoting neuronal differentiation 
and/or the survival of new neurones, rather than promoting proliferation.  
GOAT is necessary for the acylation of AG, not only does it perform 
this acylation in the stomach, but it is able to perform this locally in the 
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hippocampus. This has been shown in a study by Mohammad Murtuza and 
Masako Isokawa, where immunohistochemical staining demonstrated GOAT 
immunoreactivity (IR) in the hippocampal DG of WT Sprague-Dawley rats 
and C57BL/6 mice and expression was unchanged between controls and 18 
hour fasted animals, which was not present in the GHSR1a KO of both rats 
and mice.  Ghrelin IR was also demonstrated in the cell soma of DG cells, 
with GOAT IR around the cell soma. The same GOAT IR was seen in 
hippocampal slice cultures of both WT animals, and was absent in the 
GHSR1a KO’s. They also demonstrated that GHSR1a was required for the 
production of GOAT in the hippocampus by incubating tissue slices in a 
GHSR1a antagonist overnight, WT antagonist treated slices show no 
difrerence to the control, whereas GHSR1a KO slices showed a significant 
decrease in GOAT IR compared to WT control. Local acylation was 
demonstrated in live hippocampal slices incubated overnight with 
fluorescent AG or UAG, and both showed intense fluorescent signals in WT 
but not in GHSR1a KO, indicating that UAG had bound to GHSR1a. Finally, 
they treated WT slices with GOAT inhibitor, followed by incubation in 
fluorescent AG or UAG, and saw that UAG incubated slices showed no 
binding of UAG, indicating that GOAT is active and is octanoylating UAG in 
the hippocampus  (Murtuza & Isokawa, 2018). 
The ghrelin system also has a deacylating enzyme, acyl-protein 
thioesterase 1 (APT1) (Satou, Nishi, Yoh, Hattori, & Sugimoto, 2010). This has 
also been shown to be located in the hippocampus of C57BL/6 mice by in-
situ hybridisation of APT1 mRNA, showing expression in the DG, CA1-CA3 
and motor cortex. Immunohistochemical staining demonstrated that APT1 is 
present in apical dendrites in the DG (Tatro et al., 2013). 
 
To conclude, this chapter has elucidated a previously unknown 
function of UAG in negatively modulating adult hippocampal neurogenesis 
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and plasticity, and provides evidence of an essential role for GOAT in 
supporting AHN in the adult mouse brain. 
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Chapter 6 The Effect of Calorie Restriction 
on circulating AG-UAG in Healthy, 
Parkinson’s Disease and Parkinson’s 
Disease Dementia patients 
 
6.1 Introduction 
Due to an ever increasing aged population, the prevalence of 
neurodegenerative disorders such as PD has increased. PD is characterised 
by the progressive loss of dopaminergic neurones in the substantia nigra 
pars compacta and intracellular α-synuclein aggregation. The most notable 
symptoms of PD are those that affect motor function; resting tremor, rigidity, 
bradykinesia and postural instability. The most common treatment for PD is 
L-DOPA that treats these motor dysfunctions and deep brain stimulation 
(Morgan, Rees, Andrews, & Davies, 2018; Parkinson’s, 2018). Non-motor 
symptoms associated with PD are olfactory dysfunction, dementia, 
depression, dysautonomia such as gastrointestinal dysfunction and 
disturbances to sleep (Ziemssen & Reichmann, 2007). Much is known about 
the neuropathology of these disorders, but the causative mechanisms that 
underpin the neuronal loss and cognitive deficit associated with them still 
remain unknown. PD affects approximately 127,000 people in the UK, that’s 
1 in every 350 people (Parkinson’s UK 2018). 
The circulating orexigenic peptide, ghrelin, is neuroprotective in  
murine models of PD (Bayliss & Andrews, 2013). Ghrelin promotes synaptic 
plasticity and improves spatial memory deficits in the mouse hippocampus 
(Hornsby et al., 2016; Kent et al., 2015) indicating that it is important in 
memory function. Mild CR is also known to confer neuroprotection in rat 
and non-human primate models of PD (Colman et al., 2014; Wenzhen Duan 
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& Mattson, 1999). Indeed, CR-mediated neuroprotection in the mouse MPTP 
neurotoxin-based model of PD is dependent upon ghrelin-AMPK signalling 
in dopamine neurones (Bayliss, Lemus, Stark, et al., 2016). Furthermore, the 
ghrelin response to fasting is reportedly impaired in PD patients, but only 
total ghrelin (TG) was analysed (M. M. Unger et al., 2011). A more recent 
study showed that TG and AG levels are reduced in PD (N. Song et al., 2017), 
but a diagnosis of dementia was an exclusion criteria, so these patients were 
not assessed.  
Ghrelin is not the only affected factor, other circulating factors such as 
IL-6 and TNFα have been shown to be affected in PD patients that have non-
motor related symptoms (Lindqvist et al., 2012). Also, factors such as leptin, 
growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are affected 
(Fiszer et al., 2010) and is associated with the symptom of weight loss in PD. 
Interestingly, PD patients were significantly impaired on an object 
pattern separation task that required DG-dependent discrimination between 
similar pictures (Wesnes & Burn, 2014; Michael A. Yassa & Stark, 2011). 
These data suggest a possible reduction in hippocampal neurogenesis in PD, 
which is essential for pattern separation memory function in mice (Clelland 
et al., 2009). However, further analysis of this paradigm is needed in PD.   
  
6.1.1 Aim of the chapter 
We hypothesize that the acylated to un-acylated ghrelin (AG:UAG) 
ratio will be reduced in PD and PDD patients compared to healthy age-
matched controls. Also, based on the work in chapter 4 that indicated that 
increased UAG has an opposing effect on neurogenesis in mice, 
PD/PDD/PD-MCI (PD with Mild Cognitive Impairment) patients who 
display deficits in cognition will have reduced levels of circulating AG.  
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This work is important as it could potentially lead to ghrelin becoming 
a new therapeutic target for neurodegenerative disorders and cognitive 
decline in humans.  
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6.2 Materials & Methods 
 
6.2.1 Study Design and Criteria 
This study was designed in order to determine whether AG is an 
appropriate biomarker for Parkinson’s disease dementia (PDD), and to 
determine whether there is a difference in the dynamic ghrelin response in 
PD, PDD and age-matched controls, following an overnight fast and re-
feeding. 
Levels of TG and AG were measured from blood plasma samples which 
were taken from approximately 60 participants divided into 4 groups 
(controls, PD, PD-MCI and PDD). As ghrelin does not act alone, but in 
synergy with multiple factors and hormones, the following analytes were 
also examined: insulin, leptin, PYY, GLP-1, IL-6, TNFα, IGF-1 and GH.  
This study was performed in collaboration with the David Burn group 
situated at Newcastle University with appropriate ethical consent and 
intuitional approval in place. 
 
6.2.1.1 Participant criteria 
The participants of this study were of both sexes and between the ages 
of 60 and 85 and had to fit the following criteria (Table 6.1): 
Parkinson ’s disease (PD) - have a recognised diagnosis of idiopathic PD made 
by a neurologist and have normal cognitive function (Montreal Cognitive 
Assessment (MoCA) ≥26) and no sign of functional impairment caused by 
cognitive decline. 
Parkinson’s disease dementia (PDD) – have a recognised diagnosis of idiopathic 
PD for more than 1 year made by a neurologist, meet the Movement 
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Disorder Society task Force Criteria for PDD and have a MoCA <21/30. They 
must also show evidence of activities of daily living (ADLs) are affected on 
the Informant Questionnaire on Cognitive Decline in the Elderly (IQ-CODE) 
and carer interviews. 
Age-matched Controls – show no symptoms or signs of dementia or disorders 
that affect movement. 
 
Table 6.1. Demographic information of study participants. 
 Healthy 
Controls 
(n = 20) 
Parkinson’s 
disease 
(n = 20) 
Parkinson’s 
disease – mild 
cognitive 
impairment 
(n = 8) 
Parkinson’s 
disease 
dementia 
(n = 8) 
Age 
(mean ± sd) 
74 ± 6.28 72.2 ± 5.51 74.31 ± 6.01 74.75 ± 5.99 
Male (%) 55% 55% 56.2% 87.5 
MoCA 
(mean ± sd) 
28.35 ± 1.14 27.55 ± 1.47 14.12 ± 5.14 14.12 ± 5.14 
BMI (kg/m2) 
(mean ± sd) 
24.75 ± 2.04 25.31 ± 2.82 24.03 ± 3.31 24.41 ± 3.20 
 
6.2.1.2 Test Visit 
Upon the test visit, participants were asked to arrive fasted and without 
having taken any of their usual PD medication. They were fitted with a 
peripheral venous cannula and blood taken to be able to measure fasting 
levels of the analytes. The participants were then given a 300 kcal test meal 
typical of a British diet (1 slice of white toast with butter, 1 pot activia 
strawberry yoghurt, 1 shortbread biscuit, jam and a glass of water). Blood 
was then taken from the cannula at 5, 15, 30, 60, 120 and 180 minutes after the 
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standardised meal and taking approximately 200 ml blood from each 
participant. 120 ml of water was also given at 60 and 120 minutes following 
the meal. At 180 minutes the participants were given an ad libitum meal 
consisting of a selection of pre-measured foods (1 medium banana, 1 
chocolate mousse, 1 bag ready-salted crisps, grated cheddar cheese, tomato 
and mozzarella pasta bake and 1 large glass of water), they were allowed to 
eat as much as they liked and to take their medication. 
 
6.2.1.3 Blood collection and storage 
As the octanoyl group of AG is unstable, it needed to be protected upon 
blood collection. The protease inhibitor AEBSF (4-(2-Aminoethyl)-
benzenesulfonyl fluoreide, Cat No: A8456, Sigma Aldrich) was added to the 
plasma collected for TG, AG and PYY analysis. 
Whole blood was collected into lavender Vacutainer® EDTA-plasma 
tubes (Cat No: 6450) up to a volume of 7ml per tube. The tubes were then 
inverted gently after collection to prevent coagulation. 1/3 of the blood was 
transferred immediately to a sterile and cold centrifuge tube containing 
AEBSF (2mg/ml) to prevent proteinase activity, and mixed gently. The 
remaining 2/3 fraction was used for analysis of insulin, leptin, PYY, IL-6, 
GLP-1 (active) and TNFα. The 2 separate fractions were then centrifuged at 
2000xg for 15 minutes at 4˚C, resulting in 3 layers (top plasma layer, mid 
white layer of leukocytes and the bottom layer which contains red blood 
cells). The top layer of plasma was carefully transferred into sterile tubes 
(200µl aliquots), labelled with the date and patient I.D, and stored at -80˚C. 
Platelet-rich plasma was used for the analysis of IGF-1 and GH, this 
fraction of blood was spun at 1000xg for 15 minutes at 4˚C, then aliquoted 
and stored as stated above.  
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6.2.2 Total Ghrelin ELISA 
For the analysis of total ghrelin (TG) levels, untreated plasma samples 
were analysed using the Human Ghrelin (Total) ELISA Kit (Cat. No. EZGRT-
89K, Millipore). All reagents were brought to room temperature prior to 
performing the assay. 
Firstly, the wells of the microtiter assay plate were washed with 300µl 
diluted wash buffer, this was decanted and the excess liquid removed by 
tapping the plate smartly on paper towels. This was done 3 times in total. 
Immediately after, 20µl of Matrix solution was added to the blank, standard 
and quality control wells, 30µl of assay buffer was added to the blank and 
sample wells, and 10µl of assay buffer was added to the standard and quality 
control wells. Next, 20µl of the ghrelin standards in ascending order of 
concentration were applied to the appropriate wells in duplicate and 20µl of 
the quality controls (QC1 and QC2) were also added to the appropriate wells 
in duplicate. Subsequently, 20µl of neat plasma sample was added to the 
sample wells in duplicate, and then 50µl of the antibody solution mixture (1:1 
mixture of capture and detection antibodies) was added to all wells of the 
microtiter plate. The plate was sealed with a plate sealer and placed on an 
orbital plate shaker (400-500rpm) for 2 hours at room temperature. 
After the incubation the plate’s contents were emptied and the plate 
was washed 3 times as described above. 100µl of enzyme solution was added 
to all wells and the plate was re-sealed and incubated for 30 minutes at room 
temperature on the shaker. The plate’s contents were decanted and the plate 
tapped over paper towels to remove any residual solution, the plate was then 
washed 6 times in the manner described above. Finally, 100µl of substrate 
solution was added to all wells and the plate was sealed and placed on the 
shaker for 5-20 minutes until a blue colour had developed in the ghrelin 
standards. Subsequently, 100µl of stop solution was added to the wells - the 
blue colour turned yellow due to acidification. The plate was analysed using 
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a BMG Labtech POLARstar Omega, with absorbance read at 450nm and 
590nm, within 5 minutes. 
 
6.2.3 Multiple analyte analysis with Milliplex system 
AEBSF treated plasma samples were analysed using the Milliplex MAP 
Kit- Human Metabolic Hormone Magnetic Bead Panel 96-well plate assay 
(Cat. No. HMHEMAG-34K, Millipore), with beads to the following targets: 
leptin, insulin, IL-6, TNFα, PYY, GLP-1 active and acyl ghrelin (termed active 
ghrelin by the Millipore assay). The plasma samples were taken out of -80˚C 
freezer storage and defrosted slowly at 4˚C. 
Firstly, reagents were brought to room temperature (RT, 20-25˚C) 
before use, and some reagents required preparation before use in the assay. 
Using the 96-well plate provided, 200µl of Assay buffer was added to each 
well and the plate sealed and placed on a plate shaker (500-800 rpm) for 10 
minutes at RT. The assay buffer was removed by inverting the plate and 
tapping it onto paper towels numerous times. Then 25µl of each Standard or 
Control was pipetted into the allocated wells, with assay buffer being used 
for the background (0pg/ml standard). 25µl Assay buffer was then added to 
all of the sample wells, followed by 25µl of Serum Matrix solution to the 
background, standard and control wells. Next, 25µl of each plasma sample 
was added to the allocated wells (samples were added in duplicate), and 
finally 25µl of the mixed magnetic bead solution was added to each well. The 
plate sealed with a plate-sealer, wrapped in foil and placed on a plate shaker 
overnight (16-18 hours) at 4˚C. 
After overnight incubation the plate’s contents were removed and 
washed using the following method: as a solid plate was used, a handheld 
magnet was used for the wash steps. The plate was applied to the magnet 
and allowed to rest for 60 seconds to allow the settling of the magnetic beads. 
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The well solutions were removed by emptying into a waste container and the 
plate tapped gently onto paper towels to remove any remaining liquid. The 
plate was separated from the magnet and 200µl of wash buffer was added to 
all wells and the plate was shaken by hand for 30 seconds. The plate was 
then reattached to the magnet for 60 seconds to allow the beads to settle and 
the plate contents were removed as described before. This was repeated 3 
times. 
Subsequently, 50µl of detection antibody was added to each well of the 
96-well plate, then sealed and covered in foil and placed on a plate shaker for 
1 hour at RT. After this incubation the plate’s contents were not removed, 
50µl of Streptavidin-Phycoerythrin was added to each well and then re-
sealed and covered for 30 minute incubation at RT on the plate shaker. 
Following this incubation, the plate was washed 3 times as previously 
described. 100µl of Sheath Fluid (#171000055, Bio-Rad) was added to all 
wells of the plate which was placed on the plate shaker for 5 minutes to re-
suspend the beads. Finally, the plate was analysed on a Bio-Rad Bio-Plex 200 
system. Prior to each use of the Bio-Rad Bio-Plex 200 system, calibration was 
performed with the Bio-Plex Calibration kit (#171203060, Bio-Rad) as 
instructed by the Bio-Plex Manager software. 
 
6.2.4 GH and IGF-1 ELISA’s 
For the analysis of human IGF-1 and GH, platelet-rich plasma samples 
were analysed using Human IGF-1 DuoSet ELISA (cat. No. DY291, R&D 
Systems), and Human GH DuoSet ELISA (Cat. No. DY1067, R&D Systems), 
using half-volume Nunclon Microwell 96-well plates. All reagents were 
brought to room temperature before they were used. 
The capture antibody was diluted to its working concentration using 
PBS and 100µl was used to coat each well of a 96-well plate, this was 
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incubated overnight. The wells were aspirated and washed 3 times with 
wash buffer, filling each well with 200µl of wash buffer and inverting the 
plate and tapping on paper towels to remove excess liquid. The plate was 
blocked by the addition of 150µl of reagent diluent to each well and 
incubated for 1 hour at room temperature on a plate shaker (450rpm). 
Following this block, the plate was washed 3 times as described above. 
Subsequently, 50µl of each plasma sample and 50µl of standards in 
reagent diluent were added in duplicate to the appropriate wells. The plate 
was sealed and incubated for 2 hours at room temperature on a plate shaker. 
Following this incubation the plate was washed as previously described, and 
50µl of detection antibody was added to each well. The plate was sealed and 
incubated for 2 hours at room temperature on a plate shaker. Next, the 
contents of the wells were removed and the plate was washed as before. 50µl 
of Streptavidin-HRP was added to each well of the plate before it was sealed 
and protected from direct light and incubated for 20 minutes on the plate 
shaker. The plate was then washed as above.  50µl of substrate solution was 
added to each well; the plate was sealed, protected from direct light and 
incubated for 20 minutes on the plate shaker at room temperature. Finally, 
50µl of stop solution was added to each well. The plate was then analysed 
using a BMG Labtech POLARstar Omega, with optical density read at 450nm 
and 570nm, immediately after the stop solution was applied. 
 
6.2.5 Data handling, Analysis and Statistics. 
The levels of circulating hormones associated with aspects of 
neurodegenerative disorders were analysed from the blood plasma of 
patients with PD (n = 20), PD+MCI (n = 8), PDD (n = 8) and age-matched 
controls (n = 20). After fasting overnight, plasma was collected before a 
calorie controlled meal, and at specified time points following the meal (5, 15, 
30, 60, 120 and 180 minutes). From the mean concentration (pg/ml) of each 
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analyte, the data was plotted along a time course to determine whether any 
differences occurred in response to fasting and re-feeding. The area under 
the curve (AUC) was calculated and plotted in a separate graph. Statistical 
outliers in the data were removed using the ROUT method (Q = 10%), and 
any patients that had incomplete blood collection were excluded. Statistical 
analysis performed on the AUC data used the Kruskal-Wallis test, as you 
could not assumed normal distribution of the data and more than 3 groups 
were being compared, followed by Dunn’s post-hoc multiple comparison 
test.  
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6.3 Results 
 
6.3.1 The effects of fasting and re-feeding on circulating analytes in the 
blood plasma of PD and PDD patients, and age-matched controls. 
Analysis of total ghrelin (TG) levels has shown that there was no overall 
significance (P = 0.2788), and compared to age-matched controls there was 
no significant effect on TG levels in the PD (P > 0.9999), PD+MCI (P > 0.9999) 
or PDD (P = 0.9290) groups (Figure 6.1A, B). For acyl-ghrelin (AG) there was 
an overall significance between the groups (P = 0.0094), and compared to 
age-matched controls there was no significant effect with PD (P > 0.9999), 
PD+MCI (P > 0.9999) or PDD (P = 0.1202) group. However, a significant 
difference between the PD and PDD group was observed (P = 0.0055), 
suggesting that the significant decrease in AG levels is indicative of the 
presence of dementia (Figure 6.1C, D).  
No overall significance was seen in the insulin response (Figure 6.1E, F) 
(P = 0.6055), and there was no significant difference between any of the 
groups compared to age-matched controls (P > 0.9999). The leptin response 
(Figure 6.1G, H) appears reduced in AUC, but was not statistically significant 
overall (P = 0.3717), with no significant differences between the PD and 
MD+MCI (P > 0.999), PDD group (P = 0.5800) compared to controls, or 
between the PD and PDD group (P = 0.6251). 
No overall significance was observed in the gut hormone GLP-1 
response (P = 0.2814, Figure 6.2A, B), and relative to controls there was no 
significant difference in PD (P > 0.9999), PD+MCI (P > 0.9999) or the PDD 
group (P = 0.60047460). Also, compared to the PD group there was no 
significant difference in PD+MCI (P > 0.999) and PDD (P = 0.5716). PYY 
(Figure 6.2C, D) was also statistically unaffected, although the graphs do 
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indicate reduction in concentration compared to controls (overall P = 0.4199; 
control vs PD P > 0.9999, PD+MCI P > 0.9999 and PDD P = 0.6004). 
The pro-inflammatory cytokines IL-6 (Figure 6.2E, F) and TNFα (Figure 
6.2G, H) were also unaffected (P = 0.1913; P = 0.1300) in their overall 
response, and relative to controls there was no significant difference with PD 
(P > 0.999) PD+MCI (P > 0.9999; P = 0.1568) or PDD (P > 0.9999). These data 
indicate that the circulating inflammatory response is unaffected in 
individuals with PD. 
Finally, circulating IGF-1 and GH was also unaffected (Figure 6.3A – D) 
(P = 0.6605; P = 0.8202), with no significant differences in any of the groups 
(P > 0.9999) compared to age-matched controls. 
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Figure 6.1 Timelines and Area Under Curve (AUC) for circulating plasma analytes.  
Graphs demonstrating the effect of fasting and re-feeding response in circulating blood plasma 
analytes, and the AUC for each of the following analytes; Total Ghrelin (A, B), Acyl-ghrelin (C, D), 
Insulin (E, F) and Leptin (G, H). n = 20 (controls), 20 (PD), 8 (PD-MCI) and 8 (PDD). Statistical analysis 
performed on AUC, Kruskal-Wallis test and Dunn’s post-hoc multiple comparisons test. Data 
represented as mean± SEM. 
 
130 
 
 
Figure 6.2 Timeline and AUC graphs continued.  
Graphs demonstrating the effect of fasting and re-feeding response in circulating blood plasma 
analytes, and the AUC for each of the following analytes; GLP-1 (Active) (A, B), PYY (C, D), IL-6 (E, F) 
and TNFα  (G, H). n = 20 (controls), 20 (PD), 8 (PD-MCI) and 8 (PDD). Statistical analysis performed on 
AUC, Kruskal-Wallis test and Dunn’s post-hoc multiple comparisons test. Data represented as mean± 
SEM. 
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Figure 6.3 Timeline and AUC graphs continued. 
 Graphs demonstrating the effect of fasting and re-feeding response in circulating blood plasma 
analytes, and the AUC for each of the following analytes; IGF-1 (A, B) and  GH (C, D), IL-6. n = 20 
(controls), 20 (PD), 8 (PD-MCI) and 8 (PDD). Statistical analysis performed on AUC, Kruskal-Wallis 
test and Dunn’s post-hoc multiple comparisons test. Data represented as mean± SEM. 
 
6.3.2 Fasting and re-feeding effects on the AG:UAG. 
AG plasma levels, as a percentage of TG (AG:TG ratio), in the fasted 
condition (baseline) was significantly reduced in patients with PDD, P = 
0.0302 (Figure 6.4A) compared to age-matched controls. This difference was 
also detected in the post-prandial (180 minutes) levels of AG in the PDD 
cohort (P = 0.0144) compared to controls (Figure 6.4B). These data suggest 
that PD patients diagnosed with dementia have significantly reduced 
circulating AG:TG ratio in comparison to PD patients who do not exhibit 
severe cognitive impairment or healthy individuals. This novel finding 
indicates that ghrelin may be a suitable biomarker for cognitive decline. 
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Figure 6.4 The fasted and post-prandial AG:UAG ratio is significantly reduced in PDD patients, 
compared to age-matched controls. 
Circulating AG in healthy controls (n=20), PD (n=20), PD-MCI (n=8), PDD (n=8), in the fasted 
(baseline) (A) and post-prandial (180 minutes) state (B). Statistical analysis performed by Kruskal-
Wallis test followed by Dunn’s post-hoc multiple comparison test. 
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6.4 Discussion 
Current treatments for PD are targeted towards alleviating specific 
symptoms, such as L-DOPA for motor dysfunction. Calorie restriction 
promotes the survival of new-born NSPC’s  in the ageing brain of mice, 
which is important for mneumonic function (J.-H. Park et al., 2013), and 
improves cognitive function in other neurodegenerative disorders (Kang, 
Moon, Kim, Kim, & Park, 2015). 
At present, there is no pre-symptomatic treatment or preventative 
therapeutic measure in place. From this pilot study examining concentrations 
of circulating factors in the blood plasma, PD patients diagnosed with 
dementia have a reduced AG response compared to age-matched controls. 
They exhibited lower fasting and post-prandial AUC, showing an alteration 
in the usually dynamic ghrelin response to food. 
PD patients suffer from reduced gut motility (M. M. Unger et al., 2010), 
which may also be an indication of a disruption to ghrelin action in PD (M. 
M. Unger et al., 2011). Gut dysfunction can occur early on in PD pathology 
before motor function impairments (Sung, Park, & Kim, 2014), and include 
symptoms such as sialorrhea, dental disorders, dysphagia, gastroparesis, 
constipation and intestinal bacterial overgrowth. Gastric dysfunction is 
shown in 70-100% of PD patients with symptoms such as nausea, vomiting, 
weight loss, delayed gastric emptying, dehydration and malnutrition, which 
can lead to the malabsorption of drugs given to treat the disorder 
(Mukherjee, Biswas, & Das, 2016). A recent study involving gut epithelial 
cells has shown that they may play a role in the transmission of PD 
pathology from the gut to the brain via the vagal nerve. The death of 
neurones in PD is characterised by the aggregation of mis-folded α-synuclein 
forming Lewy bodies in cell bodies and axons, and the movement 
dysfunction is caused by the death of neurones in the SNpc. This study 
showed that gut entero-endocrine cells (EEC) contain α-synuclein that forms 
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connections with α-synuclein containing nerves, thereby forming a gut-brain 
neuronal circuit. α-Synuclein was detected in STC-1 cells (mouse intestinal 
cell line), CCK cells (mouse duodenal cells) and in enteric nerves in human 
duodenal tissue (Chandra, Hiniker, Kuo, Nussbaum, & Liddle, 2017). 
From the work in this chapter, concentrations of the circulating pro-
inflammatory immune cytokines IL-6 and TNFα were unaffected in PD, 
PD+MCI and PDD patients, compared to age-matched controls. Circulating 
immune factors such as TNFα and IL-6 have been linked with PD. For 
example, activation of microglia associated with central inflammation, results 
in the release of TNFα and IL-6 and other pro-inflammatory factors that 
contribute to nigral cell death via NFκB activated apoptosis. There is 
evidence that TNFα and IL-6 are elevated in the plasma and serum of PD 
patients (Su & Federoff, 2014).  
The analysis of leptin in this study showed no significant difference 
between any of the groups, although there was a reduction in AUC (Figure 
5.1) in PDD. Another study showed that there was no correlation between 
serum leptin levels and PD and PD patients with lower cognition scores, 
compared to controls. They assessed blood serum levels of leptin in 30 
healthy controls (mean age 58) and PD patients (mean age 59) after overnight 
fasting (Kenangil & Ozdilek, 2016). Leptin (100nM) was neuroprotective in 
dopaminergic (TH+) midbrain primary neuronal cultures (C57BL/6 mice) 
following cell death induction with TNFα (20mg/ml) and  6-OHDA (25µM) 
(Doherty, Oldreive, & Harvey, 2008). Also, whilst no change was seen in the 
insulin response in this study, insulin has been linked to neuroprotection in 
human cell models of PD. A study used human SH-SY5Y (neuroblastoma) 
cells that had been differentiated into neurones with retinoic acid (SH-
SY5Y+RA) and exposed to MPP+ (1-methyl-4-phenyl pyridinium) to induce 
neurone death. Pre-treated for 1 hour with insulin (100nM) before 24 hour 
treatment with or without MPP+ (500µM), resulted in increased cell viability, 
and a reduction in nitric oxide and reactive oxygen species. Western blot 
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analysis for TH (tyrosine hydroxylase) also demonstrated that insulin pre-
treatment was neuroprotective in these dopaminergic neurones. 
(Ramalingam & Kim, 2015). 
The analyte GLP-1 was not significantly altered in any of the groups 
studied, despite a decrease in the PD+MCI and PDD groups. The GLP-1 
receptor is a drug target for diabetes, and the drug Exenatide has been 
shown to have potential as a therapeutic in PD. The lab of Tom Foltynie 
examined the effect of Exenatide treatment (twice daily subcutaneous 
injections for 12 months) on MDS-UPDRS (Movement Disorders Society 
Unified Parkinson’s disease scale) and the MDR scale (Mattis Dementia 
Rating) in PD patients (n = 20) and controls (n = 24). They report that after 24 
months (12 months following the final Exenatide injection) PD patients 
showed a 5.6 point improvement in MDS-UPDRS and a 1.8 point 
improvement in MDR scale compared to controls (Aviles-Olmos et al., 2014). 
Biomarkers for the detection of early PD stages are essential for the 
development of new treatments and aid in earlier diagnosis of those most at 
risk of developing PD. Blood-based biomarkers are essential for PD diagnosis 
as non-motor symptoms can occur years before PD pathology becomes 
apparent. Potential blood-based biomarkers include; α-synuclein, the protein 
found in Lewy body lesions, which has been identified in plasma and 
cerebrospinal fluid (CSF); DJ-1 gene (PARK7), which is mutated in familial 
PD has also been detected in plasma and CSF, but multiple cohort studies 
have given conflicting outcomes of there being significant changes in PD 
compared to controls. Another potential biomarker is uric acid, as it has been 
found in the SNpc of PD patients and shown to contribute to DA neuronal 
loss due to increased oxidative stress (Chahine, Stern, & Chen-Plotkin, 2014). 
Neuroimaging is a non-invasive form of biomarker, with the most commonly 
used being DaTSCAN, which images the dopamine system by targeting the 
dopamine transporter (DAT). A DAT ligand is administered by injection and 
it’s binding ability is measured in the basal ganglia via SPECT (Single-photon 
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emission computed tomography) imaging, where in PD cases you would 
observe reduced binding (Sherer, 2011). Notably, there have been recent 
developments in PET (positron emission tomography) imaging with the 
design and synthesis of fluorine-bearing Quinazolinone derivatives for the 
ghrelin receptor (GHSR1a). 2 fluorine-bearing compounds were found to 
have high binding affinity to GHSR1a, and are currently awaiting testing in 
in vivo models of murine cancer (Hou, Kovacs, Dhanvantari, & Luyt, 2018). 
There are initiatives in place dedicated to the development of diagnostic 
biomarkers the Michael J. Fox Foundation Parkinson’s Progression Markers 
Initiative (PPMI) and the National Institute of Neurological Disorders and 
Strokes (NINDS) initiative Parkinson’s Disease Biomarkers Program (PDBP). 
These initiatives aim to standardize data collection protocols, support 
existing and new studies in PD patients, and help to develop the bioassays 
and tools for analysing bio-specimens and the data it produces (Chahine et 
al., 2014). 
The data generated in this chapter has demonstrated that fasting and 
post-prandial levels of AG are significantly decreased in PDD compared to 
age-matched controls. Other neurodegenerative disorders such as 
frontotemporal lobar degeneration (FTLD) have been linked with increased 
levels of ghrelin (FTLD n = 69 vs controls n = 88) (Zanardini et al., 2017). In 
addition, in moderate AD there was no reported difference between basal 
ghrelin levels (overnight fast) in mixed gender age-matched controls (n = 23) 
and AD patients (n = 27). However, they did observe a significant decrease in 
ghrelin AUC in male AD patients compared to controls, indicating a 
potential sex difference. Therefore, the significant reduction in AG in PDD 
could be specific to this disorder. 
AG has been shown to illicit neuroprotective effects in mouse models of 
PD. A study using GOAT KO mice, that lack circulating AG, treated with 
MPTP (1-methyl4-pheyl-1,2,3,6,tetrahydropyridine) after chronic AG 
injections, prevented dopaminergic neurone loss. Whereas, UAG had no 
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neuroprotective effect on the number of dopaminergic neurones following 
MPTP treatment, and also increased levels of the stress hormone, 
corticosterone  (Bayliss, Lemus, Santos, et al., 2016).  
To conclude, the reduction in AG:UAG levels following fasting and 
post-prandially in PDD patients is a novel finding. To the best of our 
knowledge, no other study looking at levels of AG in PD has taken cognitive 
decline into account. This finding signifies the potential importance of AG 
and UAG as an indicator of cognitive dysfunction in neurodegenerative 
disorders. 
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Chapter 7 General Discussion 
 
7.1 Summary 
The experiments in this thesis have led us to better understand the role of 
ghrelin in AHN. The work in chapter 3 investigated the expression of GHSR 
in extra-hypothalamic areas of the brain that are important for learning and 
memory i.e the DG, BLA, LEnt and CingC. Characterisation of the cells that 
express GHSR, within the hippocampal neurogenic niche of the DG, 
indicated that only mature dentate granule neurones (NeuN+) expressed 
GHSR. No expression was seen on dividing, type I or type II NSPC’s, 
however the type II NSPC’s were in close proximity to the GHSR-eGFP+ 
cells. 
Following on from this, the experiments in chapter 4 allowed us to study 
the mechanism by which ghrelin mediates its beneficial effects on AHN. CR 
was used to observe the effects on AHN in mouse models lacking GHSR and 
circulating ghrelin. This work provided us with the novel finding that the 
positive effects on AHN mediated by CR are dependent on the presence of 
GHSR. Also, the increase in neuronal cell activation by CR and AG treatment 
was more robust in cells that did not express GHSR, leading to the 
assumption that there may be another factor involved in promoting AHN. 
Chapter 5 experiments using GOAT KO mice and UAG treatment 
showed a unique role for UAG as a negative regulator of AHN, by inhibiting 
cell proliferation and immature neurone production, as well as highlighting 
an important role for GOAT.  
Finally, the pilot study performed in chapter 6, involved measuring 
concentrations of TG and AG, along with other factors affected in 
neurodegenerative disorders, in the blood plasma of PD patients with 
varying degrees of cognitive impairment. These data showed that PDD 
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patients (compared to age-matched controls) had an impaired ghrelin 
response. Notably, the AG:UAG ratio was reduced after fasting and post-
prandially, suggesting that the decrease of AG relative to UAG is a potential 
indicator of cognitive decline.  
 
7.2 Ageing and Ghrelin 
The effect of ageing on plasma ghrelin levels in C57BL/6 mice has 
been studied by Yuxiang Sun in the lab of Roy Smith. The TG and AG levels 
of 70 male and female C57BL/6 mice, ranging from 5 - 35 months of age, 
were analysed. Bloods were collected from the tail vein following a 24 hour 
fast and analysed by radioimmunoassay for each target. Plasma levels of TG 
increased significantly and AG was increased, but not reaching significance 
(p = 0.059) with advancing age; however ghrelin activity (AG x 100/TG) was 
also measured and showed no correlation with age. Also, mRNA levels of 
ghrelin from the brains of young (2-6 months), middle-aged (12-18 month) 
and aged (24-28 month) mice were analysed by quantitative real-time PCR. 
The 2, 6, 12 and 28-month old mice had very similar expression, whereas the 
18 and 24 month old mice showed a significant increase in ghrelin mRNA 
expression. This increase could indicate an offset response to negative energy 
balance caused in ageing (Sun, Garcia, & Smith, 2007). 
In addition to the work in the chapter 4 that showed AHN was 
unaffected in 15-17 month WT C57BL/6, the TG levels in these C57BL/6 WT 
and Ghrelin KO mice were analysed. There were mice of varying ages within 
this study (WT 6-7 months, 8-10 months and 15-17 months; Ghrelin KO 6-7 
months, 8-10 months and 15-17 months of age) allowing us to quantify not 
only the effect of genotype on TG levels, but the effect of ageing. ELISA 
analysis of plasma that was collected from trunk blood (Figure 7.1), revealed 
no change in TG concentration with increasing age (Tukey’s multiple 
comparison: WT 6-7 month vs WT 8-10 month, P = 0.9841; WT 6-7 month vs 
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WT 15-17 month, P = 0.9927). These data are in contrast to the findings in 
Sun, Garcia, & Smith, 2007. There may be a difference between these data 
sets due to the age ranges used; the oldest mice used in the Yuxiang Sun 
study were 35 months old, whereas the oldest mice were only 17 months old 
in my study. 
 
Figure 7.1 Blood plasma levels of Total Ghrelin of WT and Ghrelin KO mice at different ages.   
Comparison of age against TG levels in ghrelin KO and WT mice. Age showed no effect on TG 
concentration in WT mice, no TG was detectable in ghrelin KO mice. N = 4/7 per group. Statistical 
analysis performed Two-way ANOVA followed by Tukey’s post-hoc multiple comparisons test. **** = 
P < 0.0001. 
 
The somatotropic axis (GH – IGF-1 action) is known to decline with age 
and these circulating factors are important for regulation of cell function and 
development (Ashpole, Sanders, Hodges, Yan, & Sonntag, 2016). These 
factors were also examined in Sun et al. 2007. IGF-1 plasma levels were 
analysed in male C57BL/6 mice aged 3 – 29 months, no change was observed 
with increasing age. GH release was measured following 0.5 and 15 minutes 
after ghrelin treatment (i.p. 50mg/kg) in mice aged between 7 and 30 
months; GH response to ghrelin was not affected by increasing age (Sun et 
al., 2007). The plasma analysis of IGF-1 and GH performed in chapter 5 also 
showed no changes in response to an indirect elevation of ghrelin (via CR) in 
healthy controls and PD patients. 
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7.3 GPCR Dimerization  
Inactive GHSR1a (apo-GHSR1a) has been to shown to dimerise with 
the dopamine receptor DRD1 in hippocampal neurones, which form 
preassembled heteromeric complexes in these neurones. Activation of this 
complex by DRD1 agonists enhances expression of synaptic plasticity 
markers in the hippocampus, by promoting NMDA-R exocytosis and 
synaptic reorganisation. In the absence of GHSR1a, DRD1 signalling is 
blocked, which also causes inhibition of DRD1-mediated hippocampal 
dependant memory. From the work presented in chapter 4 we know that 
GHSR is required for the CR-mediated increase in neurogenesis observed in 
WT but not GHSR KO mice. Also, the absence of circulating ghrelin had no 
effect on levels of new neurone production in ghrelin KO mice. A possible 
explanation for the positive effects of CR on AHN through GHSR could be 
related to another circulating factor that promotes AHN. As described above, 
GHSR1a can dimerize with DRD1 (Kern et al., 2015), and dopamine has been 
shown to play a role in AHN via signalling through DRD1 (Takamura et al., 
2014). 
GHSR1a has also been shown to dimerise with the serotonin receptor, 
5HT2C. Both of these GPCR’s play roles in the control of appetite and energy 
homeostasis. The interaction of this heteromer has been shown to inhibit 
calcium signalling and is expressed in primary hippocampal and 
hypothalamic rat neurones in culture. When 5HT2C signalling is blocked the 
orexigenic effects of ghrelin are enhanced, however, treatment with a 5HT2C 
agonist attenuates these effects (Schellekens et al., 2015). Interestingly, 
decreasing the central levels of serotonin (5HT) enhances AHN in mice. The 
hTM-DTA mouse model, that results in a reduction in 5HT-ergic neurones in 
the brain, showed significant increases in immature DCX-positive neurones, 
enhanced proliferation of NSPCs (shown by increases in BrdU+/MCM2+ 
(minichromosome maintenance protein 2) and BrdU+/Ki67+ cells in the SGZ) 
and increased new adult-born neurone survival (BrdU+/NeuN+ cells in the 
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SGZ) (N. N. Song et al., 2016). These data indicate that 5HT plays an 
important role in regulating AHN and that acyl-ghrelin mediated AHN may 
involve modulation of 5HT2C. 
 
7.4 Ageing and Activation of Ghrelin 
Ageing may affect the enzymatic processes that result in the acylation of 
ghrelin. Age may have an effect on the levels or activity of the ghrelin 
activating enzyme, GOAT. A study looking at the effects of a 5 month long 
period of CR (35% reduction in calories compared to ad-lib fed group) on 
plasma ghrelin levels and GOAT mRNA expression in young 5 week old and 
adult 5 month old rats reported that GOAT mRNA expression in stomach 
was increased 21-fold in adult ad-lib fed rats compared to young ad-lib fed 
rats, and was 14-fold higher in adult CR rats compared to adult ad-lib rats. 
There was a 2.5 fold elevation in UAG levels and TG levels in the adult CR 
and young ad-lib rats compared to adult ad-lib (Reimer, Maurer, Lau, & Auer, 
2010). Previous to this, another study showed that GOAT mRNA expression 
was unchanged in the gut mucosa of male Sprague-Dawley rats of increasing 
age (10, 25 and 60 days), indicating stability with age (González, Vázquez, 
López, & Diéguez, 2008). These two studies may have elicited differing 
results due to the fact they used different strains of rat; Reimer study used 
male Wistar rats whereas the Gonzalez study used male Sprague-Dawley 
rats. However, it is more likely due to the length of their CR regimes; the 
Reimer study CR’d its rats for 5 months, whereas the Gonzalez study only 
used an acute 48-hour CR. 
As we know, ghrelin is acylated by the addition of octanoic acid to serine 
(Ser3), but the majority of circulating ghrelin is the inactive form, UAG. Acyl-
protein thioesterase 1 (APT1), also known as lysophospholipase 1 (LYPLA1), 
has been identified as a de-acylation enzyme for ghrelin in the stomach. 
Homogenate of rat stomach was separated by ammonium sulphate 
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precipitation and chromatography, and further separated by SDS-PAGE and 
Western blotting (Shanado, Kometani, Uchiyama, Koizumi, & Teno, 2004). 
Further analysis on APT1’s deacylating activity was done by mass 
spectrometry of fetal bovine serum (FBS) and HepG2 cells (Satou et al., 2010). 
APT1 may have a role in memory and ageing; in a study comparing ‘young’ 
6-month old and ‘aged’ 26-month old male mice, the expression of 
microRNA-138 (controller of APT1 translation) and APT1 in the 
hippocampus was examined. The mice were also subject to the hippocampal 
dependent novel object recognition (NOR) memory test.  The aged mice had 
impaired memory function and in-situ hybridisation showed increased 
hippocampal miR-138 expression in mice that had no memory impairment. 
APT1 mRNA from hippocampal homogenates was quantified by qPCR, 
which was increased in the aged mice but not memory impaired mice. Cells 
that exhibited higher miR-138 expression had reduced APT1 protein 
expression. This work suggesting that APT1 and miR-138 play a role in age-
related memory function (Tatro et al., 2013). 
 
7.5 Adult Hippocampal Neurogenesis in Ageing 
AHN in humans is a highly debated topic. The seminal study 
performed on human brain tissue in the lab of Fred Gage in 1998 brought to 
light the ability of the human brain to produce new neurones throughout life. 
They used post-mortem human brain tissue (hippocampus and SVZ sections) 
from adult cancer patients (n = 5, aged 58 – 72) that had been administered 
the thymidine analogue, BrdU (250mg; 2.5mg/ml, 100ml), during their 
treatment. BrdU incorporated into the DNA of dividing cells and was 
detected immunohistochemically. Analysis of BrdU immunoreactivity 
revealed BrdU-positive cells in the GCL of the DG and the SVZ. To 
determine whether these new adult-born cells were of a neuronal lineage, 
triple immunohistochemical staining was performed using the mature 
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neuronal marker NeuN and the astrocyte marker GFAP, in conjunction with 
BrdU. BrdU-NeuN positive cells were shown in the adult human DG, 
indicating that the human adult brain has the ability to generate new 
neurones throughout the course of life (Eriksson et al., 1998). 
Another study supporting the idea that neurogenesis occurs in the 
adult brain was performed in the lab of Jonas Frisén. Hippocampal neuronal 
cells were isolated from post-mortem adult brains (aged 19 – 92) by flow 
cytometry with an anti-NeuN antibody, and birth dated using carbon-14 
(14C). 14C content in the genomic DNA of the hippocampal neurones, 
assessed by accelerator mass spectrometry, revealed that the cellular 
concentration of 14C correlated with atmospheric 14C after the individual was 
born, confirming postnatal hippocampal neurogenesis. The eldest individual 
studied displayed higher cellular 14C levels than that found in the 
atmosphere before 1955, this individual was 42 in 1955, indicating that 
neurogenesis continued past the 5th decade of life (Spalding et al., 2013). 
However, more recently there has been data questioning the process 
of AHN in humans. Work from the lab of Arturo Alvarez-Buylla reported 
that neurogenesis declines drastically in children and is almost indiscernible 
in adults. Human post mortem brain tissue was used from 14 gestational 
weeks (GW) to 77 years of age, with donors suffering from a range of clinical 
conditions such as sepsis, heart failure, pneumonia and respiratory failure. 
Also, the rhesus macaque (macaca mulatta) hippocampus was examined as 
part of their study. Using immunohistochemical techniques they showed that 
proliferation of cells in the human DG (Ki67) declines rapidly with increasing 
age from 14 GW to 1 year, and that proliferating progenitor cells 
(Ki67+/SOX1+, Ki67+/SOX2+) also decreased rapidly within the 1st year and 
didn’t form in the SGZ. Furthermore, young neurone (DCX+/PSA-NCAM+) 
number also decreased from infancy to childhood (7/13 years old), with very 
few immature neurones seen after 13 years of age. In the macaque 
hippocampus, between birth and 1.5 years of age the number of proliferating 
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Ki67+ cells in the SGZ declined eight-fold. This decreased a further 35-fold 
from 1.5 years to 7 years of age, with the SGZ becoming less defined with 
increasing age. Similarly, DCX+/PSA-NCAM+ cell number also decrease in 
the same time-frame, becoming extremely rare by 7 years of age. Two 1.5-
year old and one 7-year old macaque were administered BrdU (50mg/kg, 2 
times a day for 5 days) in order to subsequently identify new adult-born 
young neurones (DCX+/BrdU+) and new-born mature neurones 
(NeuN+/BrdU+). These cell types were observed in the GCL of 1.5-year old 
macaques, but not in the 7-year old. These data indicate that neurogenesis 
declines rapidly in the 1st year of life (Sorrells et al., 2018). 
These opposing studies indicate that more work needs to be done in 
order to understand the mechanisms of AHN in humans. We know that 
AHN occurs in mice and rats, shown by the work in this thesis, and that it 
occurs in various other species. Age-dependent neurogenesis has been 
shown in birds, such as the homing pigeon. Birds that require long-distance 
navigation such as the homing pigeon develop their ability to navigate in the 
first few months they gain the ability of flight. However, they also require 
the ability to remember information of their environment needed for 
navigation in the future. Homing pigeons ranging from 1 month – 14 years of 
age were analysed, one hemisphere of the brain was sectioned to determine 
neurone number using Giemsa stain (a stain that has a high affinity for 
neurones), and the other hemisphere was used to analyse DCX 
immunoreactivity in the hippocampus.  Along with increased hippocampal 
volume, there was a large increase in the number of neurones with 
increasing age, approximately 740,000 in 1-month old pigeons to 1.9 million 
neurones in the old pigeon of 14 years. In comparison, the number for DCX+ 
neurones decreased with advancing age, from approximately 20,000 in 1 
month to 11,000 in 14 year old birds, with the sharpest decline happening 
within the 1st year of life (Meskenaite, Krackow, & Lipp, 2016). This is also 
reported in the hippocampal DG of rhesus monkeys (Macaca mulatta) ranging 
from 6.1 to 31.5 years of age (n = 42).  Using immunohistochemistry they 
146 
 
demonstrated a 68% decline in cell proliferation (Ki67+) and a 53% decline in 
survival capacity in new-born cells, as some monkeys were administered 
BrdU 3 weeks before perfusion in the aged DG. There was also an age-related 
decline in immature neurone DCX+ cell number in the GCL of the DG. 
Moreover, new adult-born immature neurones (BrdU+DCX+) and new adult-
born mature neurones (BrdU+NeuN+) also decline in number with advancing 
age (Ngwenya, Heyworth, Shwe, Moore, & Rosene, 2015). 
Of late it has been shown that there are conserved properties 
concerning embryonic and post-natal DG neurogenesis. Single-cell RNA 
sequencing has revealed 4 distinguishable groups of cells, immune cells 
(microglia and macrophages), vascular cells (endothelial cells), glial cells, and 
neuronal cells (immature and mature dentate granule cells, RGLs) in the 
DG’s of mice ranging from embryonic day (E) 16.5 to post-natal day (P) 132. 
These cell types are unchanged over the course of time, but the quantity of 
these cells differ through the various stages of development and maturation, 
along with where they are found in the DG. RGL’s of the DG seemed to be 
mostly quiescent during early development, but after re-entering the cell-
cycle at later post-natal stage they become neuronal intermediate progenitor 
cells (nIPC’s) and commit to a neuronal lineage. This process was conserved 
from E16.5 to P132 (Hochgerner et al., 2018). 
As is commonly described, the production of new neurones by AHN 
and their functional integration into existing circuits contributes to 
enhancing learning and memory. It has been shown that AG-mediated 
increases in AHN result in improved pattern separation memory function 
(the ability to discriminate between similar contexts) in rats (Kent et al., 
2015). With increasing age there are age-related cognitive impairments in 
humans. A study comparing the effects of age on spatial pattern separation 
in cognitively normal young (18 – 25 years old, n = 30) and old (>65 years, n 
= 30) adult humans has been performed. Participants were asked to take part 
in a delayed match-to-sample task that had various degrees of spatial 
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separation. In the sample phase, a circle was shown on screen and the 
individual was asked to remember its location. In the choice phase, 2 circles 
were shown and the participant was asked to indicate which circle was in the 
same location as observed in the sample phase. The 2 circles were separated 
by 0, 0.5, 1.0 or 1.5cm. Both groups showed increased memory function with 
increasing separation of the circles, but the young group out-performed the 
old group in accurately identifying the sample circle, indicating a reduction 
in efficiency with increasing age (Holden et al., 2012). This age-related 
decline in pattern separation function may be due to structural and 
functional changes to the DG/CA3 hippocampal network.  High resolution 
BOLD fMRI scanning on DG/CA3 activity was performed in 20 young 
(mean age 21 years) and 20 old adults (mean age 71 years), whilst 
participating in a pattern separation task viewing pictures of every-day 
objects to distinguish if they were indoor or outdoor items, some of which 
were repeated or similar (lure activity). No difference in DG/CA3 fMRI 
activity was reported between young and old adults with distinct stimuli, 
but when stimuli were similar the DG/CA3 response was reduced in the 
older group (representational rigidity). Ultra-high resolution diffusion 
imaging showed changes to DG/CA3 dendrites that correlated with the 
rigidity observed in the older group (M. A. Yassa, Mattfeld, Stark, & Stark, 
2011). 
Dysfunction of AHN has been shown in models of AD. The APP-PS1 
model of AD that expresses chimeric mouse/human amyloid precursor 
protein and human presenilin (female 3, 10 and 13-month old), and the 
Tg2576 mouse model that over expresses human APP (3 and 5 month old), 
were used to determine rates of AHN in AD. The APP-PS1 mice received 
daily i.p. injections of BrdU (10mg/ml at 50mg/kg body weight) for 5 days, 4 
weeks prior to being euthanized, in-order to analyse cell survival. Using 
immunohistochemical techniques to show hyper-proliferation of immature 
neurones (PCNA+DCX+) in the GCL of the DG, specifically in the pre-plaque 
stage in both models (APP-PS1, 3 months; Tg2576, 3 months), there was a 
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significant increase compared to WT controls, which was not seen in the 
older ages of either model. An increase in proliferating cell number (PCNA+) 
was also reported in 3-month old mice of both models, but was significantly 
reduced in older mice. Also, in the 3-month old APP-PS1 mice, the rate of 
new DG cell survival (BrdU+) was reduced compared to WT controls, as was 
the number of new adult-born neurones (BrdU+/NeuN+). This work 
indicates, even in the pre-plaque stages of AD, that AHN is negatively 
affected (M. S. Unger et al., 2016). 
 
7.6 Calorie Restriction and Ageing 
As discussed in the introduction to this thesis, the effects of CR are 
conserved across various species. The work presented in chapter 3 indicates 
that elevating levels of endogenous ghrelin by CR promotes AHN and cell 
activation in murine models. Similar outcomes have been witnessed in other 
studies. 
Work performed in Rozalyn Anderson’s group studied the effect of CR in 
rhesus monkeys. A NIA (National Institute of Ageing) study to look at the 
effects of CR and the age of on-set of CR began in 1987. Using a mix of male 
and female monkeys were grouped in young-onset (juvenile, adolescent and 
adults) or old-onset (16-23 years old) CR. They found that males lived longer 
than females, independent of whether they were control animals or CR or the 
on-set of CR. This study found that in the old-onset CR group of monkeys’ 
beneficial metabolic changes such as reduced weight and decreased 
cholesterol. The young onset group did not show any of the expected 
benefits of CR such as reduced serum glucose levels. However the incidence 
of cancer, diabetes and cardiovascular disease was not reduced, but the 
detection of these diseases occurred later in the CR monkeys compared to the 
controls (Mattison et al., 2012). This contradicts work done previously at the 
Wisconsin National Primate Research centre, another 20 year study on the 
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effects of adult onset CR on rhesus monkeys. They showed that a 30% CR 
reduced the incidence of deaths due to ageing, where 50% of the control 
group animals survived at a time-point compared to 80% of CR animals 
survived (Colman et al., 2009). 
The effects of CR have also been examined in elderly humans. In a study 
of 50 healthy elderly subjects aged between 50 -80 years old and BMI >21, 29 
were female with the average age of 60.5 and an average BMI of 28. The CR 
group underwent 3 months of a 30% reduced calorie diet, where the control 
group were told not to change their eating habits. Compared to the control 
group, the CR subjects had significant decreases in weight and BMI, along 
with decreased levels of fasting insulin and increased verbal memory score 
(Witte et al., 2009). 
These studies show that CR is beneficial not only in promoting longevity 
and improving memory function, but can off-set the incidence of age related 
diseases. This is a method that could be adopted as a preventative measure 
against disease in ageing. 
 
7.7 Drug development for Ghrelin 
The ghrelin axis has been a target for drug development in multiple 
disorders. 
One such disorder is Prader-Willi syndrome (PWS). The syndrome is 
characterised by increased circulating AG and reduced UAG, accompanied 
by excessive eating or hyperphagia (Kuppens et al., 2015; Tauber et al., 2014). 
In a recent clinical trial, the UAG analogue AZP-531 that functionally blocks 
AG activity was tested for its effects on food behaviour in PWS.  This was a 
multi-centre (France, Spain and Italy), double-blind, randomized trial, with a 
placebo control. 47 clinically diagnosed patients (male and female, aged 12-
50 years) with PWS received placebo (n = 24) or AZP-531 (3-4mg/50-70kg, n 
150 
 
= 23) for 14 days via subcutaneous injection. Behaviour towards food was 
assessed with a 9-point hyperphagia questionnaire (HQ) on days 1 and 14; 
AZP-531 treated patients showed improvements in their 9-point HQ score 
(less time talking about food, less bargaining for food, less upset when 
denied food and getting up less at night to obtain food). Bloods were also 
taken from participants on day 1 and 14 following overnight fast and 
collected 30 minutes and 180 minutes after breakfast. There was a significant 
decrease in blood glucose levels in AZP-531 vs placebo treated, and was even 
greater in those who also had type-2 diabetes. AZP-531 treated patients also 
exhibited a reduction in fat mass and waist circumference from their baseline 
measurements. No change was seen in AG or UAG levels or ratio (Allas et 
al., 2018). 
Another compound, CF801, a synthetic peptide that is presumed to be a 
GOAT inhibitor, has been shown in mice to be a potential treatment for 
ghrelin-based obesity. Male C57BL/6 mice were used to observe the effects 
of CF801 treatment (low does; 11µmol/kg, high dose; 22µmol/kg, via i.p 
injection once a day for 4 days) on plasma AG levels and rebound feeding 
after fasting.  Mice given the high dose (HD) of CF801 displayed significantly 
reduced plasma AG levels compared to vehicle treated controls (~50% 
reduction in AG), and following a 24 hour fast HD CF801 treated mice 
consumed significantly less chow than vehicle treated mice. HD CF801 
treated mice had reduced fat mass and body weight gain, and attenuated 
inclination for high-fat food. Also, CF801 treated SG-1 cells, that are derived 
from stomach ghrelinomas, had reduced AG release (Wellman et al., 2015). 
Ghrelin receptor agonist, TZP-101, has been shown to promote gastric 
emptying (gastroparesis), which is a symptom of PD and diabetes. Adults 
with type 1 or type 2 (male and female, aged 18-65) diabetes exhibiting 
between moderate and severe symptoms of gastroparesis, were treated with 
placebo (n = 10) or varying doses of TZP-101 (n =14) via intravenous 
infusion, and fasted for 10 hours before receiving a standardized 
151 
 
radiolabelled low-fat meal and drink. TZP-101 treatment resulted in 20% 
increase in gastric emptying and a 34% reduction in latency of gastric and 
liquid emptying after a single dose. Plasma and serum were also obtained at 
0, 15, 45, 90, 180, 360 minutes, 12 and 24 hours after dosing, to measure GH, 
IGF-1 and ghrelin levels. All patients that received TZP-101 had increased 
GH plasma concentrations, but no effect was seen in IGF-1 and octanolyated 
ghrelin levels. The study concluded that the ghrelin receptor agonist 
improved gastric emptying in diabetes (Ejskjaer et al., 2009). 
Drugs can also be repurposed for different diseases and disorders. An 
example of this is the GlaxoSmithKline drug Rosiglitazone, which was 
initially designed to treat insulin-resistance in diabetes, has been shown to 
improve cognitive deficits in AD models. In a double-blind parallel-group 
pilot study, 30 participants with early AD and amnestic MCI (aged 55-85) 
were randomised and treated for 6 months with either placebo (n = 10) or 
4mg daily dose of Rosiglitazone (n = 20). Cognitive testing was performed, 
assessing verbal memory, selective attention and category fluency. Following 
4 and 6 months of rosiglitazone treatment, participants had improvements in 
delayed recall and selective attention compared to the placebo group. Plasma 
amyloid-β levels were also measured, the placebo group showed declining 
levels of amyloid-β which is observed in AD progression, whereas the 
rosiglitazone treated subjects had unchanged levels after 6 months. These 
findings indicate that rosiglitazone as a potential treatment for cognitive 
decline in AD (Watson et al., 2005). Subsequently, in a mouse model of AD 
that overexpresses human amyloid precursor protein (hAPP), were 
chronically treated for 4 weeks with rosiglitazone (5mg/kg/day). After 
treatment the mice were assessed using the object recognition task, and after 
16 weeks were assessed using the Morris water maze test (spatial memory 
task); both analyses showed cognitive improvements compared to control 
mice. Notably, after 16 weeks of treatment these mice showed reduced levels 
of amyloid-β in the brain and a reduction in amyloid-β plaque deposition in 
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the hippocampus. These pre-clinical findings provide further support for 
rosiglitazone treatment in AD (Escribano et al., 2010). 
GHSR agonists have shown to elicit improvements in cognition in mouse 
models. One study using the non-peptide GHSR agonists GSK894490A and 
CP-464709-18 in male Lister hooded rats, who after administration of the 
compounds (0.3 and 3mg/kg, orally). 2 hours following dosing the rats were 
then assessed in a novel object recognition test, following habituation of the 
test cage and Trial 1 where objects were placed in the cage for the rat to 
explore and 24 hours later Trial 2 where one of the objects was replaced with 
a novel object, and the exploring times were recorded. Both treatments 
resulted in increased exploration time of the novel object compared to the 
familiar object. These rats were also assessed in the Atlantis water maze task, 
where they are required to locate a hidden platform using spatial cues, after 
a training session with the platform raised. Both agonist treatments 
(administered 1-2 hours before the task) decreased the latency time to locate 
the platform and path length they took. These results indicate that these 
agonists can cross the BBB and elicit positive effects on cognition (Atcha et 
al., 2009). Another GHSR agonist that has shown to improve cognition is 
LY444711. Male 3-month old Sprague-Dawley rats had their behaviour 
assessed in the spontaneous alternation plus-maze task following 1 
subcutaneous injection of LY444711 (0.25ml 5mg/kg) 30 minutes prior to 
being placed in the centre of the maze, the number of entries to each arm 
were recorded. Compared to saline treated controls, the agonist treated rats 
demonstrated significant improvements in alternation performance, 
indicating improved spatial memory performance (Diano et al., 2006).  
These findings show that GHSR as a potential drug target for the 
treatment of disorders where cognition is impaired. 
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In conclusion, this thesis presents evidence demonstrating that the 
ghrelin-axis is an important regulator of AHN in rodents. However, more 
work is needed to unearth the underlying mechanism(s) of action. 
Furthermore, with regard to neurodegenerative disorders linked with 
dementia in humans, we provide evidence that AG:UAG may be an useful 
diagnostic biomarker. These data suggest that subsequent studies should 
focus on the therapeutic potential of increasing the bio-availability of acyl-
ghrelin to treat neurodegenerative disorders associated with cognitive 
impairment.  
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Chapter 8 Appendix 
8.1 Buffer and Reagent Recipes 
 
8.1.1  10x Phosphate Buffered Solution (PBS) (0.1M), pH 7.4 
To make a 1L bottle of 10x PBS: 
 10.9g Sodium phosphate disbasic (Na2HPO4) (Sigma-Aldrich, S3264-
1KG) 
 3.2g Sodium dihydrogen orthophosphate dehydrate (NaH2PO4) 
(Fisher Scientific, S/3720/60) 
 90g Sodium Chloride (Fisher Scientific, S/3120/60) 
 1L distilled H2O 
8.1.2  1x Phosphate Buffered Solution (PBS) (0.01M) 
To make a 1L bottle of 1x PBS: 
 100ml of 10x PBS 
 900ml distilled H2O 
8.1.3  10x Tris Buffered Solution (TBS) pH 7.6 
To make make 1L bottle of 10x TBS: 
 24.22g Tris [Tris(hydroxymethyl)aminomethane] (Melford, B2005) 
 80g Sodium Chloride (Fisher Scientific, S/3120/60) 
 1L deionised H2O 
8.1.4  1X Tris Buffered Solution (TBS) 
To make 200ml of 1x TBS: 
 20ml 10x TBS 
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 180ml distilled H2O 
8.1.5  0.1% PBS-T 
To make 200ml: 
 200ml 1x PBS 
 200µl Triton X-100 (Sigma-Aldrich, T8787) 
8.1.6  0.03% PBS-T 
To make 200ml: 
 200ml 1x PBS 
 60µl Triton X-100 (Sigma-Aldrich, T8787) 
8.1.7  2M Hydrochloric Acid (HCl) 
To make 100ml: 
 16.4ml Hydrochloric Acid (~37%) (Fisher Scientific, H/1200/PB08 
 83.6ml distilled H2O 
8.1.8  Citrate Buffer pH6 
To make 1L: 
 2.94g Sodium citrate dehydrate (Fisher Scientific, BP327-1) 
 1L distilled H2O 
 Adjust pH to pH6 with 2M HCl 
 0.5ml Tween20 (Sigma-Aldrich, P9416) 
8.1.9  0.1M Sodium Acetate pH 6 
To make 500ml: 
 4.1g Sodium Acetate anhydrous (Sigma-Aldrich, S-2889) 
 500ml dH2O 
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 Adjust to pH 6 with Acetic Acid 
8.1.10  0.2M Sodium Acetate 
To make 1L: 
 16.406g Sodium Acetate anhydrous (Sigma-Aldrich, S-2889) 
 1L dH2O 
8.1.11  1% Sodium Azide 
To make 10ml: 
 0.1g Sodium Azide (Sigma-Aldrich, S2002-25G) 
 10ml dH2O 
8.1.12  PBS-Azide (0.01%) 
To make 200ml: 
 2ml of 1% sodium azide 
 200ml 1x PBS (0.01M) 
8.1.13  30% Sucrose solution 
To make 200ml: 
 60g Sucrose (Sigma-Aldrich, S8501-5KG) 
 200ml 1x PBS (0.01M) 
 Mix and heat 
8.1.14  5M Sodium Hydroxide (NaOH) solution 
To make 100ml: 
 20g Sodium Hydroxide pellets (Fisher Scientific, BP359-500) 
 Mix into 80ml of dH2O (exothermic reaction) 
 Make up to 100ml with 20ml dH2O 
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8.1.15  4% Paraformaldehyde (PFA) solution 
This must be performed in a fume cupboard 
 100ml 1x PBS in a measuring cylinder 
 In a separate PFA labelled jar add 4g PFA (Sigma-Aldrich, P6148-1KG) 
and dissolve in 60ml dH2O, and heat to 60˚C on a heated stirrer for 
approximately 5-10 minutes. 
 Once the solution has become milky add a few drops of 5M NaOH 
until the solution becomes clear. 
 Filter the solution with filter paper into a clean conical flask, and mix 
in the 1xPBS. 
8.1.16  Glucose Oxidase 
To make 8ml: 
 8ml dH2O 
 0.04g Glucose Oxidase from Aspergillus niger (Sigma-Aldrich, G7141-
50KU) 
 Aliquot out into 500µl aliquots 
8.1.17  Nickel enhanced Diaminobenzidine (Ni-DAB) 
To make 200ml: 
 In one beaker place 100ml 0.2M Sodium Acetate: 
o 5g Nickel Sulphate Hexahydrate (Sigma-Aldrich, N4882-250G) 
o 0.4g D-Glucose anhydrous (Fisher Scientific, G/0500/53) 
o 0.08g Ammonium Chloride (Fisher Scientific, A/3880/53) 
 In 100ml dH2O: 
o 0.05g 3,3-Diaminobezidine (DAB) (Sigma-Aldrich, D-8001) 
o Gently heat to dissolve and stir for approximately 10 minutes. 
 Mix the 2 solutions together, then filter with a syringe and filter disc 
into foil wrapped 15ml tubes. 
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 Store at -20˚C. 
8.1.18  Biotinylated Tyramide (bTyr) 
To make 50ml: 
 50ml Deionised water (ddH2O) 
 0.433g Boric Acid (H3BO3) (Sigma-Aldrich, B7660) 
 0.286g Sodium Borate, Borax (NA2B4O7.10H2O) (Sigma-Aldrich, S9640-
25G) 
 Check that the pH is at pH8.0, adjust where appropriate. 
 0.125g Biotinamidoheaxanoic acid N-hydroxysiccinimide ester (NHS-
LC-biotin) (Sigma-Aldrich, B2643-250G) 
 0.039g Tyramide Hydrochloride (Sigma-Aldrich, T2879-1G) 
 Cover the mixture and stir for 16 hours at RT. 
 Filter the solution through a 0.2µm filter, then aliquot and store at -
20˚C.  
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